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 The G protein-coupled receptors (GPCRs) found in the olfactory system 
play a key role in the modulation of Ca2+ activities.  The complex intracellular 
Ca2+ transient and long-term Ca2+ oscillations affect the development, survival, 
response, and connection of the olfactory neurons and interneurons.  The 
olfactory system is used as a research model because of its unique regenerative 
capabilities within the otherwise permanent central neuron system of adulthood.  
Chapter 2 looked at the Ca2+ activity induced by PACAP primarily through the 
PACAP-specific GPCRs in neonatal mouse olfactory bulb granule cell layer 
interneurons.  The PACAP dose is recognized to be essential in the evaluation of 
PACAP modulation of Ca2+ activity.  Furthermore, the numbers of PACAP 
responsive granule cells significantly increased between postnatal day one and 
five suggesting PACAP-induced Ca2+ activity is important in neonatal 
development. Chapter 3 looked at the Ca2+ fluxes induced by ATP through ATP 
specific GPCRs in olfactory epithelial (OE) sustentacular cells, which then 
communicate with other OE cells partially through gap junctions.  The research 
on sustentacular cells has provided additional evidence that these cells are glial 
cells that coordinate the functions of neurons and basal cells in addition to fellow 
sustentacular cells.  Chapter 4 looked at the presentation of the downstream 
associates of the olfactory receptors (ORs) type of GPCRs found on olfactory 
 
sensory neurons in OE.  The centrin gene, Cetn2, was found to have an 
important role in the trafficking and localization of the proteins involved in the 
downstream elevation of Ca2+ activity.  In the absence of Cetn2, the OR 
downstream protein associates adenylate cyclase III and cyclic nucleotide-gated 
channel, which were supposed to be transported by the nonmuscle myosin II to 
the OSN dendritic knob, were absent.  The Cetn2 mutants show the failure to 
recruite the myosin in question.  The resulting cilia defect disrupted the normal 
functions of multiple organs.  All three projects have provided insights into the 
GCPR-inducedCa2+ activity modulations and the characterizations of Ca2+ 
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The Olfactory System 
One of the fundamental problems in physiology is to understand the 
mechanisms regulating the survival and death of cells.  Cell regeneration, 
proliferation, and apoptosis are controlled by multiple chemical and physical 
factors.  These factors form complex pathways with multiple negative and 
positive feedbacks to the initial stimuli originating from multiple sources and 
creating changes in cell functions, which can last msecs to hours (Kandel et al., 
2000).  My physiological studies are centered on a system of specialty neurons, 
the olfactory system.  Olfaction is evolutionarily one of the earliest developed 
senses and remains a primary, essential sense in most animal species 
(Leinwand and Chalasani, 2011).  In mammals, the olfactory system consists of 
the olfactory epithelium (OE) in the nasal cavity and the main olfactory bulb (OB) 
in the brain, which are the regions of my research studies.  The central part of the 
olfactory system also includes olfactory cortex regions, especially the amygdala 
and piriform cortex (Yokosuka, 2012).  Depending on the animal family, the 
olfactory system may also have an auxiliary olfactory sense organ called the 
vomeronasal organ (VNO).  The VNO connects to the accessory OB (AOB) 
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located adjacent to the main OB (on the posterior-dorsal side in rodents) 
(Yokosuka, 2012).  In rodents, both the OE and VNO have sensory neurons; they 
are referred to as olfactory sensory neurons (OSNs) and vomeronasal sensory 
neurons (VSNs).  The dendritic end of each OSN has between 20 and 30 ciliary 
processes expressing one of the 1063 known G-protein coupled odorant 
receptors (ORs).  Each type of receptor can respond to a variety of airborne 
odorants (Ihara et al., 2013; Imai and Sakano, 2008).  Furthermore, the OE has 
chemosensory receptors that respond to nonvolatile molecules, 15 known trace 
amine-associated receptors (TAARs), and the receptor guanylyl cyclase D (GC-
D).  The TAARs and GC-D are, to this date, generally believed to aid in 
discouraging consumption of unsafe food by being involved in the perception of 
unpleasant flavors (TAARs) and detecting unsafe food based on the natriuretic 
peptides, carbon dioxide, carbon sulfide, or uroguanylin and food-related odorant 
characteristics (GC-D) (Ihara et al., 2013).  In contrast to the mainly ciliated 
neurons of the OE, VSNs are microvillar cells that have the vomeronasal 
receptor type 1 or 2 as well as the formyl peptide receptor on their dendritic 
microvilli (Ihara et al., 2013).  Since my projects focused on the OE and OB of 
Mus musculus, the vomeronasal system will not be discussed any further.    
The primary and first project to be discussed describes the intracellular 
[Ca2+] ([Ca2+]i) activity mechanisms in the granule cells (GCs) of the OB induced 
by a specific protein called Pituitary Adenylate Cyclase Activated Polypeptide 
(PACAP).  The second project looks at the [Ca2+]i activity in the sustentacular 
cells of the OE.  The third study shows my electrical recordings of OSNs in the 
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OE as part of a collaborative work on the mechanisms of olfactory OSN signal 
transduction.  Mice were chosen as a model because genetically these mammals 
closely resemble humans, and they have the ability to accept modulated specific 
genes of interest.  All three projects involve G-protein coupled receptors 
(GPCRs) and their associates (downstream effectors, neurotransmitters, etc.) in 
the modulation of [Ca2+]i response. 
 
Function of GPCRs 
GPCRs regulate a wide range of processes and are one of the essential 
factors in cellular function within the olfactory system.  The GPCRs looked at in 
my projects have roles in the shaping of the olfactory system ranging from the 
ability to respond to odorants with the support of the surrounding sustentacular 
cells in the OE to the development, maturation and replacement of granule cells 
in the OB (Dooley et al., 2011; Hegg et al., 2009; Ogura et al., 2011; Kondo et 
al., 2010; Bath and Lee, 2010; Bovetti et al., 2011; Christie and Turnley, 2012).  
Most, if not all, GPCRs have a similar basic structure, but differ in their various 
binding sites, conformations for releasing G-protein, and heterotrimeric 
combinations of G-protein subunits (Oldham and Hamm, 2008).    
The canonical GPCR protein, which is located in the plasma membrane 
and/or intracellular membranes of organelles and endosomes, has an N-
terminus, followed by seven transmembrane (TM) domains connected by three 
interhelical loops on each side of the membrane, then finally a C-terminus on the 
opposite side of the membrane from the N-terminus (Fig. 1.1).  The C-terminus 
has various binding sites for its specific combination(s) of G-protein subunits.  
 4
The heterotrimeric G-protein unit is comprised of three subunits referred to as α 
(21 subtypes), β (6 subtypes), and γ (12 subtypes).  Various combinations of the 
subunits affect the strength and type of response (Oldham and Hamm, 2008).  In 
the most recent classic model of GPCR function, the GPCR binds a ligand and 
undergoes a conformational change that activates its associated heteromeric G-
protein. The Gα subunit dissociates from the tightly interacting Gβγ dimer.  The 
G-protein dissociation process is not yet well understood, but the conserved 
GTPase domain on the Gα is believed to provide the binding to Gβγ dimer 
(Oldham and Hamm, 2008).   
The binding sites on the N-terminus side of the GPCR vary, determining 
its affinity to specific ligands using possibly the N-terminus tail, interhelical loops, 
and/or TM domains.  Regardless of the binding modes and type of GPCR, there 
is a conformational change at the C-terminus side of the membrane.  If G-protein 
is released as a result, it may activate its effectors.  In the classic example, it is 
supposed that the Gβγ dimer stays in the membrane and modulates membrane 
proteins.  As for the Gα subunit, the various subtypes of this subunit can also 
activate (and inhibit) various pathways.  The main stimulatory subtypes of Gα (q, 
s/olf) elevate the [Ca2+]i through two major pathways known as the adenylate 
cyclase (AC) pathway and the phosphatidylinositol lipase C (PLC) pathway (Fig. 
1.1).  There is also a main inhibitory subtype, Gαi, which inhibits the AC pathway 
(Blechman and Levkowitz, 2013). The AC pathway is activated when a Gαs/olf 
activates adenylyl cyclase, which uses ATP to generate cAMP.  The cAMP then 
activates multiple downstream signals, some of them catalyzing the opening of 
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cyclic nucleotide gated (CNG) cation channels and voltage-gated calcium 
channels.  The openings of especially voltage-gated calcium channels by cAMP 
may be direct or mediated through protein kinase A (PKA) and mitogen-activated 
protein kinase (MAPK).  The opening of CNG channels and voltage-gated 
calcium channels brings extracellular Ca2+ into the cytoplasm, elevating the 
[Ca2+]i .   
In the Gαq/PLC pathway, PLC catalyzes the cleavage of 
phosphatidylinositol-4,5-biphosphate (PIP2) into cytoplasmic inositol-1,4,5-
trisphosphate (IP3) and membrane-bound diacylglyerol (DAG).  IP3 then activates 
the IP3 receptors located on the endoplasmic reticulum (ER), releasing stored 
Ca2+ into the cytoplasm, elevating the [Ca2+]i.  DAG is believed to govern the 
activity of protein kinase C (PKC), an enzyme that phosphorylates various 
downstream proteins (Fukami et al., 2010; Kandel et al., 2000) (Fig. 1.1).   
 
Anatomy and Functions of Cells in Olfactory System 
 
The elevation of [Ca2+]i through ion channels or by release from 
intracellular stores can affect enzymes, channels, and receptor potentials. If the 
cell membrane depolarizes past its threshold, an all-or-nothing action potential 
then transfers the electrical signal through the axons to neurons and 
interneurons.  In the olfactory system, the signal response to an odorant begins 
in the OSNs of the OE, travels through the OB where it is processed, and from 
there to the olfactory cortex and other brain regions (Kandel et al., 2000). 
The OE is located in the nasal cavity; the apical layer is closest to the air, 
just under the secreted mucus coat.  It has four primary cell types: OSNs, 
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sustentacular cells [which function as epithelial and glial support cells (Hegg et 
al., 2009)], microvillar cells [MVC; act as stimulators and aid in the regeneration 
of olfactory cells between OE to OB, (Pfister et al., 2012)], and basal progenitor 
cells [which give rise to new OSNs and MVCs, (Elsaesser et al., 2005)].  The 
widely accepted idea is that an individual OSN contains only one OR subtype in 
its cilia.  This seemingly single-function OR is, however, believed to perform 
multiple functions, starting when the OSN is immature and lacking an axon 
projection to the OB.  The process by which a particular OR gene is activated is 
not well understood, but the activity of the chosen OR subtype, using Gαs protein 
(which activates the AC pathway), appears to guide the OSN axon to their 
determined spots in the OB.  The OSN eventually expresses Gαolf protein, 
designed for reacting to ORs bound to odorants, also through the cAMP 
pathway.  The Gαolf-induced mechanisms appear to aid the axon targeting to 
become more precise and finally connect the OSN to the appropriate OB 
interneurons (Imai and Sakano, 2008; Fuss et al., 2013; Khan et al., 2011; Khan 
et al., 2013; Marcucci et al., 2011; Plessy et al., 2012). 
 We can follow the main olfactory signal pathway from nose to brain; it 
begins when odorant molecules in the environment become dissolved into the 
mucus coating the cilia of the OSN in the OE (Fig. 1.2).  The odor ligand binds to 
the OR subtype of the OSN, and Gαolf protein is released, turning on downstream 
signals that open cyclic-adenosine monophosphate (cAMP)-gated channels.  
Extracellular Ca2+ enters and depolarizes the membrane.  The responding 
receptor potential moves from the cilia through the OSN dendrite and soma, then 
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generates an action potential at the axon hillock (Kandel et al., 2000).  One other 
OSN axon, with the same subtype of OR, joins the OSN unmyelinated axon we 
are following.  This pair then is called an olfactory nerve filament, and it 
coalesces with other filaments, forming the olfactory nerve (Au et al., 2002).  The 
olfactory nerve filaments project through a pore in the cribriform plate before 
reaching the OB.  Each nerve filament activates what appears to be a ball of 
dendrites on the outermost part of the OB, known as a glomerulus.   Like the 
nerve filaments, each glomerulus is specific to a particular OR.  Each class of 
OSNs expressing a given subtype of OR are believed to converge their axons 
onto two glomeruli (Miyamichi et al., 2011; Furudono et al., 2013; Tan et al., 
2010).   
The signal within the glomerulus is then primarily passed on to the tufted 
cells deeper in the OB; these pass the signal to mitral cells, which carry the 
signal up the axon (De Saint et al., 2009; Gire et al., 2012).  The MC axons 
coalesce toward the center to form the lateral olfactory tract that exits the OB and 
travels onward to several higher olfactory regions, especially the amygdala and 
piriform cortex (Yokosuka, 2012; Miyamichi et al., 2011).  The stereotyped 
connection to the glomerulus we were following is just one of multiple signals for 
the same odorant.  Beyond the glomerular layer, the connections became unitary 
and spatially represented in the OB.  That said, an odorant stimulus is not broken 
into components, as is believed to happen for visual and auditory stimuli.  
Through modulation by neuropeptides and interneurons, the odorant 
representation becomes sparsely regional in the OB.  This sparse code is 
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transmitted to the higher brain centers, where it is interpreted (Leinwand and 
Chalasani, 2011; Khan et al., 2010; Munch et al., 2013).   
We have quickly traveled through the OB, following the signal from the 
OSN to the brain.  The OB is, however, a complicated network of feedback loops 
between different types of interneurons (Fig. 1.2).  Most of the interneurons are 
located in specific OB layers (Lledo et al., 2008; Parrish-Aungst et al., 2007; Au 
et al., 2002; Batista-Brito et al., 2008).   The glomeruli are located in the 
outermost layer, making it a glomerular layer (GL).  Some researchers, however, 
split this layer into the outer olfactory nerve layer and inner glomerular layer due 
to the olfactory nerve being reorganized extensively before the OSN axon 
fascicles innervate their specific glomeruli (Au et al., 2002).  The GL also has 
periglomeruli cells and horizontal axon cells, which are believed to receive and 
release signals between various types of cells (Kiyokage et al., 2010).  The 
external plexiform layer (EPL) contains uniformly positioned tufted cells (TCs) at 
various depths from the GL, but consists mostly of mitral cell (MC) dendrites 
going across the width of the EPL from the glomerular layer to the MC bodies in 
the mitral cell layer (MCL).  The granule cell (GC) dendrites are also in the EPL.  
The innermost part of the MCL has short axon cells and possibly another type or 
types of cell that are not officially characterized and named.  The internal 
plexiform layer (IPL) is on the innermost side of the MCL and appears to contain 
mainly MC axons and dendrites of GCs.  The somas of these GCs are in the final 
main OB layer, known as the granule cell layer (GCL) (Au et al., 2002; Batista-
Brito et al., 2008; Lledo et al., 2008; Parrish-Aungst et al., 2007).  99% of the 
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adult mouse interneuron cells in the GCL are GCs (Parrish-Aungst et al., 2007) 
and their primary function is to inhibit the MCs by dendrites (GCs have no 
axons!) extending to both the MCL and the EPL (Abraham et al., 2010; Ma et al., 
2012; Shao et al., 2012).  It has been believed that GCs also may inhibit TCs, but 
recent evidence suggests the TC inhibition comes from GL interneurons rather 
than GCs (Whitesell et al., 2013). 
 
PACAP Modulation of Calicum Ion Activity 
My primary research project (Chapter 2) is about the pituitary adenylate 
cyclase-activating polypeptide (PACAP)-induced modulation of [Ca2+]i activity in 
the OB.  For most of the experiments, I used a dynamic confocal imaging 
technique to track the changes in [Ca2+]i activity.  I applied different chemicals to 
an acute slice of P2-P5 neonatal mouse OB in a chamber bath using an air-
pressured perfusion system.  The perfusion system gently pushes the solutions 
through tubing onto the slice at a steady rate of 1.5–2 mL/min.  The solution and 
experimental chemicals were steadily vacuumed away at the other side of the 
chamber.  The focus was on the soma of the GCs, which are enriched with 
PACAP G-protein coupled receptors, especially PAC1 receptors (PAC1Rs) 
during the first neonatal mouse week.   
 The OB has a heterogeneous population of PAC1R isoforms that interact 
with either Gs/i or Gq protein subtypes.  The GCL has a higher expression of 
PAC1Rs than most parts of the central nervous system (CNS).  Thus, PACAP is 
capable of activating both the AC and PLC pathways in the GCs (Blechman and 
Levkowitz, 2013).  The PACAP response can furthermore release 
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neurotransmitters that turn on alternative receptors, increasing the [Ca2+]i activity 
throughout the OB and possibly beyond.  Although not investigated in this 
dissertation, PACAP has been widely studied for its neuroprotective effects. The 
PACAP-induced response generally reduces the pro-apoptosic factors such as 
the cleavage of caspaces (3, 8, 9,12 for example), Bax, JNK, and c-jun gene 
expression.  PACAP furthermore generally increases the anti-apoptosic factors 
such as PKC, PKA, ERK, Bcl-2, and c-fos gene expression (Botia et al., 2007; 
Szabadfi et al., 2014; Vaudry et al., 1998; Cowan and Roskams, 2002). A good 
example of the mechanism of the PACAP anti-apopostic effect is its 
counterbalancing of the apoptotic activity induced by ceramide proteins (Aubert 
et al., 2006; Dejda et al., 2005; Falluel-Morel et al., 2004; Falluel-Morel et al., 
2005; Falluel-Morel et al., 2006; Falluel-Morel et al., 2008; Vaudry et al., 2003; 
Zhokhov et al., 2008) (Fig. 1.3).  Briefly, Fig. 1.3 shows how the PACAP-induced 
kinase activity (e.g., ERK) leads to phosphorylation of c-fos, which binds to the c-
jun from the ceramide-induced pro-apoptosis route stimulated by JNK.  The 
activator protein-1 (AP-1) binds with the anti-apoptosis c-fos/c-jun pair (builds up 
Bcl-2 expression) or the pro-apoptosis c-jun/c-jun pair (builds up Bax 
expression).  Without c-fos, the gene expression elevated by c-jun alone favors 
apoptosis.  When this happens, one or more types of caspases are cleaved by 
cytochrome c, which was released from mitochondria by Bax (Jin and El-Deiry, 
2005). PACAP is thought to promote the anti-apoptotic pathway. 
   The OB being part of the CNS made it a unique research model for the 
anti-apoptosis and regeneration studies because unlike the majority of the CNS 
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neurons that stop developing by adulthood, the mature GCs (as well as other 
cells apart from the more permanent mitral and tufted cells) in the OB are 
continuously replaced throughout life (Bagley et al., 2007)!  The lifetime 
replacement of OB interneurons was shown to be necessary for normal olfaction 
functions (Breton-Provencher et al., 2009; Bagley et al., 2007).  PACAP is a 
strong candidate for contributing to the apoptosis prevention, development, 
regeneration, and proliferation of new cells.  Studying how PACAP aids the 
lifetime replacement of OB interneurons  will hopefully help in the treatments for 
CNS injuries and neurodegenerative disorders such as Alzheimer’s Disease and 
other dementias, stroke, malformations, epilepsy, Multiple Sclerosis, and others 
(Atlasz et al., 2010; Ohtaki et al., 2008; Mulder et al., 1999; Delgado et al., 2003; 
Chen et al., 2006; Doursout et al., 2013; Dejda et al., 2005; Dejda et al., 2008; 
Makela et al., 2010; Ruan et al., 2012; Sherwood et al., 2007).             
Calcium Store-Mediated Signaling in Sustentacular Cells 
 The second project (Chapter 3) used the same confocal imaging 
technique to track [Ca2+]i activity in the OE sustentacular cells, which were 
historically thought to be just epithelial support cells basically keeping the 
electrically active OSNs separate from one another (Hegg et al., 2009).  
However, more recent studies suggest that sustentacular cells are glial-like.  Our 
data of complex [Ca2+]i activity in sustentacular cells further support the glial-like 
concept.  The adenosine triphosphate (ATP) or UTP purinergics, which all living 
organisms use for energy (Kandel et al., 2000), were found to extremely elevate 
the sustentacular cell [Ca2+]i levels, as compared to OSNs.  The main factors 
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responsible for the complex calcium signaling in sustentacular cells are the 
extracellular purinergic-evoked release of [Ca2+]i through the PLC pathway and 
the ability of these cells to communicate with each other, potentially through gap 
junctions.  The ATP-induced specific calcium oscillations are suggested to 
integrate and coordinate multicellular functions. 
Dysosmia in Cetn-/- Mice 
 The third research project (Chapter 4) uses the electro-olfactogram 
(EOG), a method specialized for recording from multiple OSNs using electrodes.  
Airborne odorants were puff-delivered to the OE surface.  The amount of voltage 
change shows the overall strength of response through GCPRs from multiple 
OSNs.  The project focused on centrins, which are calmodulin-related Ca2+ 
binding proteins that we suggested aid in the trafficking and localizing of ACIII 
and the cyclic nucleotide gated channel A2 subunit (CNGA2).  I compared 
Cetn2∆Ex2,3 knockout mice (Cetn2 exon 2 + 3 of the centrin-2 gene deleted) 
with their wildtype littermates.  The OEs of the knockouts have a significantly 
reduced olfactory response. This suggests that centrin-2 is one of the proteins 
needed to coordinate the transport of proteins in the cAMP pathway to the OSN 
cilia.  Even though centrin-2 is not the sole transport coordinator for the ACIII and 
CNG channels, the lack of the proper localizing and trafficking causes the 
progressive loss of preexisting cilia in the knockouts.  Furthermore, the 




 All three projects evaluating the activities of GCPRs and their induced 
Ca2+ modulating pathways elucidate how the olfactory system uses the 
metabotropic receptors and their complex, long-term [Ca2+]i activities to support 
the development and function of olfactory neurons and interneurons. 
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Fig. 1.1:   How GCPRs activate PLC (pink arrows) and/or AC (purple arrows) 
pathways.  Blue arrows represent Ca2+ (blue stars) entry into intracellular space.  PLC 
= phosphoinositide-phospholipase C, PIP = phosphatidylinositol-4,5-bisphosphate, DAG 
= diacylglycerol, IP3 = inositol triphosphate (and receptor), ER = endoplasmic reticulum, 
RyR = ryanodine receptor, GDP/GTP = guanosine-5’-di/triphosphate, ATP = adenosine-
5’-triphosphate, AC = adenylate cyclase, cAMP = cyclic adenosine monophosphate, 
PKA/PKC/PKD = protein kinase A/C/D, MEK = mitogen-activated protein kinase, ERK = 




















Fig. 1.2:  Diaphragm of olfactory system.  (GL = glomerular layer, EPL = external 





















Fig. 1.3:  How PACAP act as anti-apoptosis factor opposing the pro-apoptosis 
pathways.  Blue represents PACAP-induced anti-apoptotic factors.  Green represents 
pro-apoptotic factors which can be induced by ceramides or other insults.  (PAC1R = 
PACAP receptor; PKA = protein kinase A; cAMP = cyclic adenosine monophosphate; 
MEK = Mitogen-activated protein kinase; ERK = extracellular signal-regulated kinases; 
AP-1 = Activator Protein-1; Bcl-2 = B-cell lymphoma 2; JNK = c-Jun N-terminal kinases; 
Bax = BCL2-associated X protein; tBid = truncated Bcl2 Interacting Protein; cytochrome 











PACAP MODULATION OF CALCIUM ION ACTIVITY IN  




Pituitary Adenylate Cyclase Activating Peptide (PACAP) is a potential 
candidate for neurogenesis therapy following injury or neurodegenerative 
disease due to its anti-apoptotic properties (Arimura, 1998; Atlasz et al., 2010; 
Bourgault et al., 2009; Chen et al., 2006; Cowan and Roskams, 2002; Dejda et 
al., 2005; Dejda et al., 2008; Delgado et al., 2003; Di et al., 2012; Doursout et al., 
2013; Hansel et al., 2001; Kanekar et al., 2010; Makela et al., 2010; Mulder et al., 
1999; Nakamachi et al., 2008; Ohtaki et al., 2006; Ohtaki et al., 2008; Ruan et 
al., 2012; Sherwood et al., 2007; Shioda et al., 2006; Szabadfi et al., 2012; 
Szabadfi et al., 2014; Vaudry et al., 2009; Yang, 2008).  PACAP was originally 
discovered in 1989 by Miyata et al. and was described as a neuropeptide that 
stimulates cAMP formation in the pituitary cells, hence the current name (Miyata 
et al., 1989).  Today PACAP and its PACAP-specific G protein coupled receptors 
(PAC1R, VPAC1R, and VPAC2R) are studied in other parts of the central 
nervous system (CNS) such as the cerebellum, hippocampus, and olfactory 
system, as well as throughout the body (16). The functions of PACAP in the CNS 
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are largely neurotrophic during development and neuroprotective or 
neuromodulatory during adulthood (Arimura, 1998; Dejda et al., 2008; Delgado et 
al., 2003; Ravni et al., 2006; Sherwood et al., 2007; Vaudry et al., 2002).  Thus, 
despite its relatively recent discovery, PACAP is now considered to be one of the 
most important regulators of biological functions (Vaudry et al., 2000c). Our 
interest in the physiological functions of PACAP and PAC1Rs developed partly 
from the noteworthy problem of PACAP knockout mice often dying before 
weaning.  The high mortality of PACAP knockouts suggests that PACAP is 
required for normal development (Raineki et al., 2010; Sherwood et al., 2007).   
PACAP and PAC1R expression are highest in the CNS regions that 
continue to regenerate throughout adulthood such as the dentate gyrus and 
olfactory system (Hansel et al., 2001; Mulder et al., 1999) as well as in sensory 
integration areas including the retina (Atlasz et al., 2010; Delwig et al., 2013; Kiss 
et al., 2006; Markhotina et al., 2007; Silveira et al., 2002; Szabadfi et al., 2012; 
Szabadfi et al., 2014), cerebellum (Allais et al., 2007; Botia et al., 2007; Falluel-
Morel et al., 2007; Falluel-Morel et al., 2008; Jozwiak-Bebenista et al., 2007; Mei 
et al., 2004; Vaudry et al., 1998; Vaudry et al., 1999; Vaudry et al., 2000b; 
Vaudry et al., 2000a; Vaudry et al., 2002; Vaudry et al., 2003; Zhokhov et al., 
2008), hippocampus (Ago et al., 2011; Costa et al., 2009; Di et al., 2003; Kambe 
and Miyata, 2012; Liu et al., 2003; Macdonald et al., 2005; Taylor et al., 2014), 
and suprachiasmatic nucleus (SCN) (Dziema and Obrietan, 2002; Irwin and 
Allen, 2010; Kopp et al., 1999; Kopp et al., 2001; Michel et al., 2006; Webb et al., 
2013).  Ca2+ imaging studies in SCN showed that the initial PACAP-induced 
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response is variable, ranging from slow (sec) to rapid (msec) increases in 
intracellular [Ca2+] ([Ca2+]i). Following the initial response, durations of post-
PACAP Ca2+ fluctuations are also variable and can persist from minutes to hours 
(Kopp et al., 1999).  It appears that the variability in PACAP response profiles 
mainly depends on the dominate type of PAC1R splice variant being activated 
(Ago et al., 2011; Blechman and Levkowitz, 2013; Nicot and Dicicco-Bloom, 
2001; Yan et al., 2013; Zhou et al., 2002).  Either way, it is generally agreed that 
PACAP has a role in directly or indirectly inducing long-term changes in Ca2+ 
activities (Baxter et al., 2011; Dziema and Obrietan, 2002; Kopp et al., 1999; 
Kopp et al., 2001; Michel et al., 2006; Tanaka et al., 2007).   
Within the olfactory system, the constant generation of new neurons is 
required to maintain normal function of both olfactory epithelium and the olfactory 
bulb (OB) (Breton-Provencher et al., 2009).  PACAP and PAC1Rs are found 
throughout the olfactory system with high mRNA expression in the olfactory 
epithelium, OB, and anterior olfactory nucleus (Allen Brain Altas, 2013; Jaworski 
and Proctor, 2000; Shioda et al., 1997).  Our lab has been studying the 
physiological effects of PACAP and PAC1Rs in the olfactory epithelium (Han and 
Lucero, 2005; Han and Lucero, 2006; Hansel et al., 2001; Hegg et al., 2003b; 
Hegg et al., 2003a).  However, little is known about the physiological effects of 
PACAP in the OB (Olianas and Onali, 1999).  Here we provide the first 
physiological recordings of PACAP-induced [Ca2+]i responses in genetically 
identified neurons of the neonatal mouse OB.  
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The mouse OB has several discrete layers containing at least seven 
different types of interneurons and two classes of projection neurons (tufted cells 
and mitral cells) (Batista-Brito et al., 2008).  We limited our study of PACAP to 
the granule cell layer (GCL).  The GCL has two main types of GABAergic 
interneurons, 97% of which are the small (4–8 um) granule cells (GCs), and the 
other 3% are the large (12–18 um), ovoid-soma Blanes cells (Potter et al., 2009).  
The GCL has one of the highest expression levels of PAC1R mRNA in the CNS.  
Although the GCL region has little to no PACAP gene expression, the GCs 
primarily connect with the mitral cells (MCs) and receive input from the anterior 
olfactory nucleus; both are areas of enriched PACAP gene expression (Batista-
Brito et al., 2008; Jaworski and Proctor, 2000; Allen Brain Altas, 2013; Shioda et 
al., 1997).   
In the following experiments, we examined the effects of PACAP on cells 
in the GCL of P2 to P5 mice, the time period when the majority of GCs migrate 
into the OB from the subventricular zone (Batista-Brito et al., 2008; Lemasson et 
al., 2005).   
We hypothesized that the PACAP activation of GCs triggers 
developmentally important [Ca2+]i oscillations and participates in the 
establishment of OB circuitry within the first postnatal week.  In the first 
experiments, we asked whether PACAP directly or indirectly modulates [Ca2+]i in 
the developing granule neurons within the olfactory bulb by evaluating the 
kinetics of PACAP responses in the presence and absence of neurotransmission.  
In the second study, we used functionally (based on excitatory GABA responses) 
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and genetically identified cell types to determine the developmental time course 
of PACAP responsiveness in GCL neurons in neonatal mouse OB.  We 
evaluated both the GC cells (labeled Dlx2-tdTomato) and the GAD65 GC 
subtype group (labeled GAD65-tdTomato). The changes in the population of 
PACAP-responding cells within the 4 days evaluated, especially among the 
GAD67 cells, provide clues about the first week of PACAP activity in the 
developing OB.   
Understanding the role of PACAP in modulating [Ca2+]i in developing 
neurons may provide important insight for mechanisms mediating the maturation 
required for establishing sensory maps and neuronal circuits. In the future, this 
understanding may be critical for promoting therapeutic integration of neuroblasts 
during early development, following injury, or in neurodegenerative disease. 
 




All animal procedures were approved by the University of Utah 
Institutional Animal Care and Use Committee and were conducted under the 
guidelines of the NIH Guide for Care and Use of Laboratory Animals. 
 The defined Cre recombinase (IRES-CRE linked) transgenic C57/BL6 
mice for Dlx2-IRES-CRE (gift from Dr. Mario Capecchi Lab) was used.  The Dlx2-
IRES-Cre mouse line was generated in the Capecchi lab by inserting an IRES-
Cre-FRT-neo-FRT cassette in the 3’ untranslated region of the Dlx2 gene. The 
targeting vector was prepared with 129S6/SvEvTac mouse genomic DNA 
previously isolated from the RPCI-22 BAC library (BACPAC Resources). The 
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vector was electroporated in 129R1 embryonic stem (ES) cells, and successfully 
targeted clones were confirmed by Southern blotting. ES cells were injected in 
the blastocysts of C57Bl6 recipients to generate chimera founders. Positive 
offspring was bred to FLP delete mice to remove the neo selection marker, and 
the line was bred to homozygosity. Automated genotyping service for this strain 
is available from Transnetyx (probes:  “Dlx2-1 WT” and “Dlx2-1 KO”). 
 Additionally, the defined Cre recombinase (IRES-CRE linked) transgenic 
C57/BL6 mice for GAD65-IRES-CRE [JAX Stock #0101802; The Jackson 
Laboratory (Taniguchi et al., 2011)] and PCdh21 [The GENSAT Project; Stock 
#030952-UCD; Mutant Mouse Regional Resource Centers (Nagai et al., 2005)] 
were used. To specifically label the IRES-CRE linked genes as red, mice from 
each line were crossed with mice containing the Rosa-tdTomato gene (ROSA26-
CAG promoter).  The Swiss Webster transgenic mice for GAD67 are Green 
Fluorescent Protein (GFPF)-linked.  The pups were checked for specific 
expression using ultraviolet light.  Any pups with nonspecific expression, which 
appeared completely red from head to toe, were not used.   The specific 
expression of Dlx2 is primarily in the head region.  GAD65 and PCdh21 had 
expression mainly in the head, but in patterns on the body too. 
 
Live Slices of the OB 
 Live coronal slices of the OB (400 µM thick) were prepared between 11 
AM to 12:30 PM [due to circadian changes in PACAP (Granados-Fuentes et al., 
2006)] from P2–P5 mice (Hegg et al., 2003c). Briefly, following decapitation, the 
jaws, skin, and eyes were removed, and then the whole skull was embedded in 
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carrot and sliced using a vibrotome.  The slices were cut in ice cold low Na+/high 
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2, pH 7.4).  The slices recovered for at least 40 min at room 
temperature before loading with 1.3 mM Ca2+ ACSF containing the membrane 
permeant Ca2+ sensitive dye [37 MµM Fluo-4 AM (Invitrogen), which is prepared 
with 20% Pluronic F-127 (Calbiochem)] and 100 µM probenecid (Sigma) at 37ºC 
for an hour.  The slices were used between 1 to 4 hours after cutting and 
experimented on for no more than 8 hours after cutting.   
 
Confocal Calcium Imaging  
Fluo-4 loaded slices were gently stabilized in a chamber under a single 
wire over the cartilaginous parts of nose.  The gassed ACSF solution 
continuously flowed over the slices (1.5–3.0 ml/min).  Test solutions were applied 
using a small volume loop injector (500 µl) in line with the bath flow.  A Zeiss 
LSM 510 Version 3.0 SP3 confocal laser scanning system was used for data 
collection and analysis (488 nm excitation filter for Fluo-4 and 568 nm excitation 
filter for Rosa-tdTomato). Time series experiments were performed collecting 256 
x 256 pixel images at 1.27 Hz. Imaging studies were performed at 50–100 µm 
below the surface of the slice to avoid damaged cells. A z-stack of images, about 
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11–13 µm apart, was collected at the end of each experiment to confirm location 
of recording sites that were between the middle of the GCL to the edge of the 
mitral cell layer (MCL). 
 
Immunocytochemistry  
The whole skulls were prepared by removing skins, jaws, and eyes then 
fixed in 4% paraformaldehyde overnight at 4ºC.  The heads were sequentially 
equilibrated with 15% and 30% sucrose prior to embedding in OCT compound 
and were stored at –80ºC.  The 12 µm thick frozen sections were captured on 
glass slides using a cryostat microtome and stored at –20ºC. The sections were 
postfixed for 5 min in 4% paraformaldehyde/0.1 M PBS and rinsed thoroughly 
with PBS-0.2% Tween-20. Antigen retrieval was performed by incubating the 
slides in citrate buffer (10 mM sodium sodium citrate, 0.05% Tween-20, pH 6.0) 
for 2 minutes at 96oC, then cooled to room temperature and rinsed several times 
in PBS. Nonspecific binding was blocked with 2% horse serum in PBS for 30 min 
at room temperature. Sections were incubated with a rabbit anti-Pac1 antibody 
[kind gift of Dr. Seiji Shioda or Aviva ARP59945, both 1:200 (Matsuno et al., 
2008)] overnight at 4°C.  After the primary antibody was removed, the sections 
were rinsed several times with PBS, and incubated with a secondary antibody 
(goat anti-rabbit Alexa 488, Jackson ImmunoResearch Laboratory, 1:300) for 1 
hour at room temperature. The slides were washed 2 x 5 minutes in PBS, once 
for 5 minutes in water with DAPI, and cover slipped.  The tissue sections were 
imaged on a Zeiss Axio Imager microscope using Axiovision software.  Zero 
primary controls were run for all mouse lines and ages. 
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Chemicals and Drugs 
The powder form of PACAP-27 (Phoenix Pharmaceuticals) was freshly 
dissolved in ACSF with 0.01% BSA (Sigma) kept on ice and discarded at end of 
each experiment day (~4 hours.)  An ACSF loop of 0.01% BSA alone was used 
as a control.  BSA was added to all other experimental solutions apart from the 
elevated K+ (HK) solution.  HK  (95 mM NaCl, 50 mM KCl, 1 mM MgCl2, 2 mM 
CaCl2, 10 mM HEPES, 10 mM Glucose, and 100 µM probenecid) was applied to 
monitor the health of the slice and identify cells with voltage-gated Ca2+ 
channels. The PAC1R-specific antagonists M65 (Kind gift from Dr. Ethan Lerner, 
Harvard; Bachem) and PACAP 6-38 (Phoenix Pharmaceuticals) were stored at   
-40oC until day of use.  The 50 µM GABA solution was also made fresh every 
experiment day and kept on ice.   
The dose response curve of PACAP included 1 nM, 10 nM, 20 nM, 40 nM, 
60 nM, and 100 nM PACAP-27 with increasing washing times between each 
PACAP application to give the slices time to recover (>10 minutes after 10 nM, 
>20 minutes after 20 nM, >60 minutes after 40 nM, and >80 minute after 60 nM).  
To determine the possibility of partial desensitization between 40 nM and 60 nM, 
the order was reversed in a subset of slices. 
40 nM PACAP was shown to affect both Ca2+ release from intracellular 
stores through the PLC pathway (2-APB; Enzo Life Sciences) and Ca2+ entry 
from extracellular space (Ca2+-free extracellular solution) through the ACIII 
pathway (data not shown).    
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An antagonist cocktail containing 5 receptor/channel blockers was 
designed to allow recording of PACAP responses in the absence of synaptic 
transmission. The antagonist cocktail included 1 μM TTX (Na+ channels; Sigma), 
50 μM APV (NMDA; Tocris), 50 μM DNQX (AMPA/kainate; Tocris), 10 μM 
SR95531 (GABAA; Tocris), 100 μM LY341495 (mGluR1a, 2, 3,4a,5a,7a, and 8; 
Tocris), and 10 μM CGP52432 (GABAB; Tocris).  The effectiveness of the 
antagonists was confirmed by blocking 50 mM L-glutamate or 50 µM GABA 
induced [Ca2+]i responses in our slice preparation (data not shown.)  PPADS 
(P2Y1 and A2A; Tocris) was also originally included in the cocktail, but omitted for 
the present data due to its significant side effect of decreasing resting [Ca2+]i 
levels.   In addition, Doengi et al. (2008) suggested that PPADS has no effect on 
[Ca2+]i responses in the OB.  The expression of purinergic receptors in the OB is 
primarily in the astrocytes and olfactory ensheathing cells [personal observations 
using SR101 astrocyte-labeling dye (Doengi et al., 2008; Doengi et al., 2009; 
Rieger et al., 2007)].1  The interneurons in the OB, especially in juvenile mice, 
are believed to have little to no expression of purinergic receptors (Allen Brain 
Altas, 2013; Thyssen et al., 2013; Doengi et al., 2008).  
 
Analysis 
PACAP, GABA, and HK responsive cells within the tdTomato expressing 
cell population in the GCL zone were identified by measuring changes in 
                                            
1 Fischer et al. 2011 suggested that ATP acts as neurotransmitter on the glial cells, affecting the 
overall principal OB neuronal performance.  The expression of the purinergic receptor gene is 
suggested to be found in all layers of OB in all major cells, but the actual functional expression 
would be in only the glial cells.   
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fluorescence intensity compared to baseline (∆F).  The BSA control was used to 
identify spontaneously active cells, which were removed from further analysis. 
The numbers of responsive cells were analyzed by placing regions of interest 
(ROIs) on each PACAP-induced responsive cell and measuring the latencies, 
time to peak, area under curve (120 recorded seconds of response), and 
amplitudes (Fig. 2.1).  We considered measuring response durations, but these 
were difficult to measure at higher PACAP concentrations due to some post-
PACAP repetitive oscillations lasting tens of minutes.  To correct for the lag time 
between the loop injection and maximal stimulus delivery to the cells, the time 
between the start of loop injection to HK responses was subtracted from each 
PACAP trace.   To obtain the area under curve (Ca2+ flux), Origin 6.0 was used to 
subtract a baseline from the data. After baseline subtraction, the area under the 
curve of ∆F from the start of the response to 120 secs was calculated using 
GraphPad Prism 5. 
All cells that were counted as PACAP responding cells met the following 
three conditions:  Firstly, the PACAP-induced [Ca2+]i activity showed an 
amplitude increase of >5% above the baseline noise and a duration of >50 secs. 
Secondly, the response began at or after the average latency of HK (100–120 
secs).  Thirdly, the PACAP response started within the range of the HK duration, 
which is the approximate duration the antagonists would be on the tissue.  For 
the experiments involving antagonists, which might block PACAP responses in 
individual cells, one more condition was met; the HK was applied before and 
after each PACAP plus/minus antagonist treatment.  Only the PACAP-activated 
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cells that showed HK responses at the start and end of the series of runs were 
evaluated for PACAP responsiveness in the antagonists. 
For counting the total number of PACAP, GABA, control BSA, and HK-
responsive cells, the series of runs from each slice was exported from the LSM 
files (510 LSM Version 3.0 SP3) into ImageJ (http://rsbweb.nih.gov/ij/) as TIFF 
image sequence files of 200 to 500 images.  The first 20–40 images in the 
sequence were summed and used as a baseline for subtracting from the 
remainder of the sequence to yield a picture of fluorescence changes (a.k.a. 
responding cells) occurring after the baseline time range.  The baseline 
subtracted images showing responsive cells were superimposed on an image 
showing the red tdTomato labeled cells.  Responsive cell counts were 
categorized into red and nonred labeled groups for each test substance.  The 
counts were done blind. 
 
Results 
Heterogeneous PACAP Responses 
Application of 40 nM PACAP routinely elicited increases in [Ca+2]i in HK-
responsive cells in slices of P4 mouse OB (Fig. 2.2, A–E).  The PACAP-induced 
responses showed variation in latency and duration with some responses lasting 
over 20 minutes (Fig. 2.2 and data not shown).  The predominate response was 
a sustained increase in [Ca2+]i that reached a peak within seconds and then 
slowly returned to baseline over the course of minutes (796/1413 cells, 56%; Fig. 
2.2C).  The second most common response to PACAP was a single transient 
[Ca2+]i increase (simple bursts) that returned to baseline within the duration of the 
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HK response (305/1413 cells, 22%; Fig. 2.2, D and E).  Of the remaining 22% of 
PACAP responsive cells, the majority developed a slow “saw tooth” post-PACAP 
[Ca2+]i oscillation (0.01–0.04 Hz, 246/1413 cells, 17%; Fig. 2A) and a few cells 
developed a fast “saw tooth” oscillation (0.05–0.1 Hz, 66/1413 cells, 5%; Fig. 
2B). Kopp et al. (1999) found somewhat similar percentages in cultured SCNs: 
simple transients (20%), [Ca2+] oscillations (15%) and “sustained oscillations” 
(called biphasic response with initial [Ca2+] followed by plateau phase; 65%) 
(Kopp et al., 1999).  PACAP-induced [Ca2+]i oscillations lasted between 5 to 20-
plus minutes (Fig. 2.2, A and B).  Although the responses to PACAP were 
heterogeneous with cells in close proximity showing very different response 
patterns from each other, repeated PACAP application produced similar 
responses within the same cell (Fig. 2.3A). To determine the basis for the 
heterogeneity of the responses to PACAP, we examined the PACAP dose 
dependence, the kinetics, the developmental time course, and identified 
responding cell types within the GCL region of OB.  
 
PACAP Concentration-response Curve 
Dickson et al. (2006) tested the dose response curve of PACAP, VIP, and 
their antagonists using the cultured CHO cell line by measuring both the 
intracellular cAMP and Ca2+ concentrations (Dickson et al., 2006).  They reported 
the PACAP 27 EC50 to be 10 nM.  Because it is difficult to extrapolate from cell 
culture to in situ, we examined the dose dependence of PACAP 27 on slices from 
P2 to P5 pups.  Unlike most regions of the rodent CNS, PACAP and PAC1R 
were shown to be spatially enriched in the OB at P0 and maintained within the 
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OB throughout development.  The GCL in particular has high expression of 
PAC1Rs.  The MCL was shown as a mixture of PACAP and PAC1R expression 
(Jaworski and Proctor, 2000; , 2013).  For the dose curve (Fig. 2.3B), 
concentrations of PACAP were tested at 1, 10, 20, 40, 60, and 100 nM.  To 
minimize desensitization to repeated PACAP applications, the minimum 
washing/recovery time was empirically determined for each concentration.  Every 
slice had a maximum of four PACAP exposures with appropriate washing times 
between applications. 
The dose response curve is presented as the ratio of PACAP responsive 
cells divided by HK responsive cells. By normalizing to the number of HK 
responsive cells, we are counting the number of PACAP sensitive cells among 
the healthy neurons in the GCL.  For a slice to be deemed “healthy” we looked 
for approximately 80% of the visible cells to respond to HK. Thus, the dose 
response curve was based on the normalized percentage of PACAP responsive 
cells relative to the number of HK responsive cells recorded within 10 minutes of 
each PACAP application.  We found that the percentage of PACAP responsive 
cells significantly increased with concentration. Although the curve did not 
saturate, we did not use concentrations higher than 100 nM because the 
responses to 100 nM PACAP did not desensitize and were not blocked with 
PAC1R antagonists.   
Dickson et al. (2006), who used cultured CHO cells, did dose curves for a 
variety of PACAPs, VIPs, and their antagonists/agonists (Dickson et al., 2006).  
Interestingly, even though the CHO-cells PACAP [Ca2+]i EC50 was 3–5 nM, 
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blocking about 80% of the 30 nM PACAP [Ca2+]i activity required 10 µM M65 [a 
specific PAC1R antagonist from sand flies, (Yu et al., 2008)].  We found that a 
cocktail of 1 µM M65 and 150 nM PACAP 6-38 [a truncated version of PACAP 
which competitively binds the receptor (Robberecht et al., 1992)] was able to 
block an average of 84 ± 4% of 40 nM PACAP responses (52/278 cells; n = 5; p 
< 0.05 paired t-test).  This confirms that the majority of the 40 nM PACAP 
responses in slices are blocked by the well characterized PAC1R antagonists 
(Fig. 2.3C). 
  
Kinetics of PACAP Responses 
To see whether there are any age-related changes in the kinetics of the 
PACAP effects, the slices were age-grouped as P2, P3, P4, and P5.  The slices 
were treated using one of the two series of PACAP concentrations.  The 10-20-
40-60 nM PACAP series was tested on slices from 13 pups.  The 20-60-40-100 
nM PACAP series was tested on slices from 5 pups.  No significant age-
dependent or series dependent kinetic changes were found between P2 to P5 
(data not shown).  Thus, the slices were pooled together regardless of age 
between P2 to P5 for the kinetic analyses. 
We measured the kinetics and amplitude of the PACAP-induced [Ca2+]i 
activity as outlined in Fig. 2.1.  We found that on average, the latency for PACAP 
responses decreased with increasing concentrations (significant between 10 nM 
and 20 nM to all higher concentrations [p < 0.0001, unpaired t-test; Fig. 2.4A)]. In 
addition, the time to peak also shortened between 40 nM to 100 nM, but was not 
statistically significant (p = 0.06, unpaired t-test; Fig. 2.4B).   
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The dose-dependent changes in fluorescence intensity amplitude with 
PACAP application did not follow a classic dose-response curve. Figure 2.4C 
shows that the average amplitude of PACAP responses increased significantly 
with concentrations up to 40 nM PACAP (range from p ≤ 0.01 to p < 0.0001, 
unpaired t-test).  Both 60 nM and 100 nM PACAP concentrations elicited 
significantly lower average PACAP response amplitudes (p < 0.05 between 40 
nM and 100 nM; p < 0.001 between P40 and P60, unpaired t-test). By comparing 
amplitude histograms of PACAP responses to 40 nM with 100 nM PACAP, we 
observed a shift towards more cells with smaller amplitudes at 100 nM PACAP 
(Fig. 2.4E). The shift suggested that 100 nM PACAP might be recruiting 
downstream cells or perhaps cells with low PAC1R expression.  To answer 
whether the higher PACAP concentrations prolong the cell [Ca2+]i activity, the 
area under curve or Ca2+ flux was measured for the first 120 secs after PACAP 
reaches the slice (as determined by HK application).  Figure 2.4D shows an 
overall increase in Ca2+ flux with increasing PACAP concentrations.  The average 
Ca2+ flux of 100 nM PACAP responses is significantly greater than 20 nM, 40 nM, 
and 60 nM PACAP.  Additionally, the Ca2+ flux induced by 20 nM PACAP is 
significantly lower than that of 40 nM and 60 nM PACAP (p ≤ 0.0006 or p < 
0.0001, unpaired t-test).  However, the Ca2+ fluxes [areas under the curves (∆F-
seconds)] were not significantly different when comparing 40 nM and 60 nM 





Direct Versus Indirect PACAP Effects 
The observation of a larger response amplitude at 40 nM as compared to 
60 nM PACAP, as well as the ability to effectively block 40 nM PACAP, 
suggested that 40 nM was the ideal concentration for physiological experiments 
done on live acute OB slices.  Therefore we used 40 nM PACAP for evaluating 
PACAP responses in the remainder of the studies.  Because the dose-response 
curve for PACAP did not appear to saturate and showed the surprising increase 
in low amplitude responses at 100 nM PACAP, we questioned whether PACAP-
induced increases in [Ca2+]i were causing downstream glutamate or GABA 
release, which in turn increased the number of responsive cells.  To tease out the 
cells that were directly activated by PACAP from those responding to possibly 
glutamate or GABA, we applied 40 nM PACAP in the presence and absence of a 
series of cocktails of neurotransmitter antagonists described in the Methods.  The 
first cocktail (Glu/GABA/Na) was designed to block all downstream 
neurotransmission and any other possible pathways that may elevate the [Ca2+]i 
in interneurons.  
The Glu/GABA/Na cocktail contains antagonists for blocking NMDA, 
AMPA, mGluR (all types), GABAA, and GABAB receptors.  TTX was included to 
reduce occasional spontaneous action potentials.  [The sodium channels 
however may have little to no role in PACAP downstream mechanisms (Pugh et 
al., 2010)].  We found that on average, the Glu/GABA/Na cocktail reduced the 
percentage of PACAP responding cells to 32 ± 5% of the PACAP control done on 
the same slice, (41/139 cells; n = 4 slices; Fig. 2.5).  Overall, 41 of the 139 cells 
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that responded to the PACAP control also responded to PACAP + Glu/GABA/Na 
antagonists and were therefore directly activated by PACAP.  We evaluated the 
kinetics of those 41 cells using the same approach as for PACAP at different 
concentrations (Fig. 2.6A).  Only the latency was not significantly changed.  
Amplitude (p = 0.01, paired t-test), time to peak (p < 0.01, paired t-test), and the 
area under curve (p < 0.001, paired t-test) were significantly reduced in the 
presence of the antagonist cocktail, suggesting the involvement of GluRs and 
GABARs in the [Ca2+]i response to PACAP even within cells directly activated by 
PACAP (Fig. 2.6B). 
To examine the independent effects of the downstream glutamate 
receptors (GluRs) versus GABA receptors (GABARs) in the presence of PACAP, 
the antagonist cocktail described above was separated into two groups.  The 
groups are GluR-only antagonists (NMDA, AMPA, and mGluRs) and GABAR-
only antagonists (GABAA and GABAB).  The antagonist for sodium channels 
(TTX) was not included in the individually grouped cocktails because we wanted 
to see whether blocking one or another group had consequences on the 
occasional global spontaneous action potentials (none was seen within the 
duration time of blockage; data not shown).  Addition of GluR antagonists 
reduced the number of PACAP-responding cells to 26 ± 3% of PACAP control 
(31/118 cells, n = 3; Fig. 2.5).   GABAR-only antagonists reduced PACAP 
responses to 54 ± 11% of the PACAP control (67/129 cells, n = 4; Fig. 2.5).  This 
indicates that GluRs are the main contributor to the downstream [Ca2+]i activity.  
GABARs appear to augment the activity of GluRs, by either increasing or 
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decreasing the [Ca2+]i response intensity, depending on cell maturity. GABA is 
excitatory in neuroblasts and immature neurons, further increasing the post-
PACAP [Ca2+]i activity. In mature neurons, GABA is inhibitory and may decrease 
the elevation of [Ca2+]i in the PACAP control. PACAP responses in mature 
neurons show a greater increase in [Ca2+]i in the presence of GABAR antagonists 
due to less GABAergic inhibition. A subset of slices was tested with both blocker 
cocktails sequentially. PACAP-responsive cells were activated by PACAP in the 
presence of GABAR-only antagonists but their response to PACAP was blocked 
by GluR-only antagonists (24 out of 40 cells; n = 2) further supporting the 
conclusion that the majority of the downstream PACAP-induced effects are 
mediated by glutamate (Fig. 2.7).  
 
PACAP Effects on Non-GC Cells of OB 
 The GCs activity within the OB network can be influenced by negative and 
positive feedback of other types of OB cells.  The glutamatergic PAC1R+ mitral 
cells (labeled with PCdh21 tdTomato), which release glutamate onto GCs, 
responded to 40 nM PACAP, typically initiating the sinusoidal-like waves shown 
in Fig. 2.8.  Blanes cells are also PAC1R+, and they release GABA 
neurotransmitters onto hundreds of GCs throughout the GCL (Pressler and 
Strowbridge, 2006).  Cells of appropriate size and location to be Blanes cells 
responded to 40 nM PACAP with transient [Ca2+]i increases (unpublished 





Role of PACAP in Maturation of Dlx2 and GAD65  
tdTomato Expressing Cells in GCL 
The connection of GCs to the OB network depends on the maturity of the 
cells.  In the next section, we look at the rapidly developing OB between P2 to 
P5.  It is known that the interneuron precursors (neuroblasts) take about 3 days 
to migrate from their origin in the subventricular zone (SVZ) to the OB, which not 
surprisingly correlates with the rapidly growing OB increasing from 25% of adult 
interneurons at P0 to 55% by the end of the first week (Lemasson et al., 2005). 
In order to specifically identify PACAP responsive cells in the GCL, we 
primarily used two lines of IRES-CRE-linked transgenic mice:  Dlx2-CRE and 
GAD65-CRE, which were crossed with the Rosa-tdTomato (using the ROSA26-
CAG promoter) transgenic mice line to provide gene-specific red cells.  The 
ROSA26-CAG promoter was used to label IRES-CRE-linked Dlx2, an essential 
migrating gene, at the neuroblast stage (Batista-Brito et al., 2008).  The SVZ-
born Dlx2-labeled neuroblasts, which have migrated to the olfactory bulb, 
become both types of GABAergic GCs (GAD65 and GAD67) as well as 
periglomerular cells (Plachez and Puche, 2012).  Although Dlx2 is switched off in 
mature cells, the red fluorescence remains throughout the cell lifespan.  The 
Dlx2-tdTomato is expected to label the majority of GCs residing in the GCL 
(Potter et al., 2009).  Figure 2.9 shows the expression of Dlx2 tdTomato (red) in 
12 µm sections of OB from P2 and P4 mice.  PAC1R-specific antibody labeling 
(green) colocalizes with a subset of Dlx2 expressing cells in the GCL and labels 
mitral cells in the MCL. Compared to total cell counts using DAPI nuclear 
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staining, 89% (1735/1945; n = 2) of GCL cells are Dlx2+ and 21 ± 1% (535/3160 
cells; n = 3) are colabeled with PAC1R antibodies at P2, while in the P4 OB, the 
percentage of cells colabeled with both Dlx2+ and PAC1R antibody increases to 
34 ± 1% (836/2979 cells; n = 4).    The 34 ± 1%  of PAC1R+ cells in the 
immuncytochemistry (ICC) at P4 correlates nicely with the percentage of cells 
that responded directly to PACAP in the presence of Glu/GABA/Na antagonists 
(32 ± 5%; ages P4–P6; Fig. 2.6).  The second transgenic mice line was the 
GABAergic GAD65 tdTomato, in which the ROSA26-CAG promoter was used to 
label the IRES-CRE-linked GAD65 gene.  The use of the GAD65 label helps 
narrow the evaluation of the cells in the GCL down to two GABAergic subtypes.  
In 8-week old mice, about 50% of the OB GABAergic GCL cells express GAD65 
(Parrish-Aungst et al., 2007).  The other 50% are generally the larger GAD67 
expressing cells.  However, 20% of the GABAergic GCL cells are capable of 
expressing both GAD65 and 67 (Parrish-Aungst et al., 2007).  GAD65 and 
GAD67 protein expression is not turned on until the cells exit the migratory 
pathway, but these subtypes are predetermined while still neuroblasts in the 
SVZ. The similar timings of protein expression suggest that both subtypes enter 
the OB at similar developmental stages (Plachez and Puche, 2012; De et al., 
2007; Kelsch et al., 2007; Merkle et al., 2007).  Figure 2.10 shows the labeling of 
GAD65 (red) in P2 and P4 mice.  The Dlx2 and GAD65 transgenic lines were 
used for the identification of mature and immature neuronal cells in the PACAP 





Using GABA Responses to Identify Immature GCs 
To help discern whether PACAP is activating mature or immature GCs, we 
used GABA to elevate the [Ca2+]i in immature cells.  Figure 2.11 is a diagram 
showing how the GABA neurotransmitter acts as an excitatory neurotransmitter 
in migrating neuroblasts or immature neurons.  In neonatal OBs, the immature 
neuroblast cells elevate internal [Ca2+]i in response to GABA as they migrate over 
long distances to their destinations (Dzhala et al., 2010; Tong et al., 2009; Darcy 
and Isaacson, 2009; Mejia-Gervacio et al., 2011; Wang and Kriegstein, 2008).  
GABA binds to ionotropic GABAA receptors and the cell will either depolarize or 
hyperpolarize, depending on intracellular Cl- concentration. Immature neurons 
maintain high intracellular Cl- levels via activity of highly expressed Na+-K+-Cl- 
cotransporter 1 (NKCC1) transporting Cl- into the cell (Dzhala et al., 2010; 
Takayama and Inoue, 2004; Glykys et al., 2009; Wang et al., 2005).  Thus 
GABAA receptor activation of migrating neuroblasts and immature neurons 
causes Cl- to exit the cell.  The resulting Cl- efflux depolarizes the cell and opens 
the voltage-gated Ca2+ channels (Glykys et al., 2009).  In mature neurons, 
NKCC1 is downregulated and internal Cl- is kept low with the increased 
expression of K+- Cl- cotransporter 2 (KCC2), so opening of GABAA channels 
hyperpolarizes the cell. Thus immature neurons can be physiologically 
distinguished from mature neurons by [Ca2+]i responses to GABA (Wang and 
Kriegstein, 2008).  Figure 2.12A shows an example of a functionally immature 
cell responding to 50 µM GABA with an increase in [Ca2+]i.   
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Based on Ca2+ responses to sequential application of GABA and PACAP 
(Fig. 2.12B), 3 groups of cells were identified in the GCL of neonatal OB. The first 
group is the “GABA-only” GCs, which respond to GABA and not PACAP (Fig. 
2.12C).  The GABA-only GCs may or may not become PAC1R+ when mature.  
The ‘GABA+PACAP’ group in Fig. 2.12C includes the GCs that respond to both 
GABA and PACAP with increases in [Ca2+]i, implying that they are immature cells 
with either expression of PAC1Rs on the plasma membrane or some early 
connections formed.  The “PACAP-only” group in Fig. 2.12C includes the 
presumably mature GCs that respond to PACAP but do not increase [Ca2+]i in 
response to GABA.  Both transient increases and repetitive oscillations in [Ca2+]i 
activity are seen for PACAP-responsive cells in the GABA+PACAP and PACAP-
only groups (Fig. 2.12C).   
 
Age-related Increases in the Percentage of  
PACAP Responsive Granule Cells 
Figure 2.13A shows the calculated percentage of all GABA and/or PACAP 
responsive cells labeled red for Dlx2.  The graph shows a shift in the percentage 
of immature GABA-only cells at P2 (n = 8 mice; 867 cells) to mature PACAP-only 
cells at P5 (n = 5 mice; 967 cells). This shift suggests that GCs express 
functional PAC1 receptors during their maturation process.  The nonred cell 
counts in the images taken from Dlx2-dt Tomato mice made up 6% (165/2708 
cells; n = 20 mice) of the GABA and/or PACAP responsive OB GCL cells across 
all ages evaluated.  The Blanes cells, which originate in the OB and do not 
migrate from the SVZ (Plachez and Puche, 2012), may account for 2–3% of the 
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unlabeled population.  The other 3–4% of unlabeled responsive cells might be 
other non-Blanes interneurons in the GCL.2  (The glial cells such as astrocytes 
are not a factor in the analysis, please see discussion.)  
Figure 2.13B shows the calculated percentages of all GAD65+ GABA 
and/or PACAP responsive cells.  The graph shows no significant change for all 
three groups within the age range studied.  Figure 2.13C shows the percentages 
of the GAD65 dtTomato nonred cells (GAD65-), which we assume to be GAD67 
cells since all of the interneurons in the GCL are either GAD65+ or GAD67+ or 
both GAD65+ and GAD67+ (Batista-Brito et al., 2008; Lemasson et al., 2005; 
Parrish-Aungst et al., 2007).  As with the Dlx2 labeled cells, the GAD65- cells 
shifted from mostly GABA-only cells to PACAP-only cells between P2 (n = 3 
mice; 41 cells) and P5 (n = 8 mice; 67 cells).  Out of all of the GABA and/or 
PACAP responsive GAD65- cells, those responding only to GABA (immature) 
made up an average of 50 ± 3% at P2 (20/41 cells) and decreased to 24 ± 6% by 
P5 (18/67 cells) (p < 0.005).  Those cells responding to both GABA and PACAP 
(maturing) decreased from an average of 30 ± 2% at P2 (12/41 cells) to 11 ± 3% 
by P5 (8/67 cells) (p = 0.001).  Conversely, although only an average of 20 ± 5% 
of the GAD65- cells responded to PACAP at P2 (9/41 cells), their numbers 




                                            
2 Pressler et al (2006) accumulated an informal list of GCL minority cells: Golgi 
cells (deep GCL), Stellate cells (deep GCL), Vertical cells of Cajal, Bitufted 





In the studies described above, we found that PACAP is capable of 
eliciting [Ca2+]i responses in cells at various stages of maturation in the GCL and 
ML of the olfactory bulb in P2–P5 mice. We found that the PACAP-induced 
[Ca2+]i changes were heterogeneous and dependent on both direct activation of 
PAC1 receptors and on subsequent recruitment of additional cells through 
downstream release of glutamate and GABA. The percentage of functional 
PAC1R expressing cells in the GCL that were directly activated by PACAP 
increased over the P2–P5 time window and matched the percentage of PAC1R+ 
cells identified by immunocytochemistry.  By utilizing mouse lines that express 
the red tdTomato in specific cell types, we determined that the Dlx2+ cells that 
migrate into the OB via the RMS are capable of responding to PACAP before 
they transition to mature GCs. The further subdivision of the migrating GC 
population into GAD65 and GAD67 subtypes revealed the surprising observation 
that the time-dependent increase in mature PAC1R expressing cells observed in 
the Dlx2 studies occurs as a result of maturation in the GAD67 GCs but not the 
GAD65 GCs. This observation supports our hypothesis that PACAP activation of 
immature GCs initiates developmentally important [Ca2+]i oscillations during the 
first postnatal week of development.  
The OB interneuron response to PACAP in acute slices shows that the 
majority of the [Ca2+]i activity occurs through downstream activation of both the 
glutamate and GABA receptors on non-PAC1+ GCs, providing a wide variety of 
[Ca2+]i activity responses ranging from simple transients, slow to fast saw tooth 
  
47
oscillations, and sustained oscillations (Fig. 2.2).  Possible factors contributing to 
the variety of responses are the dose of PACAP (Figs. 2.3 and 2.4) and the 
downstream PACAP-induced activation of glutamate and/or GABA receptors 
(Figs. 2.5, 2.6, and 2.7).  The time to peak is constant across the concentrations 
tested, but was shown to decrease in Glu/GABA/Na antagonists.  The faster time 
to peak when downstream contributions to the [Ca2+]i signal are blocked supports 
the idea that PAC1R activation initiates the [Ca2+]i response, but it is the PACAP-
mediated GABA and glutamate release that augments the signal in both the 
directly and indirectly activated cells.  The increase in Ca2+ flux with increased 
concentrations of PACAP suggests an increasing glutamate and/or GABA 
release onto GluRs and/or GABARs.  This is supported by the observation that 
the co-application of GluRs and/or GABARs antagonists with PACAP reduced 
the PACAP-induced [Ca2+]i increases in the majority of cells (Fig. 2.7).  
Collectively, these findings suggest that PACAP may be an important modulator 
of glutamate and GABA release in developing mouse OB.  
The factor appearing to have no significant effect on PACAP-induced Ca2+ 
kinetics and intensities during first neonatal week is age; the P2, P3, P4, and P5 
age groups show similar responses in terms of latency, time to peak, amplitude 
and Ca2+ flux (data not shown).  However, the percentage of PACAP-responding 
cells does rapidly increase during the first neonatal week (Fig. 2.13.)  The day-to-
day shift from immature GABA-only neuroblasts at P2 to mature PACAP-only 
GCs at P5 appears to be driven by the maturation of the GAD67 subtype of GCs.  
The increase in PACAP responsive cells correlates with the noted increase in 
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PAC1R+ between P2 and P4 according to the ICC results [21 ± 1% in P2 (n = 3; 
3160 cells); 34 ± 1% in P4 (n = 4; 2979 cells)].   
Despite having the same rate of development as GAD65 cells upon 
entering the OB, the GAD67 cell subtype develops complicated connections to 
PAC1R+ projection neurons such as MCs (Plachez and Puche, 2012).  It is still 
unclear when, if actually ever, the GAD65 subtype GCs shift from mostly 
immature, PACAP unresponsive cells to mature PACAP-responding ones.   
 
Dose Dependence and Block of PACAP Responses 
The reported EC50 for PACAP responses ranges between 0.25 and 3 nM 
in cell culture systems, and increases to 30–50 nM PACAP in acute slices  
(Jozwiak-Bebenista et al., 2007; Kambe and Miyata, 2012; Nicot and Dicicco-
Bloom, 2001; Dickson et al., 2006).  In vitro experiments used as much as 100 
nM PACAP (one used 200 nM) to obtain maximal neuroprotective effects 
(Basille-Dugay et al., 2013; Dziema and Obrietan, 2002; Kopp et al., 1999; Kopp 
et al., 2001; Masmoudi et al., 2003; Pugh et al., 2010; Scharf et al., 2008; Vaudry 
et al., 2002).  At least one lab also used extremely high [PACAP] doses in slices 
(Sun et al., 2003).   In contrast to the studies in cell lines, Jozwiak-Bebenista et 
al. (2007) measured a PACAP EC50 ~0.25 nM for both primary cultured neuron 
and astrocyte cells.  They also tested acute cerebral cortical slices, which are 
PAC1R+ rich compared to the majority of the CNS apart from the OB and 
obtained an EC50~30 nM (Jozwiak-Bebenista et al., 2007).  At least two different 
studies (Masmoudi et al., 2003; Vaudry et al., 2002) confirmed that responses to 
100 nM PACAP in cultured cells are blocked using only PACAP 6-38 (PACAP 38 
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with first 6 peptides deleted).   Other studies used between 1 to 10 nM PACAP in 
the cultures and showed block using only PACAP 6-38 (Kambe and Miyata, 
2012; Shioda et al., 2006; Vaudry et al., 2002).  The doses of PACAP 6-38 were 
reported to be 600 to 1000 nM.  The dose-response curve for our OB slices 
suggested that 40 nM PACAP is ideal for our [Ca2+]i imaging approach because 
response amplitudes decreased at higher PACAP concentrations possibly due to 
desensitization during the PACAP application.  Unlike the previous cell culture 
studies, we were unable to completely block 40 nM PACAP-induced [Ca2+]i 
activity when using as much as 1 µM PACAP 6-38 (data not shown), perhaps 
because we study our cells in slices.  Costa et al. (2009) used hippocampus 
slices, and they were able to block 0.5 nM PACAP with 500 nM PACAP 6-38.  
However, at 10 nM, PACAP was not blockable at 500 nM PACAP 6-38 (Costa et 
al., 2009).  
PACAP has the characteristics of other cell-penetrating peptides and was 
shown capable of crossing the plasma membrane through direct translocation 
and endocytosis, without the aid of receptors (108;109).  Intracellular PACAP is 
able to activate the intracellular PAC1Rs N-terminal ends.  PACAP also moves 
from cell to cell and exits back out into extracellular space (Doan et al., 2012a; 
Doan et al., 2012b).  This is noteworthy because it may explain why responses to 
100 nM PACAP are unaffected by the PAC1R antagonist cocktail used to reduce 
40 nM PACAP by 84 ± 4%. Furthermore, 100 nM PACAP responses are not 
blocked by the cocktail of Glu/GABA/Na blockers (data not shown).  Collectively, 
our data suggest that responses to 100 nM PACAP may be insensitive to PAC1R 
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antagonists because PACAP is translocated and acting intracellularly. The 16% 
of the 40 nM PACAP responses that are not blocked by PAC1R antagonists may 
also reflect intracellular PACAP activity. Studies beyond the scope of the present 
work will be required to confirm these observations. Other less likely explanations 
include activation of VPAC1/2Rs by the 100 nM PACAP as discussed below. 
 
VPAC Receptors Are Not Mediating PACAP Responses 
PACAP acts primarily through PAC1Rs.  However, PACAP also can 
trigger Ca2+ increases through VPAC1/2Rs (Inglott et al., 2012).  The question of 
whether 100 nM PACAP was not blocked by PAC1R antagonists due to the 
activation of VPAC1/2Rs was considered.  The VPAC1/2Rs are the primary 
receptors for vasoactive intestinal peptide (VIP).  Interestingly, no VIP-induced 
Ca2+ activity was observed when up to 1 µM VIP was applied to the slices from 
mice < P5 in age with (data not shown.)  Concentrations of VIP higher than 1 µM 
were not tested because this amount has the potential of acting through the 
PAC1Rs (Dickson et al., 2006).  At least one other lab reported no [Ca2+]i activity 
when 100 nM VIP was applied to cultured suprachiasmatic nucleus from 1–7 
neonatal day old rats (Kopp et al., 1999).  The Allen Brain Atlas mRNA labeling 
of VPAC1/2Rs was shown in OBs of older mice.  The OBs of the P4 mice 
however have no detectable VPAC1/2R expression (Allen Brain Altas, 2013).  
What may correlate to the difficulty of blocking 100 nM PACAP in situ was the 
recent finding discussed above suggesting that the PACAP peptide is membrane 
permeable, activating the intracellular PAC1Rs and sometimes repermeating 
upon exit from the cells (Dickson et al., 2006; Doan et al., 2012a).    
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Direct vs Indirect PACAP-induced Ca2+ Transients  
and Oscillations 
PACAP binding to PAC1Rs is capable of activating numerous pathways 
that increase [Ca2+]i, including Ca2+-dependent synaptic release and Ca2+-
induced Ca2+ release  (Kambe and Miyata, 2012; Pugh et al., 2010; Doan et al., 
2012a; Doan et al., 2012b).  The black arrows in Fig. 2.7 show the initiation of a 
Ca2+ oscillation at the approximate time when the applied PACAP and the GluR + 
GABAR antagonists are washed out.  This suggests that the directly activated 
PAC1R+ cells increase [Ca2+]i and synaptically release glutamate and/or GABA 
onto both immature and mature cells to prolong the oscillation (Figs. 2.2, 2.5, 2.6, 
and 2.7).  The role of GluRs and/or GABARs on the pattern of oscillation was 
individual and independent.  The uniqueness of each oscillation pattern likely 
depends on the network connections, cell maturity (GABA-induced excitation 
discussed below), and expression of the GluRs and/or GABARs.  The PACAP-
induced downstream oscillations are catalogued into three general groups.  
Figure 2.7A shows an example cell believed to be PAC1R+ and directly-activated 
by PACAP because it showed strong PACAP response regardless of 
antagonists.  Figure 2.7B shows an indirectly activated cell in which PACAP-
induced Ca2+ oscillations were present when GABAR-only antagonists were co-
applied with PACAP, but the GluR-only antagonists completely blocked the 
PACAP-induced calcium activity.  Figure 2.7C shows an example cell in which 
PACAP responses are blocked by both groups of antagonists and displays only 
indirect post-PACAP activation after the antagonists and PACAP are washed out 
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(black arrows).  The example cells showed that any of these cells may have 
different post-PACAP [Ca2+]i oscillations compared to PACAP-control when 
GluRs and/or GABARs were blocked in PACAP treatment (Fig. 2.7, A, B, and C).  
Figure 2.6 showed that when antagonists block Glu/GABA input, the PACAP-
induced Ca2+ responses are significantly reduced in terms of amplitude, time to 
peak, and total Ca2+ flux.   
The vehicle controls of the antagonist cocktails showed no [Ca2+]i activity 
in the presence of the Glu/GABA/Na cocktail.  However, in the case of either 
GluR-only cocktail or GABAR-only cocktail antagonist controls, the cells often 
displayed brief [Ca2+]i transients (~50 second bursts of Ca2+ activity; blue arrows, 
Fig. 2.7) before the typically delayed start of the PACAP long-term [Ca2+]i activity.  
The antagonist-induced activity is likely due to a block of the essential 
feedforward and feedback signaling between the GABAergic and glutamatergic 
OB cells.  When blocking only the GABARs (Fig. 2.7B), a temporary lack of 
inhibition in mature cells with GluRs may account for the increased [Ca2+]i activity 
throughout the OB network.  The lower effectiveness of GABAR antagonists in 
reducing indirect PACAP responses suggested that the majority of PAC1R 
negative cells are either mature GCs or immature GCs with GluRs.   
 
GABA as an Excitatory Marker of Immature GCs 
The neurotransmitter GABA has been was shown to either inhibit or excite 
the GCs depending on the [Cl-]i.  GABA excitation occurs in immature cells with 
high [Cl-]i and can be monitored as increased [Ca2+]i in response to GABA-
induced depolarization and activation of voltage-gated Ca2+ channels. Excitatory 
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GABA is believed to aid in the precise, orchestrated development of the OB 
interneurons (Mejia-Gervacio et al., 2011; Takayama and Inoue, 2004; Gascon et 
al., 2006).  The GABA as an excitatory transmitter concept was challenged and 
proposed to be an artifact due to traumatic changes in conditions when making 
and recording from slices (Bregestovski and Bernard, 2012; Khakhalin, 2011).  
Ben-Ari (2012) counterchallenged the suggestion that GABA excitation was an 
artifact in slices.  A few of the many points presented were 1) adult slices are 
more susceptible to energy deprivation, but they do not generate the GABA 
excitatory action thought to occur in injured neurons.  2) The MCs, which were 
matured by P0, were inhibited by GABA.  GCs on the other hand are a mixture of 
immature and mature cells, especially during the first postnatal week and can be 
depolarized and/or excited by GABA.  Both of these types of cells are at similar 
depths.  3) In many studies in which both surface and deep neurons were 
recorded, the cells showed similar profiles with no signs of swelling (Ben-Ari et 
al., 2012; Wang et al., 2005; Wang et al., 2008).   
The GABA-induced simple Ca2+ transients, however, do not always show 
up, as in a couple of traces marked with a “?” in Fig. 2.7.  Chub and O’Donovan 
(2001, 2005, and 2006) used data from chick embryos to suggest that the 
occasional absence of GABA-induced Ca2+ activity is because the intracellular 
Cl- concentration has temporarily decreased to the point of being less excitatory 
when the GABAA receptors open.  The Cl- transporters are shown to be relatively 
slow in accumulating Cl- back into the cell (Chub and O'Donovan, 2001; Chub et 
al., 2006; Marchetti et al., 2005). 
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Astrocytes Are Not a Factor in Data Analysis 
Astrocytes are PACAP and GABA excitable (Hansson et al., 2009; 
Jozwiak-Bebenista et al., 2007).  The EC50 of PACAP in cultured glial cells 
(astrocytes) is almost exactly the same as for cultured neuronal cells.  However, 
when we used SR-101 (a red dye labeling astrocytes) on slices, we find 
astrocytes to be star-like shaped cells appearing as “background” and having 
little to no [Ca2+]i response to 40 nM PACAP, suggesting that the astrocytes in 
OB slices have a different physiology than in cultures and/or higher EC50 than the 
surrounding OB interneurons.  The concentration of GABA used in our 
experiments was 50 µM.  Doengi et al. (2009) used [Ca2+]i signaling to determine 
the GABA EC50 of 35 µM in neurons and 100 µM in astrocytes with a few 
astrocytes responding to 20 µM GABA (Doengi et al., 2009).  Accordingly, our 50 
µM GABA may excite a small number of astrocytes.  However, the unique star-
like shape of astrocytes with typically weak [Ca2+]i intensity is discernible from the 
smaller, rounder, stronger [Ca2+]i intensity GCs.   
 
Cell Types and Development in GCL 
For the age range (P2 to P5) studied, about 97–98% of the OB GCL is 
composed of GCs and the other 2–3% is made of primarily large, rotund, 
GABAergic Blanes cells.  [The percentage of the Blanes cells to other types of 
OB cells diminishes down to 1–2% when the OB reaches adult size (Batista-Brito 





The majority of Fig. 2.13A Dlx2-labeled GCs shifted from immature cells 
that only responded to GABA at P2 to mature GCs that only respond to PACAP 
by P5.  The relatively rapid changes in maturation over the 3-day period may be 
affected by the migration of SVZ progenitors covering the distance to the OB in a 
matter of 3 days [in rats; this may happen in less time for mice, which are smaller 
and faster developing (Yang, 2008)].  The survivorship of newly generated cells 
in the GCL may change with age, but the data in the work done by Lemasson et 
al. (2005) suggested that the density of surviving cells was unchanged between 
P3 to P7 (Lemasson et al., 2005).  This may mean the survival of cells in the age 
range studied may have little to no factor in the shift.  Dlx2 labels both GAD65 
and GAD67, so GAD65 was evaluated as a subtype of GCs.  Interestingly, 
GAD65-labeled GCs showed no significant shift from GABA-only to PACAP-only 
(Fig. 2.13B).  The significant shift from GABA-only to PACAP-only for Dlx2+ GCs 
may be the GAD67 cells, the results for which (Fig. 2.13C) are similar to the 
results for Dlx2+ GCs (Fig. 2.13A).  The PAC1R+ GAD67 cells in general may 
need to mature within the first week as they are multiglomerular neurons 
connecting to a broader complex network within the GCL, while GAD65s neurons 
have uniglomerular dendritic projections (Kiyokage et al., 2010; Parrish-Aungst et 
al., 2007).  In the GAD65 cells, the ratio of GABA to PACAP responding cells 
                                            
3 In the Batista-Brito 2008 reference, the Blane cells are said to be derived from 
the Dlx1/2 expressing precursor domain, but in the Dlx2 dt-Tomato transgenic 
mice used for both the ICC and calcium imagings, the Blane cells do not appear 




may change outside the age range studied.  The hypothesis for any future 
evaluation is that the change among GAD65 cells may occur somewhere 
between about P7 and P14.  Supporting this hypothesis are the other studies 
suggesting that the OB reaches 80% of the average adulthood number of cells at 
P7 (98% for P14) (Lemasson et al., 2005; Mirich et al., 2002).  Furthermore, 
norepinephrine modifies the OB response in neonatal pups and the supply of this 
neurotransmitter from the locus coeruleus is reduced at P10 (Raineki et al., 
2010).  In addition, Lopez-Bendito et al. (2004) showed an increase in GABA 
production in GAD65+ cells [indicating mature interneurons acting as inhibitors 
between E18 (48%) and P21 (70%) (Lopez-Bendito et al., 2004)].  Since we see 
no GAD65+ cells shift from immature excitatory GABA responsive cells to mature 
GCs that only show excitatory responses to PACAP between P2 and P5, the 
significant maturation of GAD65+ cells is expected to occur in the second to third 
postnatal week.   
 
Conclusion 
Cells that migrate into the OB during the first postnatal week initially have 
high excitatory responses to GABA and low responses to PACAP. However, 
even by P2 there are cells that are in all stages of functional maturation in terms 
of responding to both PACAP and GABA or only responding to PACAP.  Our 
studies indirectly show that the cells mediating the shift in maturation profiles are 
the GAD65- cells, which we assume are GAD67+ since that is the only other GAD 
expressing interneuron in the OB.  PACAP seems to initiate long lasting [Ca2+]i 
activity in the developing OB that is mainly amplified by glutamatergic pathways, 
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but there is also a significant contribution from GABA. While it is still unclear as to 
the developmental role of PACAP in postnatal development, these studies clearly 
show that PAC1 receptors become functional while the cells are still in the 
maturation process and remain functional after cells mature.  The GCL network 
of GluRs and/or GABARs has an important role in modulating the [Ca2+]i activity 
in both immature and mature GCs.  The suggestions for future works are to 
better understand why GAD67 and GAD65 appear to have a majority shift from 
immature to mature cells at seemingly different time windows even through both 
subtypes develop and function during a similar time window.  It is not as clear 
when most GAD65 cells will mature as it is as for GAD67 cells, but the GAD65 
window appears to not be during the first neonatal week.   
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Fig. 2.1:  The PACAP induced [Ca2+]i transient was analyzed for latency, time to 
½ peak, amplitude, and net Ca2+ flux (area under curve for the first 120 seconds 
of PACAP responses). All of the PACAP response latencies were measured 




Fig. 2.2: PACAP induces a large initial transient increase in calcium 
followed by an increase in the number of oscillating neurons in OB slices.  
A time series of confocal images from a Fluo4-loaded slice of P4 mouse OB 
shows the changes in [Ca2+]i in response to 40 nM PACAP.  The trace in (A) 
reflects the ∆F changes over time for the region of interest (ROI) within the pink 
circle. The asterisks are near two additional cells that oscillated in response to 40 
nM PACAP.  The arrows match the images in A to the time points on the trace. 
The blue bar indicates the duration of 40 nM PACAP application (~100 secs). 
The PACAP-induced calcium oscillations of 1413 cells (from 37 pups) were 
categorized into four main groups:  (A) Slow sawtooth oscillation, 17% of cells.  
(B) Fast sawtooth oscillation, 5% of cells  (C) Sustained response, 56% of cells   
(D) Initial simple transient (returns to baseline within 100 seconds), 22% of cells. 
(E) The 50 mM HK is used to confirm the vitality of the cells and 0.1% BSA, 
which is mixed in with PACAP to keep the protein from sticking to the side of 







Fig. 2.3:  PACAP elicits dose dependent increases in the numbers of 
activated cells.  (A) Two sample examples of repeated 40 nM PACAP 
application on two different cells.  (B)  A log scale plot of the number of PACAP-
responsive cells divided by the number of HK-responsive cells shows that the 
increases in cell numbers do not saturate with a relatively high PACAP 
concentration of 100 nM.  (C) The percentage of cells responding to 40 nM 
PACAP is reduced by 84 ± 4% in the presence of PAC1R antagonists (1 µM M65 
and 150 nM PACAP 6-38). Numbers near the dots indicate number of pups, then 














Fig. 2.4: The kinetic and intensity responses to increasing PACAP 
concentrations are dose-dependent.  (A) The response latency significantly 
decreased by 45% between 10 nM to 100 nM PACAP27.  (B) The time to peak 
showed no significant change.  (C) Amplitude did not follow a classic dose-
response curve, with 40 nM PACAP significantly being the peak.  (D) The Ca2+ 
flux measured during the first 120 secs increased significantly with increased 
concentration of PACAP.  (E) The histogram of the response amplitudes  fitted 
with a Gaussian distribution showed that a higher percentage of cells had lower 
amplitudes at 100 nM PACAP (75% of cell intensities are below 108) than at 40 
nM PACAP (75% of cell intensities are below 122.)  Numbers near the dots 














Fig. 2.5: PACAP directly and indirectly activates GC neurons. The bar graph 
shows the fraction of PACAP responding cells in each antagonist treatment 
relative to PACAP control (at 100%). Blocking neurotransmission and 
downstream receptors, especially glutamatergic receptors significantly reduces 
the percentages of PACAP responsive cells.  The numbers above the graph 









Fig. 2.6 The cells directly activated by PACAP have faster smaller 
responses compared to downstream cells.  (A) Only the latency is unchanged 
between 40 nM PACAP-only controls and 40 nM PACAP in Glu/GABA/Na 
antagonists done on the same slice.  The antagonists significantly reduced the 
(B) time to peak (63% of control), (C) amplitude (71% of control), and (D) area 
under curve (66% of control) (paired t-test). Numbers above the bar indicate 








Fig. 2.7:  Cells may be PACAP-activated by a combination of PAC1R+ and 
Glu and/or GABA receptors. Sample traces of three different individual cells 
treated with GABA blockers, then GluR-blockers. The blockers-only controls 
showed initial, short bursts, which were not PACAP-induced responses (blue 
arrows). The short burst does not always occur in the GABA runs (blue "?" 
signs). The post-PACAP Ca2+ oscillations after the antagonists and PACAP are 
washed out is shown with black arrows. (A) The directly-activated PACR1+ cell 
showed strong PACAP response regardless of antagonists. (B) The PACAP-
induced Ca2+ responses in this cell were completely blocked by GluRs 
antagonists, suggesting PACAP indirectly activated the cell via glutamate release 
from an upstream cell. (C) PACAP responses were blocked by both groups of 
antagonists, suggesting the cell may have only indirect PACAP activation via 





Fig. 2.8:  Mitral Cells are PAC1R+ and part of the PACAP-induced activity 
network.  (A)  Sample trace of a mitral cell starting with pre-PACAP BSA control.  
After 40 nM PACAP exposure, the mitral cell started to oscillate and the [Ca2+]i 
oscillations lasted over 90 minutes post-PACAP.  During application of PACAP + 
Glu/GABA/Na antagonists, the mitral cell responded to PACAP, but also 
responded to the antagonists by stopping oscillating for about 40 seconds. The 
scale bar indicates fluorescence intensity (∆F) vs time (sec).  (B)  A P4 td-
Tomato IRES-CRE-PCdh21 (red) OB tissue section was stained with anti-
PAC1R antibodies (green).  The arrows indicate PCdh21+ mitral cells expressing 
PAC1 receptors. The blue nuclear stain is the DAPI.  Scale bar is 50 µm.  
Abbreviations: glomerular layer (GL), external plexiform layer (EPL), mitral cell 








Fig. 2.9:  PAC1R+ expression is enriched throughout the GCL and MCL of 
the OB.  OB from P2 and P4 Rosa tdTomato IRES-CRE-Dlx2 (red) was stained 
with anti-PAC1R antibodies (green). The black and white pictures are the red or 
green channels, showing the labeling separately. The region indicated by the 
yellow box in P4 is shown at higher magnification. Scale bars are 100 µm for P2 
and P4.  The scale bars in the zoom-ins of the magnified P4 are 20 µm. 
Abbreviations: glomerular layer (GL), external plexiform layer (EPL), mitral cell 








Fig. 2.10:  PAC1R expression is enriched throughout the GCL of the OB.  
OB from P2 and P4 Rosa tdTomato IRES-CRE-Dlx2 (red) was stained with anti-
PAC1R antibodies (green). The black and white pictures are the red or green 
channels, showing the labeling separately. The region indicated by the yellow 
box in P4 is shown at higher magnification. Scale bars are 100 µm for P2 and P4.  
The scale bars in the zoom-ins of the magnified P4 are 20 µm. Abbreviations: 
glomerular layer (GL), external plexiform layer (EPL), mitral cell layer (MCL), 











Fig. 2.11:  Diagram of migrating or immature neurons, which have elevated [Cl-]i 
due to high expression of the Na+-K+-Cl- cotransporter 1 (NKCC1).  When GABA 
opens the GABAAR, the resulting Cl- efflux depolarizes the cell and opens the 









Fig. 2.12:  Physiological identification of immature and mature GCs.  (A) 
Image of the Fluo-4 loaded (green) Dlx2+ (red) cell responding to 50 µM GABA.  
Scale bars in images are 10 µm and 100 µm. (B)  HK was tested at the start and 
end of each experiment to confirm the cells are healthy throughout.  BSA and 
GABA were tested before PACAP to avoid false positives due to possible post-
PACAP activity.  Each set of runs takes about 20 minutes.  (C)  Sample 
recordings for each of three development stages with either PACAP-induced 
simple transients (left column) or [Ca2+]i oscillations (right column).  These data 
indicate heterogeneity among DLX2+ cells. Black is 0.1% BSA control, blue is 40 












Fig. 2.13:  A subtype of GCs, GAD65-, has a developmental switch from 
immature to mature between P2 to P5 that parallels increases in PACAP 
responses.  (A) The percentage of total Dlx2-labeled GCs significantly switch 
from predominately migrating neuroblasts at P2 and P3 to predominately mature 
GCs at P5 (p < 0.03).  The percentage of PACAP responsive cells also 
increases. (B) The percentage of total GAD65-labeled GCs remains fairly 
constant between P2 to P5  (C) The percentage of total unlabeled GCs in GAD65 
data significantly switch from predominately migrating neuroblasts at P2 to 
predominately mature GCs at P5 (p < 0.05 to 0.01).  Stimuli were 40 nM PACAP 
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 Cilia play important roles in cellular sensory, motility, and signaling 
functions.  In mammals, olfaction and vision both rely on the sensory cilia located 
at the nasal olfactory epithelium (OE) and retina.  Olfactory cilia emanate from 
the dendritic knob of the olfactory sensory neuron (OSN) and harbor the 
signaling proteins needed to convert odor stimuli into electrical signals.  
Photoreceptor outer segments are specialized light-sensing cilium housing 
phototransduction cascade proteins.  Meanwhile, mammalian motile cilia of 
multiciliated cells, mainly ependymal cilia lining the brain ventricle wall, 
respiratory cilia covering the surface of airway epithelium, and cilia of fallopian 
tubes, are responsible for moving cerebrospinal fluid (CSF), mucus/dirt, and eggs 
along the luminal surface, respectively.  Cilia dysfunction can cause a wide range 
of human diseases collectively called ciliopathies.  Disruption of olfactory cilia 
causes anosmia (inability to perceive odors) or dysosmia (reduced sensitivity to 
odors) (McEwen et al., 2008), while ependymal cilia dysfunction leads to CSF 
flow failure and hydrocephalus (Del Bigio, 2010). 
 Sensory receptors and other transmembrane proteins enter cilia through a 
highly conserved mechanism “intraflagellar transport (IFT),” mediated by a large 
multiprotein complex-based machinery that transports ciliary proteins 
bidirectionally (Rosenbaum and Witman, 2002; Scholey, 2003).  Motile cilia 
additionally require planar cell polarity (PCP) for proper function, e.g., the cilia 
need to be oriented uniformly so that their coordinated beating can generate a 
directional fluid flow.  In both cases of signaling protein ciliary entry and 
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establishment of motile cilia planar polarity, the function of basal body, the 
transformed centriole that templates cilia axoneme, appears to be critical.  Basal 
body distal appendage “transitional fiber” is believed to be critical for cilia entry 
regulation (Nachury et al., 2010), while subdistal appendage “basal foot” is a 
dictator of cilia polarity, and its absence causes uncoordinated cilia beating in 
mice (Kunimoto et al., 2012). 
 Centrins, small ~20 kD Ca2+-binding proteins, are core basal 
body/centriole proteins that are among several hundred so-called “signature 
proteins” of eukaryotes.  It is well established that centrins are required for basal 
body genesis and positioning in lower eukaryotes such as algae, ciliates, and 
yeast (spindle pole body) (Salisbury, 2007).  Mammals have four centrin genes: 
Chlamydomonas centrin (vfl2)-related CETN1, 2 and 4, and yeast centrin 
(CDC31)-related CETN3 (Bornens and Azimzadeh, 2007), and their exact 
functions in vivo are largely undefined.  To date, available in vitro studies showed 
controversial results regarding the function of vertebrate centrin in basal body 
replication (Dantas et al., 2011; Kleylein-Sohn et al., 2007; Middendorp et al., 
2000; Salisbury et al., 2002; Yang et al., 2010).  Germline knockout of Cetn1 in 
mouse leads to male infertility due to centriole rearrangement defect that causes 
spermiogenesis failure (Avasthi et al., 2013).  Interestingly, CETN2 was recently 
found to be required for primary ciliogenesis in mammalian cell lines (Graser et 
al., 2007) and in zebrafish embryos (Delaval et al., 2011). 
 Here, we show that Cetn2∆Ex2,3 mice develop syndromic ciliopathies 
including dysosmia, hydrocephalus, sinusitis, and situs inversus.  The dysosmia 
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phenotype is caused by impaired transport of olfactory signaling proteins to cilia 
with subsequent cilia loss, attributed to compromised basal body anchoring of 
IFT components, while the hydrocephalus is caused by impaired CSF directional 
flow attributed to disrupted ependymal cilia PCP without cilia loss.  These 
phenotypes can be rescued by transgenic expression of a GFP-CETN2 fusion 
protein.  Our findings indicate that CETN2 is required for olfactory cilia trafficking, 
survival, and ependymal cilia planar polarity establishment in mice. 
 
Materials and Methods 
Generation of Cetn2∆Ex2,3 Mice 
 Cetn2∆Ex2,3 mice were generated using standard gene targeting protocol.  
C57Bl/6 mice were purchased from Charles River, EIIa-Cre, and GFP-Cetn2 
transgenic mouse (Higginbotham et al., 2004) were obtained from The Jackson 
Laboratory. All experiments were approved by the University of Utah Institutional 
Animal Care and Use Committee (IACUC).  BAC clone RP23-307G22 (205.2KB) 
containing the Cetn2 gene was purchased from Children’s Hospital Oakland 
Research Institute.  An 8.5 Kb XhoI/ClaI fragment was subcloned into plasmid 
vector pBS-SK+. We inserted a loxP site into the first intron by NheI cloning and 
a neomycin selection cassette flanked by 2 loxP sites into intron 3 by XbaI 
cloning.  The target vector sequence was confirmed by complete sequencing of 
the insertion.  Plasmid electroporation of 129SV-derived embryonic stem cells, 
blastocyst injection, and generation of agouti and F1 heterozygous mice were 
performed by Ingenious Targeting (Stony Brook, NY).  PCR was used to screen 
correctly-recombined ES cell clones and F1 animals.  PCR primers included 1) 
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random integration: Cetn2VecScr.F: TGGCGTAATCATGGTCATAGC and 
Cetn2VecScr.R: CACGACAGGTTTCCCGAC; 2) 5’ primer recombination arm: 
Cetn2SAS.F: AGGAACAGAGTGTGAAGTTAGAC and Cetn2SAS.R: 
AGACAGAATAAAACGCACGGG ; 3) 5’ loxP: SpeLinkerChk.F: 
AAACCAATGGGAAGCGGGC and SpeLinker Chk.R: 
CTGAAGGTGACTTGGGCGAG; 4) 3’ recombination arm: Cetn2LAS.F: 
GAAGTAGCCGTTATTAGTGG and Cetn2LAS.R: TCTCTGGTACAGTCATGC. 
Animals with targeted allele are designated Cetn2 3 loxP mice and were crossed 
with an EIIa-Cre driver to generate progeny with the exon 2 and 3-deleted allele 
(Cetn2∆Ex2,3). PCR genotyping primers were 1ST loxP F: 
GAGTACGCCGTTGCCTTAAC; 1ST loxP R: GTTTGACTGAGGCGGAAGTC and 
3rd loxP R: GGCCCTGAGTCCTTGTAATG, which amplify fragments at 357 bp 
(WT) and 593 bp (mutant). 
 
RT-PCR 
 OE tissue was dissected from WT and Cetn2 mutant animals and total 
RNA was extracted using TRIzol reagent (Invitrogen).  Reverse transcription was 
done using SuperScript® II reverse transcriptase (with random primers).  PCR 
primer for centrin isoforms and cycle numbers are: Cetn1 (32cycels, 390 bp), 
forward: GTCCACCTTCAGGAAGTCAAAC and reverse: 
TCATTGGCCACACGCTTGAG; Cetn2 (27 cycles, 601bp for WT,313 bp for 
mutant,),forward: GAGTACGCCGTTGCCTTAAC and reverse: 
GTCACATGTGCTTGCAGTAG; Cetn3 (24 cycles,403 bp), forward: 
GCTCTGAGAGGTGAGCTTGTAG and reverse: 
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CCTCATCGCTCATGTTCTCAC;Cetn4 (26 cycles, 216 pb), forward: 
CCAGCCAGCGCATAACTTTAG and reverse: 
CCTTGTCGATTTCAGCGATCAG. We used GAPDH as an internal control 
(18cycles, 703bp), forward: GCCATCAACGACCCCTTCAT and reverse: 
ATGCCTGCTTCACCACCTTC. RT-PCR was repeated once. 
 
Electro-olfactogram and Electroretinogram 
 Electro-olfactograms were performed on 4–6 week Cetn2 mutant (n = 9) 
and WT littermates (n = 7).  Dose-response curves were generated for amyl 
acetate and 2-heptanone (0%, 0.1%, 1%, and 10% in mineral oil as vehicle).  
Additional odorants were tested at 10% dilution and included s-butanol, 
acetophenone, cineole, R-carvone, and citral.  Mineral oil was used as baseline 
control. Animals were sacrificed by cervical dislocation, hemisectioned, and 
olfactory turbinates were exposed.  Mounted onto a stereomicroscope stage, the 
olfactory turbinates were maintained under humidified, filtered air stream at 35oC.  
Odorants (10 µl of diluted stock solutions) were applied to a sterile pipette filter 
and introduced into the humidified air stream using a picospritzer.  Recordings 
were made at three locations (turbinates II, II’, and III) with a glass electrode filled 
with Ringer’s solution (140 mMNaCl, 5 mMKCl, 1 mM MgCl2, 2 mM CaCl2, 10 
mM HEPES, 10 mM glucose).  The preparation was grounded by a silver 
chloride wire inserted into a 3 M KCl agar bridge placed near the skull bone.  
EOG responses were acquired at a sampling rate of 400 Hz and filtered at 200 
HZ using an Axoclamp 200B and Digidata 1340 interface running Axoscope 7.2 
 103
software.  Averaged peak amplitudes from all 3 recording locations were used for 
data analysis using two-way ANOVA with Bonferroni posttests. 
 Scotopic electroretinograms were performed on 1 month-old Cetn2 mutant 
and WT littermates (n = 3 each).  After dark-adaption overnight, mice were 
anesthetized by intraperitoneal injection of a mixture of ketamine (100 mg/Kg 
body weight) and xylazine (10 mg/Kg bodyweight).  Following pupil dilation with 
1% tropicamide, animals were loaded for ERG recording using UTAS E-3000 
universal electrophysiological system (LKC Technologies).  We placed the 
recording electrode immediately adjacent to the cornea and the ground electrode 
at the skull midline. Gradually increasing light intensities, ranging from –20 to 20 
db, were used for scotopic ERG recordings.  Peak amplitudes for both a- and b-
waves were used for analysis using one-way ANOVA test.  
 
Confocal Immunolocalization of Olfactory  
Epithelia/retina Proteins 
 Animals were sacrificed by cervical dislocation.  To harvest nasal 
epithelia, animals were decapitated and lower jaws were removed from the head; 
for retinas, eyes were enucleated and anterior segments removed.  Specimens 
were fixed by immersion in ice-cold 4% paraformaldehyde for 3 to 8 hrs for 
olfactory tissue and 2 hrs for retina.  P10 to adult olfactory tissues were 
decalcified in 10% EDTA, pH 7.3, before cryoprotection in 30% sucrose; 
embryonic and neonatal olfactory tissues/retinas were directly transferred to 
sucrose after fixation. Specimens were embedded in OCT compound and frozen. 
Sections (12 µm-thick) were cut using a Micron cryostat and mounted on charged 
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Superfrost® Plus slides (Fisher). Sections were washed in 0.1M PBS, blocked 
using 10% normal goat serum or 2% BSA with 0.1–0.3% Triton X-100 in PBS 
and incubated with primary antibodies at 4oC overnight.  After washes in PBS, 
the signals were detected with Cy3 conjugated- or Alexa 488-conjuated goat anti-
rabbit/mouse, or donkey anti-goat/rabbit secondary antibodies, and 
counterstained with DAPI.  Primary antibodies and dilutions were rabbit anti-
CETN2 (1:200, Santa Cruz), ACIII (1:1000, Santa Cruz), CNGA2 (1:300, 
Alomone Labs), Gαolf (1:200, Santa Cruz), KIF3A(1:500 Sigma), and rod PDE6, 
ML- and S-opsin, rod transducin-α, rod arrestin (all 1:1000, Cell Signaling), 
DYNC2H1 (1:500, Dr. Vallee, Columbia University), OR257-17 (1:500, Dr. Breer, 
University of Hohenheim), mouse anti-acetylated α- tubulin (1:1000, Sigma), γ-
tubulin (1:500, Sigma), α-tubulin (1:1000, Sigma), CNGA1/A3 (1:2000, 
NeuroMab, UC Davis), GC1 (1:2000, IS4), and Rhodoposin (1D4), Rom1, 
Peripherin 2 (1:1000, Dr. Robert Molday, University of British Columbia); goat 
anti-CETN2 (1:400, Dr. Wolfrum, Johannes Gutenberg University), IFT88 (1:200, 
Dr. Besharse, Medical College of Wisconsin).  
 For wholemount OR256-17 immunolabeling, essentially the same 
procedure was used with antibody incubation occurring overnight. Sections and 
whole mounts were imaged using an Olympus Fluoview 1000 confocal 
microscope.  Some images were adjusted for brightness and contrast using 





 For scanning electron microscopy, P16 Cetn2 mutant and WT control 
animals were sacrificed, hemisectioned, and turbinates were exposed (n=3 
each). Tissues were fixed in 2.5% glutaraldehyde, 1% paraformaldehyde in 0.1 M 
sodium cacodylate buffer, pH7.4, at 4oC overnight.  After several washes, 
samples were dehydrated in an ascending ethanol solution series and dried in 
hexamethyldisilazane.  Dried samples were coated with gold particles and 
examined using the University of Utah EM core facility scanning microscope 
(Hitachi S-2460N) at 20 KV.  
 For transmission electron microscopy, P14 Cetn2 mutant and WT control 
samples (n = 3 each) were fixed in the same fixative used for SEM at 4oC for 2 
hrs, washed and fixed further in 2% osmium tetroxide in 0.1 M sodium cacodylate 
buffer, pH 7.4 at 4oC for 2 hrs.  Washed samples were dehydrated through 
ascending series of ethanol, dried in propylene oxide, and infiltrated with Epon 
resin mix/propylene oxide (1:1) mixture overnight, followed by 100% Epon resin 
for 2 days.  Samples were embedded and the plastic cured by incubation in a 
60oC oven for 2 days.  Samples were trimmed and 1 µm sections were cut and 
examined until the desired area was reached. Ultrathin sections were cut, stained 
with uranyl acetate and lead citrate, and examined with an electron transmission 





Co-IP and Western Blot 
 Olfactory epithelia from transgenic GFP-Cetn2 and WT mice were 
dissected while immersed under ice-cold PBS.  Pooled tissues were 
homogenized in lysis buffer (50 mMTris-Cl pH 7.6, 120 mM NaCl, 0.5% IGEPAL 
CA-630, 1 mM PMSF, 1x protease inhibitor mixture, 2 mM NaF, 2 mM Na3VO4, 
supplemented with 100 µM CaCl2, 100 µM MgCl2 for Ca2+-containing buffer or 
1mM EDTA and 1mM EGTA for Ca2+-free buffer), centrifuged at 13,000g, 4oC, 
for 20 min, and supernatants were collected. Supernatants were precleared by 
incubating with 50% protein G-sepharose beads and normal rabbit IgG for 30 
min.  Precleared lysates were mixed with GFP primary antibody for 2 hrs 
(Rockland 011-0102), followed by protein G-sepharose beads for 45 min.  Beads 
were collected by centrifugation at 3000g for 1 min, and washed 8 times in lysis 
buffer without protease inhibitors.  After a final wash, 2X SDS buffer was added, 
and the samples were boiled for 3 minutes, centrifuged briefly, and supernatant 
were collected.  Precipitated proteins were separated by SDS-PAGE and 
transferred to PVDF membrane.  For immunoblot, we followed a standard 
protocol using an ECL-plus kit (Pierce) to detect the signal.  Antibodies used for 
Western blot were rabbit anti-GFP (Rockland, 1:1000), KIF3A (1:500 Sigma), 
DYNC2H1, and DYNC1H1 (both 1:500, Dr. Vallee, Columbia University). 
 
Ependymal Cilia Beating Assay 
 P13 Wt and Cetn2 mutant brain lateral ventricle walls were isolated as 
described in L15 medium (Mirzadeh et al., 2010).  Red fluorescent microbeads 
(Sigma, 2µm diameter) were added into the medium, and the beads movement 
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was recorded using a Nikon Ti-E Widefield CCD microscope.  NIH Image J with 
manual tracking plugin was used to track individual particle movement and to 
calculate the speed.  
 
Statistical Analysis 
 Data are presented as mean ± sd. n represents the number of mice or 
OSNs analyzed.  Statistical comparisons were done using two-way ANOVA with 
Bonferroni posttest for EOG results, and one-way ANOVA for all other 
experimental data.  Differences were considered to be statistically significant for 
p < 0.05. 
 
Results 
Generation of Cetn2∆Ex2,3 Mice  
 In mice, the X chromosome-located Cetn2 gene contains 5 exons.  To 
generate a CETN2 knockout mouse, we inserted a loxP site into intron 1 and a 
neomycin selection cassette flanked by two loxP sites into intron 3 to create the 
conditional allele (Fig. 4.1).  By mating the floxed mouse with an EIIa-Cre driver, 
we generated an allele in which exons 2 and 3 were deleted in frame 
(Cetn2∆Ex2,3) (Fig. 4.1, A–C).  Truncated Cetn2 mRNA (encompassing exons 1, 4, 
and 5) was detectable by RT/PCR but at very low levels (5–10% of WT) (Fig. 4.1, 
arrow).  In the absence of Cetn2, Cetn1 and 3 mRNA levels were normal with 
Cetn4 being slightly upregulated in RT-PCR examination (Fig. 4.1D). 
Endogenous CETN2 protein localizes to the basal body/centriole of OSN 
denditric knob layer in wildtype (WT) mouse, while in Cetn2∆Ex2,3, the protein 
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encoded by truncated mRNA was undetectable (Fig. 4.1E, left panels).  In a 
GFP-Cetn2 transgenic mouse (Higginbotham et al., 2004), GFP-CETN2 protein 
is similarly concentrated in basal bodes of OSN, brain ependymal cells, or retina 
photoreceptor cells (also in connecting cilium) (Fig. 4.1E, right panels).  
 
Cetn2 Mutant Mice Display Dysosmia, Hydrocephalus,  
Sinusitis, and Situs Inversus  
 Cetn2 mutants (Cetn2∆Ex2,3/∆Ex2,3 females or Cetn2∆Ex2,3/Y males) were born 
in a Mendelian ratio as expected for an X-linked gene.  The mutant mouse 
appears normal at birth, but its body size becomes smaller with age compared to 
WT or heterozygous littermates (~30% lower than WT at weaning, Fig. 4.2A).  
Weight loss is frequently associated with olfaction-deficiency (Weiss et al., 2011).  
We confirmed that in electro-olfactograms (EOG), amplitudes of Cetn2 mutants 
were reduced by 48–69% with all tested odorants: 58% reduction for citral, 48% 
for S-butanol, 61% for acetophenone, 69% for cineole and 67% for R-carvone 
(Fig. 4.2, C and E).  Dose-dependent EOG recordings with amyl acetate showed 
amplitude reduction at every tested concentration (Fig. 4.2, D and F).  Consistent 
with EOG results, a behavioral test revealed that overnight-fasted Cetn2 mutants 
took over seven times longer to locate food than WT controls (45 sec vs. 350 
sec) (Fig. 4.2B). These results indicated that Cetn2 mutants are dysosmic.  
 Cetn2 mutants also presented with hydrocephalus with variable severity. 
About 30% of mutants develop dome-shaped heads and huge dilated brain 
ventricles (Fig. 4.2G), and die within 1.5 months.  About 70% of animals have 
normal skull shape, but their brain ventricles are also dilated in histology 
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examination (Fig. 4.2H, ages checked from 1 month to 1 year), suggesting later 
onset of hydrocephaly after the sealing of cranial sutures.  Interestingly, in 
animals with mild hydrocephalus, the dilation of the lateral ventricle is more 
obvious than that of midbrain aqueduct or fourth ventricle (Fig. 2H).  
 Finally, Cetn2 mutants also show sinusitis and situs inversus in ~30% 
animals (10 of 32 animals examined; Fig. 4.3, A and B).  We did not observe 
other primary cilia-related disease phenotypes, such as polycystic kidney 
disease, polydactyly or other hedgehog signaling-related developmental defects.  
 
Loss of Olfactory Cilia, but Maintenance  
of Ependymal Cilia in Cetn2 Mutant Mice 
 Based on ciliopathy phenoytpes, we investigated whether there is 
disruption of olfactory cilia or ependymal cilia in mutants.  In OE, cilia marker Ac-
a-tubulin immunostaining showed that there is a substantial decrease of ciliary 
layer thickness and Ac-a-tubulin-negative spots in mutant compared to WT at 
P14 and other ages (p21, P60, P180) (Fig. 4.4A).  In scanning electron 
microscopy (SEM) of P16 OE tissues (turbinates II and II’), cilia form a fine, 
dense meshwork in WT (Fig. 4.4B), but Cetn2 mutant cilia are reduced in 
density, appearing short and stubby with slightly enlarged tips (Fig. 4.4B, 
arrows).  Many dendritic knobs (arrow head) are enlarged.  In transmission 
electron microscopy (TEM), many mutant dendritic knobs were devoid of cilia 
and many remaining cilia were shorter with swelling tips (Fig. 4.5, A–D).  To 
better demarcate the cilia morphology, we labeled a subset of olfactory cilia with 
anti-OR256-17 (Olfactory Receptor 15) antibody (Schwarzenbacher et al., 2005). 
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Compared to WT, OR256-17-postive cilia are dramatically reduced in either 
coronal sections (Fig. 4.6, A and B, arrows) or in whole mount staining, and 
morphologically the remaining cilia are short and varicose (Fig. 4.6, C–F, 
arrows).  Quantification results confirmed significant decrease of knobs density 
(170.5 vs. 93, knobs per 0.1 mm2), cilia density (17 vs. 6 cilia number per knob), 
and average cilia length (22 µm vs. 7 µm) in mutants (Fig. 4.6, G–I).  
 Surprisingly, the density of ependymal cilia of lateral ventricle in Cetn2 
mutants (animals with early onset of hydrocephalus) is comparable to WT in 
whole mount Ac-a-tubulin staining (Fig. 4.6, J and K). However, the uniform 
anterior-pointing cilia orientation appears to be disrupted in Cetn2 mutants (Fig. 
4.2K, arrows). Consistently, in SEM, WT ependymal cilia tufts showed regular 
spacing and the cilia within the same tufts or between different tufts show largely 
uniform orientation (Fig. 4.6L).  Frequently, however, mutant ependymal cilia 
within a single tuft or among adjacent tufts pointed in variable directions (Fig. 
4.6M, arrows). Mutant respiratory cilia also do not show cilia loss either in TEM 
examination (Fig. 4.7, A and B) or Ac-a-tubulin staining (Fig. 4.8), and the 
axoneme ultrastructure appears normal (Fig. 4.7, C and D).  Further, IFT motor 
cytoplasmic dynein 2 and KIF3A are normally concentrated at respiratory cilia 
bases (Fig. 4.8, A–D), which is in contrast to olfactory epithelium (see below).  
 
Olfactory Cilia Trafficking Failure Occurs Prior  
to Cilia Loss 
 In investigating the onset of cilia loss phenotype, we found that at early 
stages (E14.5, P0, P5 examined), WT and mutant olfactory cilia density and 
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morphology is comparable, as judged by Ac-a-tubulin and OR256-17 labeling 
(Fig. 4.9, A and B).  Quantification of P5 whole mount OR256-17 staining verified 
that there is no difference of dendritic knob density (170 WT vs. 175 mutant, 
knobs per 0.1mm2), cilium density (19.2 WT vs 18.5 mutant, cilia number per 
knob), or average cilium length (8.2 µm WT vs 8.5 µm mutant) (Fig. 4.9, C–E).  
These observations indicate that olfactory ciliogenesis progresses normally in the 
absence of CETN2.  However, from as early as P5, many turbinate I OSNs 
showed dendrite and soma mislocalization of olfactory signaling protein ACIII in 
mutants (compare Fig. 4.9, F and G, green).  At this time point the olfactory cilia 
axoneme was present and intact as determined by a-tubulin staining (Fig. 4.9, F 
and G, red), suggesting CETN2 deficiency results in early membrane protein 
transport defects following normal cilia development and before ciliary loss.  
 Mistrafficking in cilia spreads from turbinate I and II to other turbinates and 
septum.  By P14 (or later) ACIII and CNGA2, two major transmembrane signaling 
proteins, mislocalized to mutant OSN dendrites and cell bodies (Fig. 4.9, I and L), 
in contrast to exclusive cilia layer localization in WT (Fig. 4.9, H and K).  
Localization of the olfactory G protein, Gαolf, a peripheral membrane-associated 
protein, appeared normal (Fig. 4.9, N and O).  
 
Transgenic GFP-Cetn2 Rescues Olfactory  
Mistrafficking and Other Phenotypes 
 Since overexpression of GFP-CETN2 rescues the centriole assembly 
defect in CETN2-depleted mammalian cells (Yang et al., 2010), we crossed 
Cetn2∆Ex2,3/Y and GFP-Cetn2 mice in an attempt to 'rescue' the OSN ciliary 
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trafficking defect.  As expected, ciliary localizations of ACIII, CNGA2 and Gαolf 
were normal in Cetn2∆Ex2,3/Y; GFP-Cetn2 mice (Fig. 4.9, J, M, and P).  Further, 
the body weights of Cetn2∆Ex2,3/Y; GFP-Cetn2 mice were indistinguishable from 
those of WT mice, and hydrocephalus, sinusitis, or situs inversus were not 
detected (among >10 mutants). 
 
Photoreceptor Ciliary Trafficking Proceeds  
Normally in Cetn2 Mutants 
 All four centrin genes are expressed in murine photoreceptors (Giessl et 
al., 2004).  Deletion of CETN2 did not affect the subcellular localizations of 
photoreceptor outer segment proteins, including rod and cone visual pigments 
(rhodopsin, ML-opsin and S-opsin), cGMP-gated channel subunits 
(CNGA1/CNGA3), guanylate cyclase 1 (GC1), rod arrestin, and the structural 
proteins ROM1 and peripherin-2 (Fig. 4.10).  Electroretinograms of 1 month old 
WT and Cetn2 mutant mice were indistinguishable (Fig. 4.11).  It has been 
proposed that photoreceptor centrins may regulate visual G-protein translocation 
(Trojan et al., 2008).  However, neither the light-driven translocation nor the dark-
driven return of both rod transducin-α and arrestin are impaired in Cetn2 mutants 
(Fig. 4.12). 
 
Mislocalization of IFT Components IFT88, KIF3A  
and DYNC2H1 in Cetn2 Mutant OSNs 
 Ciliary membrane proteins are presumably transported into cilia 
compartments by anterograde IFT (Rosenbaum and Witman, 2002; Scholey, 
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2003).  To test whether the mislocalization of ACIII and CNGA2 could be a result 
of altered IFT in Cetn2 mutant OSN, we examined the distributions of IFT 
components IFT88, KIF3A (the obligatory subunit of the anterograde motor 
kinesin-II), and DYNC2H1 (IFT retrograde motor cytoplasmic dynein 2 heavy 
chain 1).  As reported (Miyoshi et al., 2009), IFT-88 and KIF3A concentrate at the 
dendritic knob layer, beneath the Ac-α-tubulin-positive ciliary layer (Fig. 4.13, A 
and C), and overlap with y-tubulin (Fig. 4.13E).  In mutants, IFT88-and KIF3A-
positive layers are uneven, and portions of each are colocalized with Ac-α-tubulin 
(Fig. 4.13, B and D, arrows), suggesting that IFT88 and KIF3A are trapped in 
olfactory cilia.  KIF3A and y-tubulin double-labeling confirmed the KIF3A trapping 
in the ciliary layer (Fig. 4.13F).  Interestingly, homodimeric KIF17, another 
member of the kinesin-II family required for sensory ciliogenesis in C. elegans 
and olfactory CNG channel cilium transport in mammalian cells (Jenkins et al., 
2006; Snow et al., 2004), localized correctly in the olfactory cilium layer of mutant 
Cetn2 mice (Fig. 4.14, A–F).  Trapping of IFT88 and KIF3A in the Cetn2 mutant 
cilia layer suggests abnormal retrograde IFT, mediated cytoplasmic dynein 2 
(Collet et al., 1998; Pazour et al., 1999).  Indeed, we found that DYNC2H1 cilia 
base localization is dramatically decreased in Cetn2 mutants compared to WT, 
while DYNC2H1soma layer labeling appeared unaltered (Fig. 4.15, G and H, 
arrows).  However, using GFP CETN2 transgenic OE lysate and GFP antibody 
as a bait, we did not detect a direct interaction between CETN2 and DYNC2H1 




Uncoordinated Fluid Flow Generated by  
Cetn2 Mutant Ependymal Cilia 
 The altered orientation of ependymal cilia (Fig. 4.6, J–M) predicts there is 
a CSF flow phenotype in Cetn2 mutant.  To test this possibility, we isolated 
lateral ventricle walls from P13 animals, kept them in a culture dish, and recorded 
the movement of fluorescent latex microbeads (2 µm diameter) that were directly 
added into the culture medium.  As reported (Tissir et al., 2010), the beads move 
from posterior to anterior in WT (Fig. 4.17A), but in mutants, the directional beads 
movement is disrupted, with observed movement in multiple directions (Fig. 
4.17B).  In addition, the beads moved much more slowly than in WT (mutant 8 
µm/sec vs WT 45 µm/sec) (Fig. 4.17C).  These data suggest that the CSF flow in 
the Cetn2 mutant is decreased and less directional, which could be causative of 
hydrocephalus.  
 
Disrupted Rotational Planar Polarity of  
Ependymal Cilia in Cetn2 Mutants 
 The ependymal cilia morphology and impaired directional CSF flow 
suggest improper development of planar polarity of ependymal tissue in Cetn2 
mutants.  Indeed, in longitudinal TEM sections, we frequently observed 
misaligned ependymal cilia in mutant but not in WT (Fig. 4.17, D and E).  Since 
the basal foot direction of basal bodies determines ependymal cilia planar 
polarity and cilia beating direction (Kishimoto and Sawamoto, 2012; Wallingford, 
2010), we therefore investigated the basal foot direction using TEM in P13 
mutants.  As expected, most basal feet point to anterior in WT; in contrast, basal 
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feet pointing appears less directional, with many pointing in random directions 
(Fig. 4.17, F and G, arrows).  We also frequently observed basal bodies with two 
or more basal feet in both longitudinal (Fig. 18B, allows) and cross views (Fig. 
4.17D, dashed arrows).  Finally, ependymal cilia 9+2 axoneme organization and 
9 blade-like transitional fibers appear normal in Cetn2 mutants (Fig. 4.18), which 
rules out the possibility that the fluid flow phenotype results from ciliary structure 
deficiencies.  Taken together, these data suggest that CETN2 deficiency impairs 
ependymal planar polarity development. 
 
Discussion 
 Here we show that CETN2 is not essential for centrosome replication, 
mitotic cell division, or ciliogenesis in mice as Cetn2∆Ex2,3 pups are born normally 
and are fertile.  Rather, Cetn2 mutants showed selective ciliopathies, e.g., 
dysosmia, hydrocephalus, sinusitis, and situs inversus.  The differential etiology 
of dysosmia and hydrocephalus in postnatal Cetn2 mutants indicate that 
mammalian CETN2 is a versatile basal body protein that has adopted cell- and 
tissue-specific functions. 
 Centrins are required for the centriole/basal body duplication in various 
lower eukaryotes such as Chlamydomonas, yeast (spindle pole body) and 
Tetrahymena  (Salisbury, 2007).  CETN2 knockdown in zebrafish (Delaval et al., 
2011) and in mammalian cell lines (Graser et al., 2007; Mikule et al., 2007) lead 
to the hypothesis that vertebrate centrin may be important for ciliogenesis 
(Dantas et al., 2012).  Our results suggest that mouse CETN2 is dispensable for 
ciliogenesis since the formation of both primary cilium (renal tubule epithelia and 
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photoreceptors) and motile cilia of multiciliated cells (olfactory, respiratory, and 
ependymal cilia) progress normally in mutant animals.  Despite the normal early 
ciliogenesis in olfactory epithelium, continued olfactory cilia growth and 
maintenance appeared to be disrupted in Cetn2 mutants, which lead to massive 
cilia loss in young postnatal animals (Figs. 4.6 and 4.9).  In general, ciliogenesis 
requires coordinated microtubule axoneme assembly and ciliary membrane 
expansion, during which cilia grow relatively fast (Westlake et al., 2011).  
However, during ciliary maintenance, the turnover of ciliary axoneme tubulin is 
slow (Thazhath et al., 2004); thus, the membrane protein turnover is likely not 
coupled to the axoneme renewal.  In mouse OE, ciliary trafficking of olfactory 
signaling proteins ACIII, CNG and Golf occurs later than ciliogenesis (McEwen et 
al., 2008).  As ciliary mistrafficking occurs prior to ciliary loss in Cetn2 mutants, 
we speculate that CETN2 is required for transmembrane protein ciliary transport 
and that the olfactory cilia loss is a secondary effect of ciliary signaling protein 
trafficking failure. 
 OSN-specific mechanisms controlling the cilium entry of olfactory signaling 
proteins have been proposed (McEwen et al., 2008).  Identified regulators 
include centrosomal protein CEP290/NPHP6, which controls Gαolf and Gγ13 
ciliary entry (McEwen et al., 2007) and PACS-1 (phosphofurin acidic cluster-
sorting protein 1) regulating CNG channel trafficking (Jenkins et al., 2009).  Here 
we show that CETN2 is required for the ciliary transport of ACIII and CNGA2, but 
not cytoplasmic Gαolf, in agreement with a previous conclusion that olfactory G 
protein targeting is uncoupled to ACIII or CNG channels (McEwen et al., 2007).  
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The abnormal basal body recruitment of IFT components (IFT88, KIF3A, and 
DYNC2H1) suggests that compromised IFT may be a cause of ciliary 
mistrafficking in Cetn2 mutants.  It is also possible that the mistrafficking 
phenotype may reflect the apically polarized intracellular transport from soma to 
knob basal bodies along a dendritic microtubule track since most of centrin could 
be cytoplasmic and not centrosome-associated (Paoletti et al., 1996).  
Interestingly, we noticed that Cetn2 mutants share significant phenotypic 
similarity with a hypomorphic pericentrin mutant (Pctnocd/ocd) in olfactory cilia loss, 
ACIII mistrafficking, and defective basal body-anchoring of IFT components 
(Miyoshi et al., 2009).  Deletion of BBSome proteins and MKS proteins also 
disrupt olfactory ciliary transport including ACIII and CNGA2 and lead to cilium 
structural abnormalities attributed to compromised IFT (Kulaga et al., 2004; 
Nishimura et al., 2004; Pluznick et al., 2011). 
 In mouse ependymal cells (and other multiciliated cells), the establishment 
of ciliary polarity requires hydrodynamic forces and its coordination with PCP 
protein VangL2 (Guirao et al., 2010; Mitchell et al., 2007).  Deletion of the core 
PCP protein CELSR 3 (Drosophila flamingo ortholog) also results in ependymal 
PCP deficiency and ciliogenesis defects (Tissir et al., 2010).  How exactly flow 
and PCP signals instruct cilia orientation is poorly understood.  The elucidation of 
mechanisms is complicated by the finding that some PCP proteins can also 
locate to cilia and rootlet (Guirao et al., 2010; Park et al., 2008).  Inevitably, all 
ciliary orientation instructional cues ultimately impinge on the basal body, the 
dictator of cilia polarity.  We show for the first time that a core basal body protein, 
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CETN2, is required for PCP development in multiciliated cells.  The nature of 
CETN2 function in ependymal polarity development is currently unknown.  In 
mouse airway epithelium, the initial PCP signal can induce the polarization of 
basal body-associated microtubules that is subsequently required for orienting 
the basal body (Vladar et al., 2012).  In frog embryo epidermal cilia, it appears 
that the rootlet-associated subapical actin network and basal foot-associated 
microtubule network regulate establishment of global and local ciliary polarity, 
respectively (Werner and Mitchell, 2012).  We hypothesize that CETN2 functions 
downstream of core PCP proteins and is involved in PCP signal-mediated 
cytoskeleton rearrangement.  
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Fig. 4.1: Generation of Cetn2∆Ex2,3 mice. (A) Schematic of gene targeting strategy. (B) 
Screen of Cetn2∆Ex2,3 ES cells and mice. We used PCR to screen 1st LoxP [shown are 4 
positive mice out of  total 16 mice (top row left)], 2nd LoxP site (top row, right), the 5’ and 
3 recombination arm (lower row, left and middle) and  3rd LoxP site (lower row, right). 
(C) Representative PCR genotyping result of one litter germline deletion pups, showing 
amplification of WT band at 357 bp and mutant band at 593 bp. (D) RT-PCR 
examination of Cetn1-4 mRNA expression in Cetn2∆Ex2,3 mice. GAPDH mRNA was used 
as an internal control. Red arrow marks the faint band of truncated Cetn2 mRNA in 
mutant. (E) Anti-CETN2 antibody labels basal bodies of dendrite knob layer of WT OE, 
but is negative for Cetn2∆Ex2,3 OE (left two panels), while transgenic GFP-CETN2 
similarly concentrates at basal bodies at OE, ependyma, and retina photoreceptors 
























Fig. 4.2: Phenotypes of Cetn2∆Ex2,3 animals. (A) Cetn2∆Ex2,3 and WT animals body 
size. At P21, the average Cetn2∆Ex2,3 body weight is ~35% less than that of WT (n = 10 
for each group, one-way ANOVA, ** p < 0.01). (B) In a behavioral test, Cetn2 mutants 
require a significantly longer time to locate hidden food than WT after overnight fasting 
(n = 13 WT, n = 12 mutants, one-way ANOVA, *** p < 0.001). Dysosmia and 
hydrocephalus in Cetn2 mutant mice. (C, E) Representative electroolfactogram (EOG) 
traces for various odors (C) and dose-dependent test of amyl acetate (D). (E, F) 
Evaluation of EOG results, showing reduced voltage responses to tested odors (E), and 
at three different amyl acetate concentrations (F). Bars indicate mean ± sd. (n = 8 WT, n 
= 10 mutants, two-way ANOVA, *p < 0.05, **p < 0.01, *** p < 0.001). (G) Severe 
hydrocephalus of Cetn2 mutants, showing dome-shaped head and huge dilated brain 
lateral ventricle. (H) Cetn2 mutants with mild hydrocephalus, showing dilation of lateral 






Fig. 4.3: Overall anatomy of Cetn2∆Ex2,3 animals. (A) Sinusitis of Cetn2∆Ex2,3 animals 
shown in DAPI staining. Stars mark the dead cells and accumulated mucus. (B) Situs 




















Fig. 4.4: Loss of olfactory cilia but not ependymal cilia in Cetn2 mutants. (A) 
Decrease of cilia marker Actubulin in mutant OE at P14. (B) SEM images of P16 OE 
revealed reduced cilia density, short and stubby cilia, and enlarged knobs in mutants. 
Arrowheads point to individual knobs, dashed arrows identify cilia, and arrows in lower 



















Fig. 4.5: TEM of WT and Cetn2 mutant olfactory cilia. (A, B) In P14 OE, olfactory 
cilia emanate from dendritic knobs in WT (A), but are absent from many knobs in 
mutants (B). Dashed lines outline knobs, arrows indicate cilia, and arrowhead labels 
mislocalized basal bodies in mutants. (C, D) High power TEM image indentified shorter 
olfactory cilia with swelling tip in mutant (C, arrows) but not in WT (D) OE. Arrowheads 
indicate extra decoration of basal body wall in mutants. 
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Fig. 4.6: WT and Cetn2 mutant olfactory cilia.  (A–F) Identification of cilia with anti-
OR256-17 antibody in frozen sections (A, B) and wholemount tissues (C–F), showing 
greatly reduced cilia density and abnormal cilia morphology in mutants. Arrows point to 
cilia and arrow heads (A, B) or dashed circles (D, F) label dendritic knobs. (G–I) Knob 
density (G), cilia density (H) and average cilia length (I) are all decreased significantly in 
mutants. Data shown as mean ± sd. (nı45 OSNs from 3 animals for each group, one-
way ANOVA, *** p<0.001). (J, K) WT, and mutant wholemount Ac-a-tubulin 
immunostaining of P13 brain lateral ventricle. Mutant ependymal cilia density is 
comparable to WT, but the cilia orientation is disrupted. D, dorsal; A, anterior. (L, M) 
SEM of P13 ependymal cilia confirmed disorganized cilia orientation in mutants. Arrows 
in M and O label disorganized cilia tufts. Scale bars: A–D, J, K, 10 µm; E, F, 5 µm; L, M, 







Fig. 4.7: Respiratory cilia density and morphology in WT and Cetn2 mutants. (A, 
B) In longitudinal section TEM, both the cilium density and morphology are comparable 
between P14 WT (A) and mutant (B). (C, D) Cross sections TEM showed both WT (C) 
and mutant (D) have typical motile cilium 9+2 axoneme microtubule structures. Scale 

















Fig. 4.8: IFT motor localization in Cetn2 respiratory epithelium. (A, B) Double 
staining KIF3A (red) and Ac-α-tubulin (green) showed KIF3A concentration at cilia 
base in both P14 WT (A) and mutant (B). (C, D) Double staining of DYNC2H1 (red) 
and Ac-α-tubulin (green) showed cytoplasmic dynein 2 concentration at cilia base in 

















Fig. 4.9: Mislocalization of ACIII and CNGA2 in Cetn2 mutant and rescue by 
transgenic GFP-CETN2 expression. (A, B) Wholemount identification of cilia with 
anti-OR256-17 in P5 WT (A) and mutant (B) OE. (C–E) Quantification of knob density 
(C), cilia per knob (D) and average cilia length (E). Data are mean ± sd (one-way 
ANOVA, p > 0.8, nı45 OSNs from 3 animals for each group). (F, G) 
Immunolocalization of ACIII and a-tubulin at turbinate I of P5 OE. ACIII (green) 
colocalizes with atubulin (red) at cilium layer in WT (F), but is mislocalized to the 
dendrite and cell body (arrows) in mutant (see arrows in G). Note that mutant 
olfactory cilia appear intact at this stage. (H–P) Immunolocalization of ACIII (green; 
H–J); CNGA2 (green; K–M), Gαolf (green; N–P) and Ac-a-tubulin (red) in P14 WT (H, 
K, N), Cetn2 mutant (I, L, O) and Cetn2 Mut;GFP-Cetn2 (J, M, P) OE. Note the 
mislocalization of ACIII and CNGA2, but not Gαolf in mutants and the rescue in Cetn2 









Fig. 4.10: Immmunolocalization of phototransduction components in WT and 
Cetn2 mutant photoreceptor cells. The  photoreceptor outer segment proteins include 
rhodopsin (A), PDE6 (B), GC1 (C), Rom-1 (D), Peripherin2 (E), ML-opsin (F), S-Opsin 
(G), and CNGA1/A3 (H). All outer segment proteins are correctly targeted in 1 month 
















Fig. 4.11: Electroretinograms of WT and Cetn2 mutant mice. (A, B) Typical Scotopic 
ERG trace of WT (A) and Cetn2 mutant (B) at 20 db. (C, D) No significant difference 
was detected for a-wave or b-wave amplitudes at multiple light intensities tested. Data 























Fig. 4.12: Transducin and arrestin translocation in Cetn2 mutant mice. (A–D) Rod 
transducin-α is concentrated at the outer segment after overnight dark-adapted animals 
of both genotypes (A, B) and translocated into the inner segment, outer nuclei layer and 
synaptic layer for 1 hr light-adaptation in both WT (C) and mutant (D) animals. (E–H) 
Rod arrestin is concentrated in the inner segment, outer nuclei layer and synaptic layer 
in overnight dark-adapted animals of both genoytypes (E, F) and is translocated into the 
outer segment after 1 hr light adaption in both WT (G) and mutant (H) animals. Scale 





















Fig. 4.13: Mislocalization IFT components in P14 Cetn2 mutant OE. (A, B) 
Colabeling of IFT88 (red) and Ac-a-tubulin (green), showing overlap in the cilia layer in 
mutant (B, arrows), but not in WT (A). (C, D) Colabeling of KIF3A (red) and Ac-a-tubulin 
(green) in the cilia layer in mutant (D) in comparison to WT (C). (E, F) Colocalization of 
KIF3A (red) with y-tubulin (green) in WT (E), but separation of KIF3A and y-tubulin in 


















Fig. 4.14: KIF17 localization in WT and mutant olfactory cilia and GFP-Cetn2 co-
immunoprecipitation. (A–F) Double immunofluorescence showed that KIF17 (green) 
colocalizes with cilia layer marker Ac-tubulin (red) in both WT (A, C, and E) and Cetn2 

























Fig. 4.15: Mislocalization IFT components in P14 Cetn2 mutant OE. (A, B) 

























Fig. 4.16: Co-IP of GFP-CETN2 and DYNC2H1 or KIF3A. Antibody directed against 
GFP was used to immunoprecipitate CETN2-binding proteins from transgenic GFP-
Cetn2 olfactory epithelia lysate. WT type OE lysate was used as control. All input bands 
appeared as expected (lanes 1 and 2), yet we were unable to detect immunoblot bands 



















Fig. 4.17: Impaired CSF flow and disrupted ependymal planar polarity in Cetn2 
mutants. (A, B) Tracking of latex bead movements along the lateral ventricle surface. 
Dashed lines outline the edge of lateral ventricle. Colored lines indicate the trajectory of 
several tracked particles, and circles mark the end of tracking. Fluorescent beads 
largely moved in one direction from posterior to anterior in WT (A), but moved in 
multiple directions in mutant (B). D, dorsal, A, anterior. (C). Microbeads moved 
significantly slower in mutant than in WT. Data shown as mean ± sd (> 20 beads from 2 
animals in each group, one-way ANOVA, ***p < 0.001). (D, E) Sagittal TEM of P13 
lateral ventricle ependymal tissue, showing well-aligned WT cilia (D) but disoriented 
mutant cilia (E). (F, G) TEM image of ependymal tissue at basal foot level. In WT, the 
basal feet uniformly point to the anterior (F), but in mutant, they point to random 




















Fig. 4.18: TEM examination of WT and mutant ependymal cilia. P13 ependymal 
basal body showed additional basal feet in mutant (B) but not WT (A) in longitudinal 
sections (first panel, arrows). In cross sections, basal body triplet microtubule structure 
and distal transitional fibers (middle panel), as well as 9+2 cilia axoneme organization 












 The olfactory system is sometimes used as a model to better understand 
neuronal mechanisms and functions in the central nervous system (CNS) 
(Doursout et al., 2013; Riggio et al., 2013; Ruan et al., 2012; Shepherd and 
Charpak, 2008).  Unlike most of the CNS, mammalian (including human) 
olfactory systems are capable of replacing some types of neuronal cells 
throughout life (Kelsch et al., 2007; Breton-Provencher and Saghatelyan, 2012).  
This unique CNS feature is made possible by a steady supply of migrating 
precursor cells from the subventricular zone (SVZ), where stem cells are being 
produced (Bath and Lee, 2010; Bovetti et al., 2011; Lemasson et al., 2005).  The 
ability to replace olfactory cells is essential for the sense of smell to be effective 
(Breton-Provencher et al., 2009; Cowan and Roskams, 2002).  Research has 
been done on the regenerating CNS neurons in hopes of finding effective ways 
to treat neurodegenerative diseases and possibly ischemic injuries to the more 
permanent CNS neurons (Kuwabara and Asashima, 2012; Ubeda-Banon et al., 
2013; Christie and Turnley, 2012; Cowan and Roskams, 2002; Ohtaki et al., 
2008).   
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G-protein coupled receptors (GPCRs) have a wide variety of binding sites, 
types of G-protein specific to receptor, G-protein combinations, and 
dependencies of GPCR-induced mechanisms on strength of receptor activation 
(Oldham and Hamm, 2008; Zhou et al., 2002).  Supplying neuropeptides and 
transmitters to GPCRs is one of the most popular methods for medical/clinical 
treatments and therapies (Pierce et al., 2002; Oldham and Hamm, 2008).  The 
functions of GPCRs include the modulation of [Ca2+]i, and all three of the projects 
in this dissertation involve some aspect of GPCRs. In Chapter 2 we studied 
neonatal olfactory bulb [Ca2+]i activity in response to activation of the PAC1 
receptor (PAC1R), which is a GPCR specific to a pleiotropic neuropeptide called 
PACAP (Blechman and Levkowitz, 2013; Zhou et al., 2002).  We also studied the 
modulation of intracellular [Ca2+]i through two other GPCRs (P2Y purinergic 
receptors and muscarinic acetylcholine receptors) in sustentacular cells of the 
olfactory epithelium.  The sustentacular cells act like glial cells to the olfactory 
neurons and basal cells, and may be important for integrating communications 
within the OE (Chapter 3).   Lastly, we identified the roles of a centrin, Cetn2, in 
transporting GPCR-associated proteins to the cilia of OSNs.  Studies of the 
readily accessible cilia in the OE can provide clues relating to the reasons 
various GPCRs are dysfunctional in various organs (Chapter 4). 
 
Experiments Using PACAP in Neonatal Mouse OB 
 Chapter 2 is about PACAP, which is a neuropeptide that has the potential 
to clinically treat neurodegenerative diseases.  This peptide has a strong effect 
on reducing cell mortality (Atlasz et al., 2010; Bourgault et al., 2009; Chen et al., 
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2006; Dejda et al., 2008; Kanekar et al., 2010; Ohtaki et al., 2006; Vaudry et al., 
2002; Yang et al., 2006).  Furthermore, PACAP aids cells that develop during 
adulthood to mature and proliferate throughout the body, especially in the 
nervous system (Makela et al., 2010; Scharf et al., 2008; Sherwood et al., 2007; 
Shioda et al., 2006; Ravni et al., 2006).  The anti-apoptotic and developmental 
effects of PACAP are often times studied in cultured neurons from various parts 
of the nervous system, including but not limited to the retina (Atlasz et al., 2010; 
Delwig et al., 2013; Kiss et al., 2006; Markhotina et al., 2007; Silveira et al., 2002; 
Szabadfi et al., 2012; Szabadfi et al., 2014), cerebellum (Botia et al., 2007; 
Jozwiak-Bebenista et al., 2007; Allais et al., 2007; Falluel-Morel et al., 2007; 
Falluel-Morel et al., 2008; Mei et al., 2004; Vaudry et al., 1998b; Vaudry et al., 
1999; Vaudry et al., 2000b; Vaudry et al., 2000a; Vaudry et al., 2002; Vaudry et 
al., 2003; Zhokhov et al., 2008), hippocampus (Kambe and Miyata, 2012; Ago et 
al., 2011; Costa et al., 2009; Di et al., 2003; Liu et al., 2003; Macdonald et al., 
2005; Taylor et al., 2014), and suprachiasmatic nucleus (SCN) (Dziema and 
Obrietan, 2002; Irwin and Allen, 2010; Kopp et al., 1999; Kopp et al., 2001; 
Michel et al., 2006; Webb et al., 2013).  A few studies were done in the OE 
region, but there are no physiological studies of PACAP in the PAC1R-rich OB 
(Han and Lucero, 2005; Han and Lucero, 2006; Hegg et al., 2003).  However, it 
is the readily accessible CNS OB that has a straightforward entrance route from 
the rostral migratory stream (RMS) for the newly generated precursor cells, 
which actively replace interneurons, especially granule cells and periglomerular 
cells, throughout life. One significant aspect of my work is that it provides the first 
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physiological studies of PACAP in the mammalian olfactory bulb and lays the 
foundation for future studies on the role of PACAP in neuronal maturation and 
survival in the CNS.  I chose to look at the rapid actions of PACAP on the Ca2+ 
activity in the granule cell layer of the neonatal mouse olfactory bulb.  This is 
mainly because in other developing brain regions, the experience-independent 
(before the onset of any external sensory input) [Ca2+]i signal is suggested to be 
an essential part of neuronal development during the migrating neuroblast and 
immature neuron stages (Delwig et al., 2013; Hanganu-Opatz, 2010; Momose-
Sato and Sato, 2013; Cameron et al., 2009).   First week neonatal mice pups 
were used both for their adaptability to a relatively simple acute live slicing 
method and for study of PACAP effects during early maturation.  Rodents in 
general are valuable tools for studying neuronal development because they are 
born at the development stage corresponding to the end of the second 
gestational trimester in humans.  Thus, the majority of rodent brain network 
development occurs postnatally (Hanganu-Opatz, 2010).   
One of the biggest problems in the usage of PACAP for experiments or 
therapy is its rapid degradation.  Bourgault et al. (2008) evaluated the kinetics of 
two sizes of PACAP, the 38-amino acid version and the 27-amino acid version, 
using a calcium mobilization assay.  Both PACAP 38 and PACAP 27 are 
produced throughout the body and have similar EC50 and efficacy maximums.  
PACAP 38 was, however, more unstable in plasma, having a half-life of only 5 
minutes.  PACAP 27 has a half-life of more than 120 minutes (Bourgault et al., 
2008) and the degradation process should be slowed down by keeping the 
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solutions on ice for the day.  For the initial PACAP experiments, we used PACAP 
38 and found considerable variability in eliciting Ca2+ responses. For the 
experiments in Chapter 2, a new vial of dry PACAP 27 powder was freshly 
dissolved every experiment day and kept on ice until use.   
 The interesting question about PACAP in the granule cell layer (GCL) of 
the OB is where the peptides are naturally made.  We had some difficulty 
discerning endogenous PACAP protein expression in both OE and OB of 
neonatal mice because control studies revealed that the antibody staining was 
not specific.   
 The available published data for PACAP expression in the mouse OB 
pertains to the pattern of expression of messenger RNA for PACAP, which is 
seen mostly in the mitral cell layer (MCL) of OB, RMS, hippocampus, and 
cerebellum, whereas mRNA for PAC1 receptors is expressed in the granule cell 
layer (GCL) of OB and other regions of mouse brain (Allen Brain Altas, 2013; 
Jaworski and Proctor, 2000; Shioda et al., 1997; Matsuno et al., 2008).  Whether 
the patterns of mRNA expression give a practical answer as to where proteins 
are actually made is open to question.  For example, neuroblast cells do not 
express their GAD65 or 67 proteins until they enter the OB, but the cell 
characters are predetermined in the SVZ as shown by mRNA expression (Lopez-
Bendito et al., 2004; Plachez and Puche, 2012).  All we reliably know at this point 
is that most of the mRNA expression for PACAP peptide is in the MCL and RMS, 
while the highest mRNA expression for PAC1R within the OB is in the GCL.  
Either way, the mRNA expression suggests that PACAP is endogenously made 
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in neonatal OB.  Until we have a better idea of which regions and types of cell 
release PACAP, we may assume that PACAP is released into the GCL from the 
MCL and perhaps the RMS.  
 
Effects of PACAP on Granule Cells 
of the Neonatal Mouse OB 
 Briefly, the application of PACAP in acute OB slices shows that the 
activation of PAC1R+ granule cells (GCs) leads to activation of PAC1R- GCs, and 
provides a wide variety of [Ca2+]i activity responses ranging from simple 
transients (22%), slow to fast sawtooth oscillations (22% total), and sustained 
oscillations (56%) (Fig. 2.2).  Kopp et al. (1999) found somewhat similar 
percentages in cultured SCNs:  simple transients (20%), [Ca2+]i oscillations (15%) 
and “sustained oscillations” (called biphasic response with initial [Ca2+]i followed 
by plateau phase; 65%) (Kopp et al., 1999).  Possible factors contributing to the 
variety of responses are the dose of PACAP (Figs. 2.3 and 2.4) and the amount 
of downstream PACAP-induced activation of glutamate and/or GABA receptors 
(Figs. 2.5, 2.6, and 2.7).  The noted variable responses and mechanisms of 
PACAP-induced [Ca2+]i signaling in the CNS (Ago et al., 2011; Bath and Lee, 
2010; Costa et al., 2009; Dziema and Obrietan, 2002; Irwin and Allen, 2010; 
Kopp et al., 1999; Kopp et al., 2001; Vaudry et al., 1998a; Vaudry et al., 1999; 
Vaudry et al., 2000a) were also suggested to depend on the majority expression 
of PAC1R splice variants (Ago et al., 2011; Blechman and Levkowitz, 2013; Yan 
et al., 2013; Nicot and Dicicco-Bloom, 2001; Zhou et al., 2002).  The similar 
results between OB slices and Kopp et al. (1999) cultured SCNs suggest that 
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both regions may have similar heterogeneous expression of PAC1R splice 
variants.  It is, however, not clear whether the cultured SCNs have a similar 
amount of downstream PACAP-induced activation.  According to my work and 
that of Hanganu et al. (2009), glutamate and/or GABA do not need synaptic 
connections to activate multiple cells (Hanganu et al., 2009).  Further support 
that synaptic connections are not required for post-PACAP-induced types of 
[Ca2+]i responses is the observation that many aspects of the responses are not 
age-dependent.  OB slices from mice from the P2, P3, P4, and P5 age groups 
show similar PACAP-induced kinetics, intensity, and types of [Ca2+]i responses 
(data not shown).  The lack of age dependence occurs despite day-to-day 
changes in the percentage of immature versus mature PACAP-responding cells 
during the first neonatal week (Fig. 2.13).  The data suggest a decrease in the 
population of immature, non-PACAP-responding GCs (excitatory response to 
GABA) and an increase in the population of mature PACAP-responding GCs 
between P2 and P5. Thus PACAP appears to be increasingly active in 
modulating [Ca2+]i within days after birth, especially with the increasing number of 
PAC1R+ GCs and their increasingly complicated connections with the PAC1R+ 
MCs in particular (Fig 2.8).  Despite the age-related increase in the population of 
mature PACAP-responding GCs, the average kinetics and intensities of PACAP-
induced [Ca2+]i are not age-dependent. 
 Eight PAC1 splice variants have been officially identified and seven of 
these activate the phosphoinositide-phospholipase C (PLC) or/and acetylate 
cyclase (AC) second messenger pathways.  The eighth splice variant of PAC1 
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has no effect on PLC or AC pathways, but has been suggested to activate the L-
type voltage-gated [Ca2+]i channels (Zhou et al., 2002).  Recently, Basille-Dugay 
et al. (2013) showed that the immature cerebellar granule neurons have a partial 
decrease in PACAP-induced [Ca2+]i activity in N-type Ca2+ channel blocker, and 
the L, P, and Q blockers have no effect (Basille-Dugay et al., 2013).  It is not 
known why these neurons have what may be a unique PACAP-induced [Ca2+]i 
activity, but the actions of PACAP are apparently complex.  Variations in the 
mechanisms and intensities of PACAP-induced [Ca2+]i activity responses can 
arise from the type of PAC1R splice variant expressed (Ago et al., 2011; 
Blechman and Levkowitz, 2013; Nicot and Dicicco-Bloom, 2001; Yan et al., 2013; 
Zhou et al., 2002).  Adding to the complicated [Ca2+]i activity is the relationship 
between PACAP-induced indirect release of glutamate and GABA transmitters.  
Figures 2.5, 2.6, and 2.7 show evidence that PACAP indirectly releases 
transmitters, which was also observed in SCN (Dziema and Obrietan, 2002; 
Kopp et al., 1999; Kopp et al., 2001) and the hippocampus (Roberto and Brunelli, 
2000; Roberto et al., 2001).  However, several labs suggested that PACAP 
mainly acts as an excitatory or inhibitory modulator of glutamatergic activity and 
has no significant effect on GABA activity in SCNs (Dziema and Obrietan, 2002; 
Kopp et al., 2001; Michel et al., 2006), hippocampus (53), and retina (Webb et 
al., 2013).  On the other hand, the scientists who accept the concept of excitatory 
GABA responses believe that coordinated [Ca2+]i activity through the release and 
modulation of glutamate and GABA is critical to the development of the CNS, 
especially during the stage when the animal has no experience-dependent 
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activity for shaping sensory perception (Hanganu-Opatz, 2010).  Hanganu et al. 
(2009) showed that the depolarizing GABA is released within the developing 
neonatal cortex from both synaptic and nonsynaptic sources (Hanganu et al., 
2009), which may be what happened to the OB GCs in my findings.  My work is 
the first to show the significant involvement of PACAP-induced GABA release as 
an excitatory factor in developing CNS neurons.  Furthermore, I have shown that 
PACAP by itself induced an overall strong increase in [Ca2+] activity, and that this 
increase of [Ca2+] activity is often further boosted by the cell-supplied glutamate 
and GABA.      
 
Dose-dependent Effects of PACAP 
 My interpretation of the dose-dependent effects is based on the changes 
of [Ca2+]i.  There is not a good way for me to know whether PACAP actually 
depolarized or hyperpolarized the membrane potential because PACAP could in 
many cases be simply modulating/enhancing the activity of other 
neurotransmitters, which we know usually leads to depolarization (Costa et al., 
2009; Michel et al., 2006; Pugh et al., 2010).  PACAP is capable of 
hyperpolarizing mature cells via the release of GABA.  Although the 
overwhelming percentage of migrating and immature neurons have a GABA-
induced excitatory response, I did rarely find cells (out of 90 slices I used for the 
paper) displaying a clear PACAP-induced rapid decrease in [Ca2+]i activity with a 
recovery of less than 120 seconds.  Two possible factors for having so few 
decreased Ca2+ responses are that GABA usually only reduces (not blocks) 
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glutatmatergic responses and there are not as many mature GCL cells during the 
first neonatal week as in adult.   
 Based on PACAP dose-response studies and use of PAC1R antagonists, 
I believe that the dose of PACAP used in experiments should be carefully 
determined for future investigations.  The main reason is that there are possible 
artifactual effects in using excessive PACAP, which is suggested to be toxic (Di 
et al., 2012; Freson et al., 2004; Lang et al., 2006). Some researchers that did in 
vitro experiments used extremely high [PACAP] doses of 100–200 nM to obtain 
maximal neuroprotective effects and to avoid the variability in kinetics and 
intensities of responses observed at the lower concentrations (Masmoudi et al., 
2003; Pugh et al., 2010; Scharf et al., 2008; Vaudry et al., 2002; Basille-Dugay et 
al., 2013; Dziema and Obrietan, 2002; Kopp et al., 1999; Kopp et al., 2001). At 
least one lab also used extremely high [PACAP] of 100 nM in slices (Sun et al., 
2003).  The concern of using lower doses closer to EC50 is warranted because 
my data had an overall larger standard error at lower PACAP concentrations for 
latency, time to peak, amplitude, and area under curve (Fig. 2.4).  There, 
however, may be drawbacks with using high doses because 100 nM PACAP had 
lower average amplitudes than 40 nM PACAP (Fig. 2.4C). Our frequency 
histogram analysis suggests that 100 nM PACAP activates more cells that either 
have excessively low PAC1R+ expression or weaker GluR and/or GABAR 
connections (Fig. 2.4E).   
 My studies focused on the GCL region of the OB, where PAC1R mRNA 
expression is very high (Allen Brain Altas, 2013; Jaworski and Proctor, 2000).  
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Michel et al. (2006), who tested PACAP on hippocampal slices using Ca2+ 
imaging, used 10 nM as an experimental working concentration.  This lab, 
however, did test 100 nM PACAP and recorded that the slices have a small 
[Ca2+]i increase (only 6% ± 1%) (Michel et al., 2006).  In comparison, I observed 
a small [Ca2+]i average increase at concentrations below 10 nM, but significantly 
larger average PACAP-induced [Ca2+]i  for concentrations above 10 nM PACAP 
(Fig. 2.4C) than what Michel et al. (2006) found for 100 nM.  Part of the reason 
for the difference between my OB slices and those in the hippocampus may be 
the expression of PAC1Rs and the dominant PAC1R splice variety (Ago et al., 
2011; Blechman and Levkowitz, 2013; Nicot and Dicicco-Bloom, 2001; Yan et al., 
2013; Zhou et al., 2002).  Thus, although 40 nM PACAP was optimal for the OB 
slices, it may not be the most fitting for other regions.  In the case of the first 
week neonatal mouse OB, a concentration of 10 nM PACAP yields fewer cells 
with more variability (high standard error as seen in Fig. 2.4) and 100 nM may be 
excessive.   
Another reason to carefully determine the dose of PACAP is the difference 
in the ability to block PACAP between cultured cells and slices.  Despite using 
PACAP concentrations as much as 10–30 fold higher (10–100 nM) than the 
known EC50 (0.25–3 nM for cultured cells) (Jozwiak-Bebenista et al., 2007; 
Kambe and Miyata, 2012; Nicot and Dicicco-Bloom, 2001; Dickson et al., 2006), 
the researchers using in vitro assays successfully proved that they could block 
their chosen PACAP doses with 600–1000 nM PACAP6-38 (PACAP 38 with first 
6 peptides deleted) (Masmoudi et al., 2003; Shioda et al., 2006; Vaudry et al., 
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2002; Ohno et al., 2005).  Unfortunately, we never had the same success in our 
in situ work without adding 1 µM M65 [a PAC1R-specific antagonist (Uchida et 
al., 1998)] to the 150 nM PACAP6-38 (Fig. 2.3C).  Costa et al. (2009) had a 
similar PACAP 6-38 blockage problem in their hippocampus slices.  They were 
able to block 0.5 nM PACAP with 500 nM PACAP 6-38.  However, at 10 nM, 
PACAP was not blockable at 500 nM PACAP 6-38 (Costa et al., 2009).  
Furthermore, the recent findings by Doan et al. (2012) suggested that the 
prolonged, post-PACAP [Ca2+]i activity perseveres, especially in situ, and 
requires higher antagonist concentrations compared to in vitro (Doan et al., 
2012a; Doan et al., 2012b).  This is possibly because of intact cell connections in 
acute slices that are rarely present in culture.   
 
Future Directions for Evaluating PACAP-induced 
[Ca2+]i Activity in OB 
 The following paragraphs discuss the experimental projects I did not 
foresee we would like to do until the data was analyzed.   
 I would have liked to directly confirm that GAD67+ GCs are responsible for 
the observed shift in PACAP responsiveness between P2 and P5 by using GAD 
67 tdTomato mice. Unfortunately, I did not have access to this mouse line and 
did not realize they would be important until after all of the experiments using 
Dlx2+ and GAD65+ labeled cells were completed and analyzed. On the other 
hand, given that there are so many studies showing that almost all GAD65- GCL 
cells are GAD67+, I am convinced it is safe to call the unlabeled GCL cells in 
GAD65 dt Tomato mice “GAD67 cells” (Parrish-Aungst et al., 2007).   
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 A second experiment I would have liked to do was to follow the time 
course of glutamate responses in P2–P5 OB. Since glutamate amplifies the 
PACAP response, I hypothesized that the increase in PACAP responsive cells at 
P5 is a combination of increased glutamatergic connectivity in addition to the 
increased PAC1R expression that I found using ICC.  
 The third experiment of interest would be to address the possibility of 
action potentials having an influence on the pattern of PACAP-induced [Ca2+]i 
activity.  The role of PACAP-induced action potentials is thoroughly dismissed in 
Baxter et al. (2011) (Baxter et al., 2011).  TTX was shown to block PACAP-
induced [Ca2+]i activity in cultured brain (cortical) neurons.  Curiously, I found no 
significant reduction in the number of PACAP [Ca2+]i activity responding cells in 
the presence of TTX (data not shown).  The main reason I used TTX in the 
cocktail containing both glutamate and GABA antagonists was to reduce possible 
spontaneous [Ca2+]i activity not induced by PACAP (Baxter et al., 2011; Costa et 
al., 2009).  Baxter et al. (2011), however, used cultures and I used slices.  On the 
other hand, other investigators acquired data indicating that TTX did not block 
PACAP-induced changes in [Ca2+]i activity in cultured cells (Kopp et al., 2001) 
and brain slices (Sun et al., 2003; Michel et al., 2006; Costa et al., 2009).  This 
leads me to the question of whether the PACAP responses obtained in the 
presence of the glutamate and GABA antagonists were a direct effect of PACAP 
binding to PAC1Rs and increasing [Ca2+]i, or some of the PAC1R- cells are 
mediated through gap junctional-couplings (Hanganu et al., 2009).  The more 
straightforward mechanism would be the PAC1R-direct increase of [Ca2+]i activity 
 156
through mainly the PLC and/or AC pathways in the neurons [data not shown  
(Azuma et al., 2013; Kanekar et al., 2010; Pardi and Margiotta, 1999; Zhou et al., 
2002)]. 
 
PACAP-induced Activation of PLC and/or AC Pathways 
  
There is still some controversy over the type of pathways activated by 
PACAP in CNS.  The factors for the controversy include types of experiments 
done, the kind of cells used, and especially the stage of development.  According 
to the majority of references, usually using H89 or cAMPS-Rp as a PKA inhibitor 
for the AC pathway, the PKA-dependent pathway activates multiple 
neuroprotection mechanisms, which reduce the cleavage of pro-apoptotic 
caspace (Botia et al., 2007; Inoue et al., 2000; Masmoudi et al., 2003; McIlvain et 
al., 2006; Mei et al., 2004; Onoue et al., 2002; Payet et al., 2003; Shoge et al., 
1999; Vaudry et al., 1998a; Vaudry et al., 2003; Wang et al., 2005; Costa et al., 
2009; Dziema and Obrietan, 2002; Vaudry et al., 2000a; Bhave and Hoffman, 
2004; Nakamachi et al., 2006).  Evidence of the neuroprotective roles of the PLC 
pathway, which include PKC, is sparse (Bhave and Hoffman, 2004; Han and 
Lucero, 2006; Kanekar et al., 2010; Nakamachi et al., 2006; Vaudry et al., 
2000a).  This is because some references directly addressing the PKA pathway 
in neuroprotection do not provide data concerning the PKC pathway (McIlvain et 
al., 2006; Onoue et al., 2002; Shoge et al., 1999; Costa et al., 2009).  The study 
of the PKC pathway used various approaches.  For some work, PMA was used 
as an agonist to support the involvement of the PKC pathway in neuroprotection 
(Kanekar et al., 2010; Masmoudi et al., 2003; Vaudry et al., 2000a; Watanabe et 
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al., 2006).  Other labs indirectly block downstream PKC by blocking the upstream 
PLC pathway.  U-73122, is commonly used as an indirect inhibitor of PKC in this 
way (Han and Lucero, 2006; Masmoudi et al., 2003; Payet et al., 2003; Bhave 
and Hoffman, 2004; Nakamachi et al., 2006; Watanabe et al., 2006).  However, 
the inhibition of PKC can be done with bisindolylmaleimide I or chelerythrine 
(Kopp et al., 1999; Vaudry et al., 2003; Vaudry et al., 1998a; Dziema and 
Obrietan, 2002; Masmoudi et al., 2003; Vaudry et al., 2000a).  Additionally, there 
are PACAP-induced neuroprotective pathways that are suggested to be 
independent of PKA or/and PKC.  For example, the AC pathway can bypass 
PKA, activating the mechanisms that inhibit apoptosis (Baxter et al., 2011; 
Vaudry et al., 2003).  Although not included, my preliminary studies showed that 
in mouse OB slices, both the AC and PLC pathways are activated by PACAP; 
however, further work is needed to verify the results. 
 
Ca2+ Activity in Sustentacular Cells of Mouse OE 
 Chapter 3 evaluated the recently evolving understanding of the role of 
sustentacular cells in the OE.  Sustentacular cells are one of the four primary cell 
types found in the OE.  These cells were thought to be simply epithelial support 
cells before evidence produced in the 1970s and 1980s suggested that they also 
have glial-like functions (Breipohl et al., 1974; Getchell, 1986; Okano and Takagi, 
1974; Rafols and Getchell, 1983).  What we did was to use the modern calcium 
imaging technique to evaluate the regulation of [Ca2+]i, observing the effect of 
sustentacular cells on neighboring cells.  The ATP/UTP or ACh-induced [Ca2+]i 
oscillation among the sustentacular cells shows that the GPCRs responding to 
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ATP/UTP or ACh have a key role in initiating [Ca2+]i oscillations through the PLC 
pathway (Figs. 3.2, 3.3, 3.5, 3.6, and 3.7).  Given that the PLC pathway is 
involved and there was no significant evidence for electrically signaled 
extracellular Ca2+ entry (Fig. 3.4), the coordination of the [Ca2+]i oscillation 
between cells is suggested to be primarily through gap junctions (Vogalis et al., 
2005a; Vogalis et al., 2005b).  The Ca2+ and IP3 ions and molecules are believed 
to diffuse through gap junctions and provide a communication method between 
adjacent sustentacular cells, basal cells, and neurons.   
 I did the Ca2+ imaging data for Fig. 3.1 (calcium waves, UTP-induced Ca2+ 
transient starting at apical surface and reaching the basal cell layer), 3.2 (multiple 
applications of UTP), 3.4C and D (BAPTA-AM treated and odorant treated), and 
3.6B, C, and D (PLC antagonist) for the project covered in Chapter 3.  This 
project was one of my first successful experimental projects, and the paper was 
published in 2005.  Back then, I used Ringer’s solution for running experiments 
on OE slices.  After my later work, using the extremely vulnerable OB slices 
(Chapter 2), I wonder what kind of intracellular [Ca2+] oscillation I would see in 
the OE if I were able to have more intact neurons to work with, that is, if I sliced 
and tested the OE using the solutions (low Na+/high Mg2+ bicarbonate buffer for 
cutting and low Ca2+ artificial cerebral spinal fluid for imaging) I used for the OB in 
Chapter 2.  According to the data using Ringer’s solution, we saw spontaneous 
intracellular calcium waves in 4 out of 524 slices tested (Fig. 3.1) and fast 
sawtooth [Ca2+]i oscillations among the sustentacular cells (Fig. 3.2).  If we had 
used the solution used in Chapter 2, would we have seen more slices with 
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spontaneous intracellular calcium waves?  Larger intensity sustained [Ca2+]i 
activity, since more of the sensitive neurons possibly would be intact?  Since only 
a few of the possible OSNs responded to odorants (Fig. 3.4D), would we see 
more OSNs responding to the odorant cocktail mixture (containing a wide variety 
of odorants)?  Would the odorant-induced [Ca2+]i activity of the OSNs have a 
larger intensity?  
 Figure 3.1C shows the Ca2+ transients starting at the apical surface and 
reaching the basal layer.  This was one of the things I noticed and pointed out.  
Unfortunately, the drawback of using slices was the high flexibility of severed 
connections and not having all of the cells from the apical to basal layer present 
in the same imaging range.  Since we suggested that the gap junctions between 
sustentacular cells (Vogalis et al., 2005a) may be a potential unopposed route 
factor in the ongoing post-UTP [Ca2+]i oscillation, it would be a good project to 
study the mechanisms of initiation and propagation of the intercellular calcium 
waves.  If one could improve the opportunities to Ca2+ image the connections 
between sustentacular cells as well as OE connections between the apical to 
basal layer, we could get data showing whether the spread of elevated [Ca2+]i 
between sustentacular cells was done mostly through gap junctions or not. 
 
Role of Cetn2 in Development and 
Maintenance of Olfactory Cilia 
 Chapter 4 is the evaluation of an evolutionarily well-preserved calmodulin-
related Ca2 +-binding protein in the mouse OE.  The Cetn2 gene was one of the 
four identified centrins, and it was chosen for its ubiquitous expression across 
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eukaryotes from protists and yeast to humans (Dantas et al., 2011; Kleylein-Sohn 
et al., 2007; Koblenz et al., 2003; Selvapandiyan et al., 2004).   
So far, the known germline centrin study done was on Cetn1, which is 
expressed mainly in male germ cells (Avasthi et al., 2013).  We looked at the 
Cetn2 knockout, which showed multiple signs of mutation deficiencies (Fig. 4.1). 
Previously, a Cetn2 study was done in zebrafish (Delaval et al., 2011), but since 
the role of centrins appears to vary among species and cell types, the fish results 
may not be similar to those in mammal models such as mice.  As an association 
with basal bodies of OEs, the Cetn2 deletion mutant has shown its effect on 
mouse cilia development (e.g., loss of cilia) (Figs. 4.2, A, G, and H, 4.3, 4.4, 4.5, 
and 4.17) and function (impaired transport of transmembrane signaling) (Figs. 
4.2, B–F, 4.8, 4.9, 4.13, 4.14, 4.15, 4.16, and 4.17).  The project was a 
collaboration with the Baehr lab, which developed the knockout mice lines for 
both the Cetn2 and Pde6δ gene (Appendix B) projects.  The target genes in both 
projects were believed to have roles in the transportation of proteins for 
transmission mechanisms, which models some of the defects in ciliagenesis 
seen in human patients.  The study of ciliagenesis is currently a popular field of 
research because better understanding of defects in cilia (and flagella) may aid in 
the treatment of ciliated cells in multiple organs from sensory systems to lungs 
(Benadiba et al., 2012; Bontems et al., 2014; Dammermann et al., 2009; Gate et 
al., 2012; Liu et al., 2011; Mata et al., 2012; Rachel et al., 2012; Wu and Tang, 
2012).  For the Cetn2 case, we summarized that the CETN2 proteins may recruit 
nonmuscle myosin II to the OSN dendritic knob, a question for further 
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investigation.  That is because the nonmuscle myosin II may have a role in 
regulating ACIII and CNGA2 vesicle trafficking at the cilia base (Figs. 4.9, 4.13, 
and 4.17), given that ACIII and CNGA2 are absent from the region in Cetn2 
knockouts.  As a result, the Cetn2 knockouts have dysosmia.  The knockouts 
may also have situs inversus and hydrocephalus (in ~30% of animals examined).  
Since the Cetn2 gene is expressed across a wide range of living organisms, 
there must be more systems being affected in animals with Cetn2 defection.  The 
retinal system, which has ciliary cells, was examined and no defects were noted 
(Figs. 4.10, 4.11, and 4.12).  No defects were noted in the respiratory system 
either (Figs. 4.7 and 4.8).  However, defects were noted in ependymal cells (Figs. 
4.17 and 4.18).  Further studies in collaboration with urinary/excretory and/or 
auditory system labs could lead to discovering other less obvious phenotypical 
effects. 
My part in this work was testing the OE tissue of Cetn2 mutants and their 
wild type littermates using an electro-olfactogram (EOG), which revealed that the 
Cetn2 mutants have dysomia.  The most important observation was that when 
doing EOG testing, using heterozygous mice as wildtypes has not worked out 
well.  In theory, the heterozygous mice are supposed to develop and function like 
wildtypes because they displayed normal wildtype-like phenotypes in physical 
appearance (weight, size), behavior (food locating), and physiology (no 
hydrocephalus or situs inversus).  However, odorant responses as measured by 
the EOG were always 10 to 30% lower in OE tissue from heterozygous mice than 
responses in wildtype OE.  This was true for each of the five different lines I 
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tested; I never had even one heterozygote display the expected wildtype level of 
responses. 
All of these three projects have advanced the basic understanding of 
Ca2+-dependent processes through the GPCRs in OE and OB.  In summary, 
PACAP activates multiple pathways, mainly PLC and/or AC pathways, through 
PAC1 GPCRs, elevating intracellular Ca2+.  The PACAP-induced Ca2+ activity is 
further modulated through the cell-supplied glutamate and GABA.  In 
sustentacular cells, intracellular Ca2+ is elevated through the activation of 
purinergic (UTP) and muscarinic (acetylcholine) GPCRs.  Cetn2 mutants are 
dysosmic due to the lack of cilia surface for their odorant GPCRs, which activate 
the AC pathway, in part due to the delocalization of the AC protein.   
 
Reference List 
 1.  Allen Brain Altas.  2013.  
 2.  Ago Y, Yoneyama M, Ishihama T, Kataoka S, Kawada K, Tanaka T, 
Ogita K, Shintani N, Hashimoto H, Baba A, Takuma K, Matsuda T. 
Role of endogenous pituitary adenylate cyclase-activating polypeptide in 
adult hippocampal neurogenesis. Neuroscience 172: 554–561, 2011. 
 3.  Allais A, Burel D, Isaac ER, Gray SL, Basille M, Ravni A, Sherwood 
NM, Vaudry H, Gonzalez BJ. Altered cerebellar development in mice 
lacking pituitary adenylate cyclase-activating polypeptide. Eur J Neurosci 
25: 2604–2618, 2007. 
 4.  Atlasz T, Szabadfi K, Kiss P, Tamas A, Toth G, Reglodi D, Gabriel R. 
Evaluation of the protective effects of PACAP with cell-specific markers in 
ischemia-induced retinal degeneration. Brain Res Bull 81: 497–504, 2010. 
 5.  Avasthi P, Scheel JF, Ying G, Frederick JM, Baehr W, Wolfrum U. 
Germline deletion of Cetn1 causes infertility in male mice. J Cell Sci 126: 
3204–3213, 2013. 
 6.  Azuma M, Wada K, Leprince J, Tonon MC, Uchiyama M, Takahashi A, 
Vaudry H, Matsuda K. The octadecaneuropeptide stimulates 
 163
somatolactin release from cultured goldfish pituitary cells. J 
Neuroendocrinol 25: 312–321, 2013. 
 7.  Basille-Dugay M, Vaudry H, Fournier A, Gonzalez B, Vaudry D. 
Activation of PAC1 receptors in rat cerebellar granule cells stimulates both 
calcium mobilization from intracellular stores and calcium influx through N-
type calcium channels. Front Endocrinol (Lausanne) 4: 56, 2013. 
 8.  Bath KG, Lee FS. Neurotrophic factor control of adult SVZ neurogenesis. 
Dev Neurobiol 70: 339–349, 2010. 
 9.  Baxter PS, Martel MA, McMahon A, Kind PC, Hardingham GE. Pituitary 
adenylate cyclase-activating peptide induces long-lasting neuroprotection 
through the induction of activity-dependent signaling via the cyclic AMP 
response element-binding protein-regulated transcription co-activator 1. J 
Neurochem 118: 365–378, 2011. 
 10.  Benadiba C, Magnani D, Niquille M, Morle L, Valloton D, Nawabi H, 
Ait-Lounis A, Otsmane B, Reith W, Theil T, Hornung JP, Lebrand C, 
Durand B. The ciliogenic transcription factor RFX3 regulates early midline 
distribution of guidepost neurons required for corpus callosum 
development. PLoS Genet 8: e1002606, 2012. 
 11.  Bhave SV, Hoffman PL. Phosphatidylinositol 3'-OH kinase and protein 
kinase A pathways mediate the anti-apoptotic effect of pituitary adenylyl 
cyclase-activating polypeptide in cultured cerebellar granule neurons: 
modulation by ethanol. J Neurochem 88: 359–369, 2004. 
 12.  Blechman J, Levkowitz G. Alternative splicing of the pituitary adenylate 
cyclase-activating polypeptide receptor PAC1: mechanisms of fine tuning 
of brain activity. Front Endocrinol (Lausanne) 4: 55, 2013. 
 13.  Bontems F, Fish RJ, Borlat I, Lembo F, Chocu S, Chalmel F, Borg JP, 
Pineau C, Neerman-Arbez M, Bairoch A, Lane L. C2orf62 and TTC17 
are involved in actin organization and ciliogenesis in zebrafish and human. 
PLoS One 9: e86476, 2014. 
 14.  Botia B, Basille M, Allais A, Raoult E, Falluel-Morel A, Galas L, Jolivel 
V, Wurtz O, Komuro H, Fournier A, Vaudry H, Burel D, Gonzalez BJ, 
Vaudry D. Neurotrophic effects of PACAP in the cerebellar cortex. 
Peptides 28: 1746–1752, 2007. 
 15.  Bourgault S, Vaudry D, Botia B, Couvineau A, Laburthe M, Vaudry H, 
Fournier A. Novel stable PACAP analogs with potent activity towards the 
PAC1 receptor. Peptides 29: 919–932, 2008. 
 16.  Bourgault S, Vaudry D, Dejda A, Doan ND, Vaudry H, Fournier A. 
Pituitary adenylate cyclase-activating polypeptide: focus on structure-
 164
activity relationships of a neuroprotective Peptide. Curr Med Chem 16: 
4462–4480, 2009. 
 17.  Bovetti S, Gribaudo S, Puche AC, De MS, Fasolo A. From progenitors 
to integrated neurons: role of neurotransmitters in adult olfactory 
neurogenesis. J Chem Neuroanat 42: 304–316, 2011. 
 18.  Breipohl W, Laugwitz HJ, Bornfeld N. Topological relations between the 
dendrites of olfactory sensory cells and sustentacular cells in different 
vertebrates. An ultrastructural study. J Anat 117: 89–94, 1974. 
 19.  Breton-Provencher V, Lemasson M, Peralta MR, III, Saghatelyan A. 
Interneurons produced in adulthood are required for the normal 
functioning of the olfactory bulb network and for the execution of selected 
olfactory behaviors. J Neurosci 29: 15245–15257, 2009. 
 20.  Breton-Provencher V, Saghatelyan A. Newborn neurons in the adult 
olfactory bulb: unique properties for specific odor behavior. Behav Brain 
Res 227: 480–489, 2012. 
 21.  Cameron DB, Raoult E, Galas L, Jiang Y, Lee K, Hu T, Vaudry D, 
Komuro H. Role of PACAP in controlling granule cell migration. 
Cerebellum 8: 433–440, 2009. 
 22.  Chen Y, Samal B, Hamelink CR, Xiang CC, Chen Y, Chen M, Vaudry 
D, Brownstein MJ, Hallenbeck JM, Eiden LE. Neuroprotection by 
endogenous and exogenous PACAP following stroke. Regul Pept 137: 4–
19, 2006. 
 23.  Christie KJ, Turnley AM. Regulation of endogenous neural 
stem/progenitor cells for neural repair-factors that promote neurogenesis 
and gliogenesis in the normal and damaged brain. Front Cell Neurosci 6: 
70, 2012. 
 24.  Costa L, Santangelo F, Li VG, Ciranna L. Modulation of AMPA receptor-
mediated ion current by pituitary adenylate cyclase-activating polypeptide 
(PACAP) in CA1 pyramidal neurons from rat hippocampus. Hippocampus 
19: 99–109, 2009. 
 25.  Cowan CM, Roskams AJ. Apoptosis in the mature and developing 
olfactory neuroepithelium. Microsc Res Tech 58: 204–215, 2002. 
 26.  Dammermann A, Pemble H, Mitchell BJ, McLeod I, Yates JR, III, 
Kintner C, Desai AB, Oegema K. The hydrolethalus syndrome protein 
HYLS-1 links core centriole structure to cilia formation. Genes Dev 23: 
2046–2059, 2009. 
 165
 27.  Dantas TJ, Wang Y, Lalor P, Dockery P, Morrison CG. Defective 
nucleotide excision repair with normal centrosome structures and 
functions in the absence of all vertebrate centrins. J Cell Biol 193: 307–
318, 2011. 
 28.  Dejda A, Jolivel V, Bourgault S, Seaborn T, Fournier A, Vaudry H, 
Vaudry D. Inhibitory effect of PACAP on caspase activity in neuronal 
apoptosis: a better understanding towards therapeutic applications in 
neurodegenerative diseases. J Mol Neurosci 36: 26–37, 2008. 
 29.  Delaval B, Covassin L, Lawson ND, Doxsey S. Centrin depletion 
causes cyst formation and other ciliopathy-related phenotypes in 
zebrafish. Cell Cycle 10: 3964–3972, 2011. 
 30.  Delwig A, Majumdar S, Ahern K, Lavail MM, Edwards R, Hnasko TS, 
Copenhagen DR. Glutamatergic neurotransmission from melanopsin 
retinal ganglion cells is required for neonatal photoaversion but not adult 
pupillary light reflex. PLoS One 8: e83974, 2013. 
 31.  Di MM, Cavallaro S, Ciranna L. Pituitary adenylate cyclase-activating 
polypeptide modifies the electrical activity of CA1 hippocampal neurons in 
the rat. Neurosci Lett 337: 97–100, 2003. 
 32.  Di MM, Peeters K, Loyen S, Thys C, Waelkens E, Overbergh L, 
Hoylaerts M, Van GC, Freson K. Pituitary adenylate cyclase-activating 
polypeptide (PACAP) impairs the regulation of apoptosis in 
megakaryocytes by activating NF-kappaB: a proteomic study. Mol Cell 
Proteomics 11: M111, 2012. 
 33.  Dickson L, Aramori I, Sharkey J, Finlayson K. VIP and PACAP receptor 
pharmacology: a comparison of intracellular signaling pathways. Ann NY 
Acad Sci 1070: 239–242, 2006. 
 34.  Doan ND, Chatenet D, Letourneau M, Vaudry H, Vaudry D, Fournier A. 
Receptor-independent cellular uptake of pituitary adenylate cyclase-
activating polypeptide. Biochim Biophys Acta 1823: 940–949, 2012a. 
 35.  Doan ND, Letourneau M, Vaudry D, Doucet N, Folch B, Vaudry H, 
Fournier A, Chatenet D. Design and characterization of novel cell-
penetrating peptides from pituitary adenylate cyclase-activating 
polypeptide. J Control Release 163: 256–265, 2012b. 
 36.  Doursout MF, Schurdell MS, Young LM, Osuagwu U, Hook DM, 
Poindexter BJ, Schiess MC, Bick DL, Bick RJ. Inflammatory cells and 
cytokines in the olfactory bulb of a rat model of neuroinflammation; 
insights into neurodegeneration? J Interferon Cytokine Res 33: 376–383, 
2013. 
 166
 37.  Dziema H, Obrietan K. PACAP potentiates L-type calcium channel 
conductance in suprachiasmatic nucleus neurons by activating the MAPK 
pathway. J Neurophysiol 88: 1374–1386, 2002. 
 38.  Falluel-Morel A, Aubert N, Vaudry D, Desfeux A, Allais A, Burel D, 
Basille M, Vaudry H, Laudenbach V, Gonzalez BJ. Interactions of 
PACAP and ceramides in the control of granule cell apoptosis during 
cerebellar development. J Mol Neurosci 36: 8–15, 2008. 
 39.  Falluel-Morel A, Chafai M, Vaudry D, Basille M, Cazillis M, Aubert N, 
Louiset E, de JS, Le Bigot JF, Fournier A, Gressens P, Rostene W, 
Vaudry H, Gonzalez BJ. The neuropeptide pituitary adenylate cyclase-
activating polypeptide exerts anti-apoptotic and differentiating effects 
during neurogenesis: focus on cerebellar granule neurones and embryonic 
stem cells. J Neuroendocrinol 19: 321–327, 2007. 
 40.  Freson K, Hashimoto H, Thys C, Wittevrongel C, Danloy S, Morita Y, 
Shintani N, Tomiyama Y, Vermylen J, Hoylaerts MF, Baba A, Van GC. 
The pituitary adenylate cyclase-activating polypeptide is a physiological 
inhibitor of platelet activation. J Clin Invest 113: 905–912, 2004. 
 41.  Gate D, Danielpour M, Levy R, Breunig JJ, Town T. Basic biology and 
mechanisms of neural ciliogenesis and the B9 family. Mol Neurobiol 45: 
564–570, 2012. 
 42.  Getchell TV. Functional properties of vertebrate olfactory receptor 
neurons. Physiol Rev 66: 772–818, 1986. 
 43.  Han P, Lucero MT. Pituitary adenylate cyclase activating polypeptide 
reduces A-type K+ currents and caspase activity in cultured adult mouse 
olfactory neurons. Neuroscience 134: 745–756, 2005. 
 44.  Han P, Lucero MT. Pituitary adenylate cyclase activating polypeptide 
reduces expression of Kv1.4 and Kv4.2 subunits underlying A-type K(+) 
current in adult mouse olfactory neuroepithelia. Neuroscience 138: 411–
419, 2006. 
 45.  Hanganu IL, Okabe A, Lessmann V, Luhmann HJ. Cellular mechanisms 
of subplate-driven and cholinergic input-dependent network activity in the 
neonatal rat somatosensory cortex. Cereb Cortex 19: 89–105, 2009. 
 46.  Hanganu-Opatz IL. Between molecules and experience: role of early 
patterns of coordinated activity for the development of cortical maps and 
sensory abilities. Brain Res Rev 64: 160–176, 2010. 
 47.  Hegg CC, Au E, Roskams AJ, Lucero MT. PACAP is present in the 
olfactory system and evokes calcium transients in olfactory receptor 
neurons. J Neurophysiol 90: 2711–2719, 2003. 
 167
 48.  Inoue M, Fujishiro N, Ogawa K, Muroi M, Sakamoto Y, Imanaga I, 
Shioda S. Pituitary adenylate cyclase-activating polypeptide may function 
as a neuromodulator in guinea-pig adrenal medulla. J Physiol 528: 473–
487, 2000. 
 49.  Irwin RP, Allen CN. Neuropeptide-mediated calcium signaling in the 
suprachiasmatic nucleus network. Eur J Neurosci 32: 1497–1506, 2010. 
 50.  Jaworski DM, Proctor MD. Developmental regulation of pituitary 
adenylate cyclase-activating polypeptide and PAC(1) receptor mRNA 
expression in the rat central nervous system. Brain Res Dev Brain Res 
120: 27–39, 2000. 
 51.  Jozwiak-Bebenista M, Dejda A, Nowak JZ. Effects of PACAP, VIP and 
related peptides on cyclic AMP formation in rat neuronal and astrocyte 
cultures and cerebral cortical slices. Pharmacol Rep 59: 414–420, 2007. 
 52.  Kambe Y, Miyata A. Role of mitochondrial activation in PACAP 
dependent neurite outgrowth. J Mol Neurosci 48: 550–557, 2012. 
 53.  Kanekar S, Gandham M, Lucero MT. PACAP protects against 
TNFalpha-induced cell death in olfactory epithelium and olfactory placodal 
cell lines. Mol Cell Neurosci 45: 345–354, 2010. 
 54.  Kelsch W, Mosley CP, Lin CW, Lois C. Distinct mammalian precursors 
are committed to generate neurons with defined dendritic projection 
patterns. PLoS Biol 5: e300, 2007. 
 55.  Kiss P, Tamas A, Lubics A, Lengvari I, Szalai M, Hauser D, Horvath 
ZS, Racz B, Gabriel R, Babai N, Toth G, Reglodi D. Effects of systemic 
PACAP treatment in monosodium glutamate-induced behavioral changes 
and retinal degeneration. Ann NY Acad Sci 1070: 365–370, 2006. 
 56.  Kleylein-Sohn J, Westendorf J, Le CM, Habedanck R, Stierhof YD, 
Nigg EA. Plk4-induced centriole biogenesis in human cells. Dev Cell 13: 
190–202, 2007. 
 57.  Koblenz B, Schoppmeier J, Grunow A, Lechtreck KF. Centrin 
deficiency in Chlamydomonas causes defects in basal body replication, 
segregation and maturation. J Cell Sci 116: 2635–2646, 2003. 
 58.  Kopp MD, Meissl H, Dehghani F, Korf HW. The pituitary adenylate 
cyclase-activating polypeptide modulates glutamatergic calcium signalling: 
investigations on rat suprachiasmatic nucleus neurons. J Neurochem 79: 
161–171, 2001. 
 59.  Kopp MD, Schomerus C, Dehghani F, Korf HW, Meissl H. Pituitary 
adenylate cyclase-activating polypeptide and melatonin in the 
 168
suprachiasmatic nucleus: effects on the calcium signal transduction 
cascade. J Neurosci 19: 206–219, 1999. 
 60.  Kuwabara T, Asashima M. Regenerative medicine using adult neural 
stem cells: the potential for diabetes therapy and other pharmaceutical 
applications. J Mol Cell Biol 4: 133–139, 2012. 
 61.  Lang B, Song B, Davidson W, MacKenzie A, Smith N, McCaig CD, 
Harmar AJ, Shen S. Expression of the human PAC1 receptor leads to 
dose-dependent hydrocephalus-related abnormalities in mice. J Clin 
Invest 116: 1924–1934, 2006. 
 62.  Lemasson M, Saghatelyan A, Olivo-Marin JC, Lledo PM. Neonatal and 
adult neurogenesis provide two distinct populations of newborn neurons to 
the mouse olfactory bulb. J Neurosci 25: 6816–6825, 2005. 
 63.  Liu L, Zhang M, Xia Z, Xu P, Chen L, Xu T. Caenorhabditis elegans 
ciliary protein NPHP-8, the homologue of human RPGRIP1L, is required 
for ciliogenesis and chemosensation. Biochem Biophys Res Commun 
410: 626–631, 2011. 
 64.  Liu Z, Geng L, Li R, He X, Zheng JQ, Xie Z. Frequency modulation of 
synchronized Ca2+ spikes in cultured hippocampal networks through G-
protein-coupled receptors. J Neurosci 23: 4156–4163, 2003. 
 65.  Lopez-Bendito G, Sturgess K, Erdelyi F, Szabo G, Molnar Z, Paulsen 
O. Preferential origin and layer destination of GAD65-GFP cortical 
interneurons. Cereb Cortex 14: 1122–1133, 2004. 
 66.  Macdonald DS, Weerapura M, Beazely MA, Martin L, Czerwinski W, 
Roder JC, Orser BA, Macdonald JF. Modulation of NMDA receptors by 
pituitary adenylate cyclase activating peptide in CA1 neurons requires G 
alpha q, protein kinase C, and activation of Src. J Neurosci 25: 11374–
11384, 2005. 
 67.  Makela J, Koivuniemi R, Korhonen L, Lindholm D. Interferon-gamma 
produced by microglia and the neuropeptide PACAP have opposite effects 
on the viability of neural progenitor cells. PLoS One 5: e11091, 2010. 
 68.  Markhotina N, Liu GJ, Martin DK. Contractility of retinal pericytes grown 
on silicone elastomer substrates is through a protein kinase A-mediated 
intracellular pathway in response to vasoactive peptides. IET 
Nanobiotechnol 1: 44–51, 2007. 
 69.  Masmoudi O, Gandolfo P, Leprince J, Vaudry D, Fournier A, Patte-
Mensah C, Vaudry H, Tonon MC. Pituitary adenylate cyclase-activating 
polypeptide (PACAP) stimulates endozepine release from cultured rat 
astrocytes via a PKA-dependent mechanism. FASEB J 17: 17–27, 2003. 
 169
 70.  Mata M, Sarrion I, Armengot M, Carda C, Martinez I, Melero JA, 
Cortijo J. Respiratory syncytial virus inhibits ciliagenesis in differentiated 
normal human bronchial epithelial cells: effectiveness of N-acetylcysteine. 
PLoS One 7: e48037, 2012. 
 71.  Matsuno R, Ohtaki H, Nakamachi T, Watanabe J, Yofu S, Hayashi D, 
Takeda T, Nonaka N, Seki M, Nakamura M, Itabashi K, Shioda S. 
Distribution and localization of pituitary adenylate cyclase-activating 
polypeptide-specific receptor (PAC1R) in the rostral migratory stream of 
the infant mouse brain. Regul Pept 145: 80–87, 2008. 
 72.  McIlvain HB, Baudy A, Sullivan K, Liu D, Pong K, Fennell M, Dunlop 
J. Pituitary adenylate cyclase-activating peptide (PACAP) induces 
differentiation in the neuronal F11 cell line through a PKA-dependent 
pathway. Brain Res 1077: 16–23, 2006. 
 73.  Mei YA, Vaudry D, Basille M, Castel H, Fournier A, Vaudry H, 
Gonzalez BJ. PACAP inhibits delayed rectifier potassium current via a 
cAMP/PKA transduction pathway: evidence for the involvement of I k in 
the anti-apoptotic action of PACAP. Eur J Neurosci 19: 1446–1458, 2004. 
 74.  Michel S, Itri J, Han JH, Gniotczynski K, Colwell CS. Regulation of 
glutamatergic signalling by PACAP in the mammalian suprachiasmatic 
nucleus. BMC Neurosci 7: 15, 2006. 
 75.  Momose-Sato Y, Sato K. Large-scale synchronized activity in the 
embryonic brainstem and spinal cord. Front Cell Neurosci 7: 36, 2013. 
 76.  Nakamachi T, Li M, Shioda S, Arimura A. Signaling involved in pituitary 
adenylate cyclase-activating polypeptide-stimulated ADNP expression. 
Peptides 27: 1859–1864, 2006. 
 77.  Nicot A, Dicicco-Bloom E. Regulation of neuroblast mitosis is 
determined by PACAP receptor isoform expression. Proc Natl Acad Sci 
USA 98: 4758–4763, 2001. 
 78.  Ohno F, Watanabe J, Sekihara H, Hirabayashi T, Arata S, Kikuyama 
S, Shioda S, Nakaya K, Nakajo S. Pituitary adenylate cyclase-activating 
polypeptide promotes differentiation of mouse neural stem cells into 
astrocytes. Regul Pept 126: 115–122, 2005. 
 79.  Ohtaki H, Nakamachi T, Dohi K, Aizawa Y, Takaki A, Hodoyama K, 
Yofu S, Hashimoto H, Shintani N, Baba A, Kopf M, Iwakura Y, 
Matsuda K, Arimura A, Shioda S. Pituitary adenylate cyclase-activating 
polypeptide (PACAP) decreases ischemic neuronal cell death in 
association with IL-6. Proc Natl Acad Sci USA 103: 7488–7493, 2006. 
 170
 80.  Ohtaki H, Nakamachi T, Dohi K, Shioda S. Role of PACAP in ischemic 
neural death. J Mol Neurosci 36: 16–25, 2008. 
 81.  Okano M, Takagi SF. Secretion and electrogenesis of the supporting cell 
in the olfactory epithelium. J Physiol 242: 353–370, 1974. 
 82.  Oldham WM, Hamm HE. Heterotrimeric G protein activation by G-protein-
coupled receptors. Nat Rev Mol Cell Biol 9: 60–71, 2008. 
 83.  Onoue S, Ohshima K, Endo K, Yajima T, Kashimoto K. PACAP 
protects neuronal PC12 cells from the cytotoxicity of human prion protein 
fragment 106–126. FEBS Lett 522: 65–70, 2002. 
 84.  Pardi D, Margiotta JF. Pituitary adenylate cyclase-activating polypeptide 
activates a phospholipase C-dependent signal pathway in chick ciliary 
ganglion neurons that selectively inhibits alpha7-containing nicotinic 
receptors. J Neurosci 19: 6327–6337, 1999. 
 85.  Parrish-Aungst S, Shipley MT, Erdelyi F, Szabo G, Puche AC. 
Quantitative analysis of neuronal diversity in the mouse olfactory bulb. J 
Comp Neurol 501: 825–836, 2007. 
 86.  Payet MD, Bilodeau L, Breault L, Fournier A, Yon L, Vaudry H, Gallo-
Payet N. PAC1 receptor activation by PACAP-38 mediates Ca2+ release 
from a cAMP-dependent pool in human fetal adrenal gland chromaffin 
cells. J Biol Chem 278: 1663–1670, 2003. 
 87.  Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. 
Nat Rev Mol Cell Biol 3: 639–650, 2002. 
 88.  Plachez C, Puche AC. Early specification of GAD67 subventricular 
derived olfactory interneurons. J Mol Histol 43: 215–221, 2012. 
 89.  Pugh PC, Jayakar SS, Margiotta JF. PACAP/PAC1R signaling 
modulates acetylcholine release at neuronal nicotinic synapses. Mol Cell 
Neurosci 43: 244–257, 2010. 
 90.  Rachel RA, May-Simera HL, Veleri S, Gotoh N, Choi BY, Murga-
Zamalloa C, McIntyre JC, Marek J, Lopez I, Hackett AN, Zhang J, 
Brooks M, den Hollander AI, Beales PL, Li T, Jacobson SG, Sood R, 
Martens JR, Liu P, Friedman TB, Khanna H, Koenekoop RK, Kelley 
MW, Swaroop A. Combining Cep290 and Mkks ciliopathy alleles in mice 
rescues sensory defects and restores ciliogenesis. J Clin Invest 122: 
1233–1245, 2012. 
 91.  Rafols JA, Getchell TV. Morphological relations between the receptor 
neurons, sustentacular cells and Schwann cells in the olfactory mucosa of 
the salamander. Anat Rec 206: 87–101, 1983. 
 171
 92.  Ravni A, Bourgault S, Lebon A, Chan P, Galas L, Fournier A, Vaudry 
H, Gonzalez B, Eiden LE, Vaudry D. The neurotrophic effects of PACAP 
in PC12 cells: control by multiple transduction pathways. J Neurochem 98: 
321–329, 2006. 
 93.  Riggio C, Nocentini S, Catalayud MP, Goya GF, Cuschieri A, Raffa V, 
Del Rio JA. Generation of magnetized olfactory ensheathing cells for 
regenerative studies in the central and peripheral nervous tissue. Int J Mol 
Sci 14: 10852–10868, 2013. 
 94.  Roberto M, Brunelli M. PACAP-38 enhances excitatory synaptic 
transmission in the rat hippocampal CA1 region. Learn Mem 7: 303–311, 
2000. 
 95.  Roberto M, Scuri R, Brunelli M. Differential effects of PACAP-38 on 
synaptic responses in rat hippocampal CA1 region. Learn Mem 8: 265–
271, 2001. 
 96.  Ruan Y, Zheng XY, Zhang HL, Zhu W, Zhu J. Olfactory dysfunctions in 
neurodegenerative disorders. J Neurosci Res 90: 1693–1700, 2012. 
 97.  Scharf E, May V, Braas KM, Shutz KC, Mao-Draayer Y. Pituitary 
adenylate cyclase-activating polypeptide (PACAP) and vasoactive 
intestinal peptide (VIP) regulate murine neural progenitor cell survival, 
proliferation, and differentiation. J Mol Neurosci 36: 79–88, 2008. 
 98.  Selvapandiyan A, Debrabant A, Duncan R, Muller J, Salotra P, 
Sreenivas G, Salisbury JL, Nakhasi HL. Centrin gene disruption impairs 
stage-specific basal body duplication and cell cycle progression in 
Leishmania. J Biol Chem 279: 25703–25710, 2004. 
 99.  Shepherd GM, Charpak S. The olfactory glomerulus: a model for neuro-
glio-vascular biology. Neuron 58: 827–829, 2008. 
 100.  Sherwood NM, Adams BA, Isaac ER, Wu S, Fradinger EA. Knocked 
down and out: PACAP in development, reproduction and feeding. 
Peptides 28: 1680–1687, 2007. 
 101.  Shioda S, Ohtaki H, Nakamachi T, Dohi K, Watanabe J, Nakajo S, 
Arata S, Kitamura S, Okuda H, Takenoya F, Kitamura Y. Pleiotropic 
functions of PACAP in the CNS: neuroprotection and neurodevelopment. 
Ann NY Acad Sci 1070: 550–560, 2006. 
 102.  Shioda S, Shuto Y, Somogyvari-Vigh A, Legradi G, Onda H, Coy DH, 
Nakajo S, Arimura A. Localization and gene expression of the receptor 
for pituitary adenylate cyclase-activating polypeptide in the rat brain. 
Neurosci Res 28: 345–354, 1997. 
 172
 103.  Shoge K, Mishima HK, Saitoh T, Ishihara K, Tamura Y, Shiomi H, 
Sasa M. Attenuation by PACAP of glutamate-induced neurotoxicity in 
cultured retinal neurons. Brain Res 839: 66–73, 1999. 
 104.  Silveira MS, Costa MR, Bozza M, Linden R. Pituitary adenylyl cyclase-
activating polypeptide prevents induced cell death in retinal tissue through 
activation of cyclic AMP-dependent protein kinase. J Biol Chem 277: 
16075–16080, 2002. 
 105.  Sun QQ, Prince DA, Huguenard JR. Vasoactive intestinal polypeptide 
and pituitary adenylate cyclase-activating polypeptide activate 
hyperpolarization-activated cationic current and depolarize thalamocortical 
neurons in vitro. J Neurosci 23: 2751–2758, 2003. 
 106.  Szabadfi K, Atlasz T, Kiss P, Danyadi B, Tamas A, Helyes Z, 
Hashimoto H, Shintani N, Baba A, Toth G, Gabriel R, Reglodi D. Mice 
deficient in pituitary adenylate cyclase activating polypeptide (PACAP) are 
more susceptible to retinal ischemic injury in vivo. Neurotox Res 21: 41–
48, 2012. 
 107.  Szabadfi K, Szabo A, Kiss P, Reglodi D, Setalo G, Jr., Kovacs K, 
Tamas A, Toth G, Gabriel R. PACAP promotes neuron survival in early 
experimental diabetic retinopathy. Neurochem Int 64: 84–91, 2014. 
 108.  Taylor RD, Madsen MG, Krause M, Sampedro-Castaneda M, Stocker 
M, Pedarzani P. Pituitary adenylate cyclase-activating polypeptide 
(PACAP) inhibits the slow afterhyperpolarizing current sIAHP in CA1 
pyramidal neurons by activating multiple signaling pathways. 
Hippocampus 24: 32–43, 2014. 
 109.  Ubeda-Banon I, Saiz-Sanchez D, Rosa-Prieto C, Martinez-Marcos A. 
alpha-Synuclein in the olfactory system in Parkinson's disease: role of 
neural connections on spreading pathology. Brain Struct Funct 2013. 
 110.  Uchida D, Tatsuno I, Tanaka T, Hirai A, Saito Y, Moro O, Tajima M. 
Maxadilan is a specific agonist and its deleted peptide (M65) is a specific 
antagonist for PACAP type 1 receptor. Ann NY Acad Sci 865: 253–258, 
1998. 
 111.  Vaudry D, Basille M, Anouar Y, Fournier A, Vaudry H, Gonzalez BJ. 
The neurotrophic activity of PACAP on rat cerebellar granule cells is 
associated with activation of the protein kinase A pathway and c-fos gene 
expression. Ann NY Acad Sci 865: 92–99, 1998a. 
 112.  Vaudry D, Falluel-Morel A, Basille M, Pamantung TF, Fontaine M, 
Fournier A, Vaudry H, Gonzalez BJ. Pituitary adenylate cyclase-
activating polypeptide prevents C2-ceramide-induced apoptosis of 
cerebellar granule cells. J Neurosci Res 72: 303–316, 2003. 
 173
 113.  Vaudry D, Gonzalez BJ, Basille M, Anouar Y, Fournier A, Vaudry H. 
Pituitary adenylate cyclase-activating polypeptide stimulates both c-fos 
gene expression and cell survival in rat cerebellar granule neurons 
through activation of the protein kinase A pathway. Neuroscience 84: 801–
812, 1998b. 
 114.  Vaudry D, Gonzalez BJ, Basille M, Fournier A, Vaudry H. Neurotrophic 
activity of pituitary adenylate cyclase-activating polypeptide on rat 
cerebellar cortex during development. Proc Natl Acad Sci USA 96: 9415–
9420, 1999. 
 115.  Vaudry D, Gonzalez BJ, Basille M, Pamantung TF, Fontaine M, 
Fournier A, Vaudry H. The neuroprotective effect of pituitary adenylate 
cyclase-activating polypeptide on cerebellar granule cells is mediated 
through inhibition of the CED3-related cysteine protease caspase-
3/CPP32. Proc Natl Acad Sci USA 97: 13390–13395, 2000a. 
 116.  Vaudry D, Gonzalez BJ, Basille M, Pamantung TF, Fournier A, Vaudry 
H. PACAP acts as a neurotrophic factor during histogenesis of the rat 
cerebellar cortex. Ann NY Acad Sci 921: 293–299, 2000b. 
 117.  Vaudry D, Pamantung TF, Basille M, Rousselle C, Fournier A, Vaudry 
H, Beauvillain JC, Gonzalez BJ. PACAP protects cerebellar granule 
neurons against oxidative stress-induced apoptosis. Eur J Neurosci 15: 
1451–1460, 2002. 
 118.  Vogalis F, Hegg CC, Lucero MT. Electrical coupling in sustentacular 
cells of the mouse olfactory epithelium. J Neurophysiol 94: 1001–1012, 
2005a. 
 119.  Vogalis F, Hegg CC, Lucero MT. Ionic conductances in sustentacular 
cells of the mouse olfactory epithelium. J Physiol 562: 785–799, 2005b. 
 120.  Wang C, Ohno K, Furukawa T, Ueki T, Ikeda M, Fukuda A, Sato K. 
Differential expression of KCC2 accounts for the differential GABA 
responses between relay and intrinsic neurons in the early postnatal rat 
olfactory bulb. Eur J Neurosci 21: 1449–1455, 2005. 
 121.  Watanabe J, Ohba M, Ohno F, Kikuyama S, Nakamura M, Nakaya K, 
Arimura A, Shioda S, Nakajo S. Pituitary adenylate cyclase-activating 
polypeptide-induced differentiation of embryonic neural stem cells into 
astrocytes is mediated via the beta isoform of protein kinase C. J Neurosci 
Res 84: 1645–1655, 2006. 
 122.  Webb IC, Coolen LM, Lehman MN. NMDA and PACAP receptor 
signaling interact to mediate retinal-induced scn cellular rhythmicity in the 
absence of light. PLoS One 8: e76365, 2013. 
 174
 123.  Wu KS, Tang TK. CPAP is required for cilia formation in neuronal cells. 
Biol Open 1: 559–565, 2012. 
 124.  Yan Y, Zhou X, Pan Z, Ma J, Waschek JA, Dicicco-Bloom E. Pro- and 
anti-mitogenic actions of pituitary adenylate cyclase-activating polypeptide 
in developing cerebral cortex: potential mediation by developmental switch 
of PAC1 receptor mRNA isoforms. J Neurosci 33: 3865–3878, 2013. 
 125.  Yang S, Yang J, Yang Z, Chen P, Fraser A, Zhang W, Pang H, Gao X, 
Wilson B, Hong JS, Block ML. Pituitary adenylate cyclase-activating 
polypeptide (PACAP) 38 and PACAP4-6 are neuroprotective through 
inhibition of NADPH oxidase: potent regulators of microglia-mediated 
oxidative stress. J Pharmacol Exp Ther 319: 595–603, 2006. 
 126.  Zhokhov SS, Desfeux A, Aubert N, Falluel-Morel A, Fournier A, 
Laudenbach V, Vaudry H, Gonzalez BJ. Bax siRNA promotes survival of 
cultured and allografted granule cell precursors through blockade of 
caspase-3 cleavage. Cell Death Differ 15: 1042–1053, 2008. 
 127.  Zhou CJ, Shioda S, Yada T, Inagaki N, Pleasure SJ, Kikuyama S. 
PACAP and its receptors exert pleiotropic effects in the nervous system by 

















 The grant was originally written in 2007 as part of the grant writing class 
course at the University of Utah.  Even though this proposal was not actively 
pursued, it is a project worth some consideration because of the observations 
that excessive PACAP concentrations can be toxic.  As outlined in Chapter 2 and 
Chapter 5, the dose of PACAP should be carefully determined for each 
experimental preparation.  The EC50 for PACAP activation of PAC1 receptors is 
typically in the range of 30–50 nM for slices.  Some researchers that did in vitro 
experiments used extremely high doses of PACAP (100–200 µM) (Basille-Dugay 
et al., 2013; Dziema and Obrietan, 2002; Kopp et al., 1999; Kopp et al., 2001; 
Masmoudi et al., 2003; Pugh et al., 2010; Scharf et al., 2008; Vaudry et al., 
2002a).  At least one lab used 100 µM PACAP in slices (Sun et al., 2003).  The 
rationale for not using doses closer to the PACAP EC50  is warranted because my 
data show an overall larger standard error at lower PACAP concentrations for 
latency, time to peak, amplitude, and area under curve (Fig. 2.4).   However, a 
few studies reported that there are possible artifactual effects when using 
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excessive PACAP, which is suggested to be toxic (Di et al., 2012; Freson et al., 
2004b; Lang et al., 2006a). The grant on the following pages is organized 
according to the guidelines for an NIH grant application.   
 
A:  Specific Aims 
 
Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) is an 
essential peptide in development and throughout life and is studied as a 
candidate for preventing the oxidative stress associated with neurodegenerative 
diseases.  With better understanding of PACAP’s mechanisms, possible 
treatments including therapeutic use of PACAP may be in the making.  There are 
however limits on how much PACAP is good or bad for the body.  Normal 
PACAP levels are known to have effects on proliferation, maturation, and 
preventing apoptosis, but high PACAP levels can induce apoptosis and animals 
with elevated PACAP receptor or elevated PACAP protein mutations display 
mental retardation and delayed development.  It is unknown whether the 
negative effects of elevated PACAP are due to increased proliferation, decreased 
apoptosis of cells that need to die, or increased apoptosis.  Based on our 
observations of cultured cells dying in elevated PACAP media, the increase of 
apoptosis is the most congruent hypothesis.   
 I hypothesize that higher than normal PACAP concentrations lead to 
increased apoptosis and neuronal cell death.  The pro-apoptotic effects of 
elevated PACAP may be due to a down regulation of the transcription 
processes associated with the anti-apoptotic pathway or due to stimulating 
pro-apoptotic pathways.   
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Specific Aim1:  Determine whether PACAP-induced apoptosis is mediated 
by the PAC-1, VPAC1, VPAC2, or other G-protein receptors.  Increasing 
concentrations of PACAP will be applied to OP6 and OP27 cell lines to determine 
the EC50 for inducing apoptosis.  The apoptotic cells will be identified using live 
cell labeling of activated caspases and propidium iodide.  Once the EC50 for 
PACAP-induced apoptosis is determined, the specific antagonists for PAC-1, 
VPAC1, or VPAC2 will be used to identify the receptor(s) involved in the 
apoptotic effects.  
 
Specific Aim 2:  Determine whether there is a dose-dependent shift in 
PACAP-induced expression of anti- and pro-apoptotic factors.  Increasing 
concentrations of PACAP will be applied to OP6 and OP27 cell lines and the 
dose-dependent expression of PACAP-induced anti-apoptotic factors will be 
measured through the use of RT-PCR or/and Western blotting quantification of c-
fos, Bcl-2, and ERK.  In addition, the PACAP-treated cell lines will be assayed for 
a shift in the activation or expression levels of pro-apoptotic factors such as JNK, 
BAX, c-jun, and the caspases.   
 
Specific Aim 3:  Determine whether high PACAP concentrations could 
prevent or make the cells more vulnerable to external apoptotic 
stimulation. 
The OP6 and OP27 cell lines will be treated with high PACAP concentrations in 
the presence and absence of the membrane permeant apoptosis activator C2-
ceramide. The effects of adding C2-ceramide at various time points after the 
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initial PACAP treatment will be assayed using live cell labeling of activated 
caspases and propidium iodide.   
 The picture of PACAP’s mechanisms at higher than normal PACAP 
concentrations, which are reducing the cell’s ability to proliferate and mature, 
may give better ideas about how to get the best out of PACAP treatments in the 
studies using PACAP as a tool to preserve the neuronal cells.  
 
B:  Background and Significance 
PACAP and olfactory system overview 
PACAP was first discovered and characterized as a factor/neuropeptide 
that stimulates cAMP formation in the pituitary cells by Miyata et al. in 1989 
(Miyata et al., 1989).  Even though PACAP’s official discovery came after the 
majority of hypophysiotropic neurohormones had been identified, PACAP is now 
considered to be one of the most important regulators of biological functions and 
affects proliferation, maturation, and apoptosis.  Not surprisingly, PACAP is 
highly evolutionarily conserved from protochordates to mammals.  PACAP is 
important in a wide spectrum of tissues including the pituitary gland, liver, 
respiratory system, immune system, and even bones (Vaudry et al., 2000).  The 
functions of PACAP in the central nervous system are largely neurotrophic during 
development and neuroprotective or neuromodulatory during adulthood (Vaudry 
et al., 2002b; Delgado et al., 2003; Arimura, 1998).  Within the central nervous 
system, PACAP expression is highest in the sensory systems such as the 
olfactory system (Mulder et al., 1999; Hansel et al., 2001a; Shioda et al., 1997). 
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Starting in the periphery of the olfactory system, PACAP and PACAP 
receptors are expressed in the olfactory epithelium and the ensheathing glia, 
which escorts the unmyelinated axons of olfactory neurons to the olfactory bulb 
(OB).  The distinctive glomeruli of the olfactory bulb are the site of the first 
synapse of olfactory sensory neurons (OSNs) and the periglomerular cells 
surrounding each glomerulus have both PACAP and PACAP receptors.  The 
mitral cells or output neurons that synapse with olfactory receptor neurons 
(ORNs) in the glomeruli also have high levels of PACAP and PACAP receptors.  
Importantly, some of the highest densities of PACAP receptors in the adult 
central neuron system (CNS) are on the adult-born granule neurons in the OB as 
well as olfactory epithelium (OE).  These granule neurons originate in the 
subventricular zone (SVZ), a region also high in PACAP signaling throughout life 
(De Marchis et al., 2007).  Despite the anatomical presence of PACAP and 
PACAP receptors in the olfactory system, only a few functional studies have 
been performed in the olfactory epithelium (Han and Lucero, 2005; Hegg et al., 
2003; Hansel et al., 2001b) and no functional studies on PACAP have been done 
in olfactory bulb or SVZ. 
 
Nature of PACAP’s anti-apoptosis function 
 PACAP stimulates two groups of PACAP receptors:  1) Type I with a 
higher affinity for PACAP over VIP (PAC1 receptors) and   2) Type II with equal 
affinity for both PACAP and VIP, (VPAC1 and VPAC2 receptors).  The PAC1 
receptor has splice variants with slightly different binding affinities for PACAP and 
differential coupling to second messenger pathways.  Depending on the type of 
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cell and receptor subtype involved, the second messenger pathways stimulated 
by these receptors generally govern the expression of transduction factors and 
channels, which determine cell fate.  The known channels that are modulated by 
PACAP are the K+, Ca2+, Ca2+-dependent K+, Cl-, nonselective cation, IP3-
coupled, and/or TRP channels (May et al., 1998). 
 In normal circumstances, PACAP has been found to be neuroprotective in 
the central nervous system and sensory systems.  The neuronal tissues 
expressing high levels of PACAP and PACAP receptors are thought to prevent 
apoptosis in conditions that normally induce apoptosis  (Canonico et al., 1996).  
PACAP has been found to be of therapeutic use in recovery of function in 
PACAP deprived cultured cells and knockout mice (Przywara et al., 1998; 
Bhattacharya et al., 2004). Thus, PACAP may be promising as a novel 
therapeutic agent for regenerating lost neurons and for preventing apoptosis in 
neurodegenerative diseases such as Alzheimer’s (Nonaka et al., 2002) and 
Parkinson’s disease (Reglodi et al., 2004; Reglodi et al., 2006). 
 
Nature of apoptosis and where PACAP comes in        
 In normal conditions, apoptosis is a delicate, balanced process found in all 
types of cells and occurs especially during development and immediately 
following injury to OB, nerve or epithelium.  The characteristics include cell 
shrinkage, DNA fragmentation, increased activation of caspases in response to 
ongoing increase of pro-apoptotic factors, and then reversing of 
phosphatidylserine from cytoplasmic side to external surface of cell membrane.  
Cowan and Roskams (Cowan and Roskams, 2002) further discussed these 
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characteristics and the pro- and anti-apoptotic factors in the olfactory system.   
Figure 1.3 shows the known anti-apoptotic factors triggered by activation of 
PAC1 receptors and the pro-apoptotic factors that cross paths with these anti-
apoptotic factors.   
 PACAP-induced factors activate kinases such as ERK, which lead to 
phosphorylation of c-fos, which binds to the c-jun from the pro-apoptosis route 
stimulated by JNK (Fig. 1.3).  The c-fos/c-jun pair then binds to the activator 
protein-1 (AP-1) complexes.   The c-fos/c-jun AP-1 complex builds up the 
expression of Bcl-2, which can inhibit the mitochondrial apoptotic pathway.  
However, without c-fos, the AP-1 complex is formed with the c-jun/c-jun pair for 
carrying out the Bax expression favoring apoptosis.  When the expressions of 
genes are in favor of apoptosis, the mitochondrial cytochrome c is released to 
activate caspase-9 and so forth.  (Be aware that other signals such as caspase-8 
activated by the death receptors may be involved. These were reviewed by (Jin 
and El Deiry, 2005; Falluel-Morel et al., 2008).) 
 As one will see in Aim 3, Fig. 1.3 shows C2-ceramide, which will be used 
to test the high PACAP treated cell’s susceptibility to cell death.  The cell-
permeable C2-ceramide mimics natural ceramides, which are involved in the 
control of the cell survival or death during central nervous system development 
and during stress.  Natural ceramides are produced by sphingolipid catabolism or 




PACAP overexpression may be killing cells 
 As for many physiologically-beneficial proteins, too much of a good thing 
could be bad.  Initial experiments on PACAP in our lab suggest that 
overexpression of the neuropeptide can be harmful to the organism because our 
cultured cells were dying [unpublished].  Freson et al. 2004 (Freson et al., 2004a) 
reported that a family with the genetic history of three copies of the PACAP gene 
yielding higher than normal PACAP concentrations in plasma, suffered from 
severe mental retardation.  Lang et al. 2006 reported that overexpression of the 
human PAC1 receptor in the mouse nervous system reduced neuronal 
proliferation and massively increased neuronal apoptosis in the developing 
cortex.  Furthermore, the ependymal cilia, which are important for directing the 
cerebrospinal fluid flow, are disrupted in these PAC1 overexpressing mice, 
leading to hydrocephalus.   
 In Studies of Bcl-2, a downstream factor for PACAP, reported that when a 
cell expresses more Bcl-2 than Bax, pro-apoptotic characters are reported. To 
have Bcl-2 act as an anti-apoptotic factor, the concentrations of both Bcl-2 and 
Bax need to be equal (Belizario et al., 2007; Hanson et al., 2008).   
 
Olfactory bulbs as an ideal research model 
 Jaworski and Proctor (Jaworski and Proctor, 2000) examined the murine 
expression patterns of both PACAP and PAC1 expression from E12 to adult.  By 
about P4, the mice started expressing a significantly higher level of PAC1 
receptors in the olfactory bulb compared to the cerebral cortex.  In the mice with 
overexpression of PAC1 receptors, which is parallel to prolonged elevation of 
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PACAP, the picture published showed what appears to be either a reduce or 
absence of olfactory bulb (Lang et al., 2006b) (Fig. A.1).  This suggests a 
possible role of PACAP initiating necessary apoptotic effects on the PAC1 
enriched region of olfactory bulb. 
 Even though neurodegenerative diseases are of prime importance in the 
cerebral cortex, the olfactory glomerulus may be considered as a viable research 
model for the cortex as a whole.  In addition to being anatomically easy to 
discern from the remainder of the cortex, many of the olfactory bulb’s principles 
are believed to be applicable to other parts of the brain (Shepherd and Charpak, 
2008).  Furthermore, PACAP is proven to be ubiquitous in the central nervous 
system (Arimura, 1998).  Thus, the olfactory bulb with its enriching PAC1 
receptor concentration is a favorable model to examine the role of PACAP in 
both pro-apoptotic and anti-apoptotic functions in the CNS.  
 Since our lab studied PACAP in the olfactory placode-derived cell lines 
OP6 and OP27 (Illing et al., 2002) for years, the parameters of timing and 
concentrations will be established on the cell lines first in part to avoid the 
unnecessary number of mice used for primary cultures.  Furthermore, the cell 
lines are more stable and pure than the primary cultured cells, providing the 
confidence that the apoptosis not due to non-PACAP causes.  Once the details 
have been worked out in cell lines, the experiments will be done on primary 
cultures of adult OE as well as the more PACAP receptor enriched OB cultures.  
It is possible that the parameters between the lines and the primary cultures will 
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be different, but they will be good comparisons and beneficial to previous works 
done on OP6 and OP27.   
 
Specific antagonists for PACAP receptors 
 We will use a number of antagonists to determine the effects of elevated 
PACAP.   M65, a relatively specific antagonist for PAC1 receptors, was made 
through the deleting portions of a specific PAC1 receptor agonist named 
maxadilian.   The agonist maxadilian was isolated from sand fly salivary gland 
extracts in 1991.  Maxadilian specifically binds to mammalian PAC1 even though 
maxadilian has no significant amino acid sequence in common with PACAP.  
Apparently, the deleted peptide of maxadilian, known as M65, is proven as a 
specific antagonist of PAC1 (Reed et al., 2002; Uchida et al., 1998). 
 PG 97-269 came into the scene as a new highly selective VIP1 (currently 
known as VPAC1) receptor antagonist in 1997 and was proven up to 300 nM 
concentration to not affect the functions of VIP2 (currently known as VPAC2) and 
PAC1 receptors (Gourlet et al., 1997).  PG99-465 is an antagonist for VPAC2 
receptors and it was a modified VIP peptide already used by various labs (Reed 
et al., 2002). GDP beta-S is a non-phosphorylatable analogue of GDP that blocks 
any of the G-protein receptors involving PAC1 and VPAC1/2’s activation through 
the block of the G protein activation.   
 
Significance 
 PACAP is a promising candidate as a therapeutic drug for clinical 
treatment against neurodegenerative diseases such as Alzheimer’s (Nonaka et 
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al., 2002) and Parkinson’s (Reglodi et al., 2004; Reglodi et al., 2006).  Over 
expression of PACAP, however, is suspected to be potentially harmful. The 
potential use of PACAP as a therapeutic agent makes it extremely important to 
determine the effective therapeutic dose as well as any potential harmful effects 
of over-dosing.   No one has looked at how PACAP over expression affects its 
function as an anti-apoptotic factor in the CNS.  We propose to look at various 
aspects of the effects of PACAP over expression in the olfactory epithelia and 
olfactory bulbs, including the receptor subtypes and anti-apoptotic and pro-
apoptotic factors employed at different doses of PACAP expression. A look at 
exactly how high doses of PACAP can kill or otherwise harm cells will be highly 
beneficial in fine-tuning the therapeutic use of PACAP in diseases of both the 
CNS and other tissues, such as elimination of unfavorable side effects.  
 
D1:  Research Design 
Specific Aim 1:  Determine whether PACAP-induced apoptosis is mediated 
by the PAC-1, VPAC1, and/or VPAC2 receptors.  
 PACAP activates PAC-1, VPAC1, and VPAC2 receptors, but the 
differences in affinity of PACAP for each type of receptor and the levels of other 
signaling proteins available lead to differences in potency for PACAP (Lutz et al., 
2006).  While it is known that PACAP’s affinity for each type of receptor varies, it 
is not known whether PACAP’s effects are different at higher doses.   It is 
however known that in mice, PAC-1 over expression reduced their overall growth 
(Lang et al., 2006b).   In the following Aim 1, the effects of elevated PACAP on 




Aim1A:  What concentration of PACAP is required to induce apoptosis?   
 We will apply PACAP to cultures of OP6/OP27 cell lines in increasing 
concentrations from 10-8M to 10-3M (10-7M is the estimated normal concentration) 
for up to 120 minutes.  This will give cells a long enough time to produce the anti-
apoptotic mRNAs such as c-fos and Bcl-2 (Falluel-Morel et al., 2004; Aubert et 
al., 2006).  The percentage of cells showing activated caspases in each of the 
PACAP concentration treatments will be sampled from the cultures and 
measured at 30, 60, 90, and 120 minutes using the live cell labeling of activated 
caspases assay (see detailed Methods).  To support the confirmation of 
apoptosis onset leading to cell death, the propidium iodide (PI) dye assay, which 
measures dead cells, will be applied to a subset of samples at 30, 60, 90, and 
120 minutes.  The controls will be the cultures getting vehicle instead of PACAP 
treatments.  The control levels will be compared to the treatments and any 
significant differences will be determined with ANOVA and post-hoc testing.  
After the parameters have been optimized using the OP6/27 cells, this 
experiment will be repeated in OE and OB primary cell cultures prepared from 
young adult mice. 
Predicted outcomes:  Elevated PACAP will induce apoptosis in the cell lines. 
The percentage of the cells showing activated caspases may start increasing 
starting at 10-6M of PACAP and become significant at 10-5M or 10-4M.  Higher 
concentrations of PACAP will show activated caspases at earlier time points than 
lower concentrations.  The percentage of cells at the late apoptosis stage will 
increase after the increase in the activated caspase.  The PACAP concentration 
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that induces apoptosis in 50% of the cells (EC50) will be used as the minimum 
PACAP concentration in Aims 1B, 2 and 3.   
Potential Problems:  If little to no apoptosis is observed, the cells likely need 
longer than 120 minutes for apoptotic mechanisms to be triggered.  In this case, 
the cells will be incubated in PACAP treatments and measured at four or five 
time intervals for up to 8 or 24 hours and compared with controls. 
 
Aim1B:  Which receptor(s) are involved in the apoptotic process? 
 After completing Aim 1A to find the PACAP EC50 concentration needed to 
trigger apoptosis in the OP6/OP27 cell lines, the receptor(s) involved will be 
identified by testing whether specific antagonists of PAC-1, VPAC1, VPAC2, or 
other G-protein receptors can block the apoptotic effects of high PACAP.  We will 
use the EC50 point of the PACAP concentration found in Aim 1A as a minimum of 
PACAP concentration required to kill cells to see if the receptor antagonists make 
cell overall survival higher or lower.  Various G-protein receptor antagonists will 
be added to OP6/OP27 cell cultures in the following tests: 
Test 1:  Block PAC-1 with 100 uM M65 (Cunha-Reis et al., 2005; Dickson et al., 
2006; Girard et al., 2007; Girard et al., 2008; Uchida et al., 1998) 
Test 2:  Block VPAC1 with 100 uM PG97-269 (Cunha-Reis et al., 2005; Dickson 
et al., 2006; Fizanne et al., 2004; Gourlet et al., 1997; Grant et al., 2006) 
Test 3:  Block VPAC2 with 100 uM PG99-465 (Cunha-Reis et al., 2005; Cutler et 
al., 2003; Grant et al., 2006; Itri and Colwell, 2003; Reed et al., 2002) 
Test 4:  Block VPAC1 and VPAC2 
Test 5:  Block PAC-1 and VPAC1 and VPAC2 
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Test 6:  Block all G-protein receptors with 300uM (in pipette) GDP-beta-S-block 
(Gerevich et al., 2007) 
 The level of apoptosis (% caspase activated cells/total cells) in all tests will 
be compared to cultures that received PACAP and vehicle.  Higher or lower 
PACAP concentrations than Aim1A’s EC50 amount required to trigger apoptosis 
may be required to confirm the improvement or worsening of the cells.   After the 
parameters have been optimized using the OP6/27 cells, this experiment will be 
repeated in OE and OB primary cell cultures prepared from young adult mice. 
Predicted outcome:  PAC-1 will be the key receptor and the blockage of PAC-1 
[24] as shown in Test 1 will significantly reduce the apoptotic effects of elevated 
PACAP.  VPAC1/2 blockage in Test 2, 3, and 4 will likely yield a partial reduction 
of PACAP-induced apoptosis and is expected to be minor in comparison to PAC-
1 receptor blockade.  If PACAP peptides act only on the G-protein coupled 
receptors, then an observation of incomplete apoptotic blockage in Test 5 and 
complete apoptotic blockage in Test 6 will indirectly indicate that non-PACAP 
specific receptors are also stimulated by high PACAP concentrations.   
Potential Problems:  The potential problem will be there may be insufficient 
concentrations of the specific receptors types in OP6/27 cells for observable 
EC50 apoptotic results.  Overexpression of one or another receptor types may be 
required to obtain significant levels of apoptosis and rescue.   
 
Aim 2:  Determine whether there is a dose-dependent shift in PACAP-
induced expression of anti- and pro-apoptotic factors. 
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 Under normal circumstances, PACAP stimulates the expression of what 
are determined as anti-apoptotic factors (Fig. 1.3).  The question is whether there 
is a shift in these factors’s expression in a high PACAP environment toward 
apoptosis instead of anti-apoptosis.  There are no published data looking at the 
quantification of the key anti-apoptosis or pro-apoptosis factors induced by 
abnormally high PACAP concentrations over 10-6M (Falluel-Morel et al., 2004).  
Aubert et al. (Aubert et al., 2006) however showed indirect data that at normal 
PACAP concentrations, anti-apoptosis factors increased then decreased over 
120 minutes.  The following experiments will hopefully give clues on how the 
mechanisms may be working 
 
Aim2A:  Do anti-apoptotic factors decrease or increase in abnormally high 
PACAP situations? 
 Using RT-PCR and Western blotting, the quantity of anti-apoptotic factors 
c-fos and Bcl-2 will be measured at 30, 60, 90, and 120 minutes (Falluel-Morel et 
al., 2004; Aubert et al., 2006) after application of the PACAP concentration found 
to induce apoptosis in Aim 1.  We will also measure the ratio of c-fos to actin 
(using Western blotting) as an indirect measure of the transportation and usage 
of c-fos protein.  The control levels will be compared to the treatments and their 
significant differences will be checked with ANOVA test.  Caspase-3 will be 
measured as a positive control to ensure apoptosis is indeed occurring.  Both 
OP6/OP27 and adult mouse OE and OB primary cultures will be used. 
Predicted outcome:  The high PACAP exposure will make the anti-apoptosis 
factors’s mRNA expression increase then decrease due to the likelihood of 
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PACAP receptors desensitizing in response to high PACAP concentrations as 
shown in previous experiments (Niewiadomski et al., 2002; Taupenot et al., 
1999). 
Potential Problems:  If it takes longer than 120 minutes to get the results in Aim 
1A, the time required to complete Aim 1A will be applied here.  If we instead find 
a continuous overexpression of any anti-apoptotic factors compared to controls, 
then we will have to consider whether the balance rather than the absolute 
amounts of the anti-apoptotic versus pro-apoptotic pathways has shifted. 
 
Aim2B:  Do the pro-apoptotic factors increase in abnormally high PACAP 
environment?   
 Using RT-PCR and Western blotting, the quantities of pro-apoptotic 
factors c-jun and Bax will be measured at 30, 60, 90, and 120 minutes (Falluel-
Morel et al., 2004; Aubert et al., 2006) after application of the PACAP 
concentration found to induce apoptosis in Aim 1.  We will also measure the ratio 
of phophorylated c-jun to normal c-jun (using Western blotting) as an indirect 
measure of the transportation and usage of c-jun protein.  The control levels will 
be compared to the treatments and their significant differences will be checked 
with ANOVA test.  Caspase-3 will be measured as a positive control to ensure 
apoptosis is indeed occurring.  Both OP6/OP27 and adult mouse OE and OB 
primary cultures will be used. 
Predicted outcome:  After about 90 or so minutes in the presence of elevated 
PACAP, the pro-apoptosis factor expression will increase. 
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Potential Problems:  If elevated PACAP is instead able to keep the pro-
apoptotic factors’s expression from increasing, this may mean the pro-apoptotic 
factors are interfering with the PACAP-induced anti-apoptotic factors.  Thus, 
these PACAP-induced factors are not part of the apoptosis process.  To ensure 
apoptosis is nonetheless still occurring in the elevated PACAP treated cells, the 
caspase expression will be monitored as a positive control. 
 
Aim 3:  Determine whether high PACAP concentrations could prevent or 
make the cells more vulnerable to external apoptotic stimulation. 
 So far, we were looking at high PACAP concentrations on healthy cells, 
which are different from the cells in the neurodegenerative diseases people want 
to treat with PACAP.  Here, we will look at whether the high PACAP 
concentrations could prevent or make the cells more vulnerable to external 
apoptotic stimulation.  The experiments involve three different timings of high 
PACAP and C2-ceramide applications to include all of the possible systems we 
may find in the neurodegenerative diseases:  1) Both high PACAP and C2-
ceramide added at same time;  2) High PACAP first then C2-ceramide;  3) C2-
ceramide first then high PACAP. 
C2-ceramide is an apoptotic stimulating factor that interferes with the PACAP 
pathway and was previously used to better understand PACAP’s anti-apoptotic 
mechanisms (Falluel-Morel et al., 2008; Aubert et al., 2006).   
 
Aim3A:  In ceramide treated cells, do high concentrations of PACAP 
protect against or promote apoptosis? 
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 The high PACAP concentration found in Aim 1A to trigger apoptosis and 
30 µM C2-ceramide will be applied to the OP6/OP27 cells at the same time.  The 
early apoptosis characteristics will be determined by taking samples from the 
cultures at 30, 60, 90, and 120 minutes (Falluel-Morel et al., 2004; Aubert et al., 
2006) and measured using the live cell labeling of activated caspases assay (see 
Methods).  To support the confirmation of apoptosis onset leading to cell’s death, 
the propidium iodide (PI) dye assay, which measures dead cells, will be applied 
to a subset of samples at 30, 60, 90, and 120 minutes.  The controls will be the 
cultures getting vehicle, only PACAP, or only C2-ceramide treatments instead of 
both PACAP and C2-ceramide treatments.  The control levels will be compared 
to the treatments and their significant differences will be checked with Student’s 
t-test (Fig. A.2.)  After the parameters have been optimized using the OP6/27 
cells, this experiment will be repeated in OE and OB primary cell cultures 
prepared from young adult mice. 
Predicted outcome:  We predict that in the presence of both elevated PACAP 
and C2-ceramide, the cells will show a delay in shifting toward apoptosis 
compared to cells treated with ceramide alone.  A potential mechanism for this 
observation is that elevated PACAP’s apoptotic-like effects will possibly be 
reduced with probably more pro-apoptotic factors to act upon.  
Potential Problems:  Once again, if the time required for results to occur is 
found to be longer in Aim 1, the time course outlined above will be adjusted 
appropriately.  The other possible problem will be that 30 µM of C2-ceramide 
concentration may be insufficient in this experiment because it was the 
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concentration used by Aubert 2006 (Aubert et al., 2006) to shift the balance of c-
fos and c-jun expression in the presence of normal PACAP concentrations in 
cerebellar granule neurons.  More C2-ceramide may be needed to offset the 
abnormally high PACAP levels in our proposed experiments.  However, it is 
possible that higher C2-ceramide concentrations may not increase pro-apoptosis 
factor expression and we will perform a dose-response for C2-ceramide alone if 
necessary.   
 
Aim3B:  Will the pre-incubated application of high PACAP fail to prevent 
the apoptotic influences of the C2-ceramide? 
 OP6/OP27 cells will be preincubated in the high PACAP concentration 
required to trigger apoptosis before the addition of apoptosis stimulating C2-
ceramide at 20, 30, 40, 50, and 60 minutes after PACAP application.  The anti-
apoptosis resistance performance of high PACAP on the C2-ceramide at 30, 60, 
90, and 120 minutes after the addition of C2-ceramide will be measured.  The 
data of the samples will be collected using the live cell labeling of activated 
caspases assay. The results from Aim 3B will be compared to the results from 
Aim 3A.  To support the confirmation of apoptosis onset leading to cell death, the 
propidium iodide (PI) dye assay, which measures dead cells, will be applied to a 
subset of samples at 30, 60, 90, and 120 minutes.  The controls will be the 
cultures receiving only PACAP and C2-ceramide treatments.  The control levels 
will be compared to the treatments and their significant differences will be 
checked with Student’s t-test (Fig. A.2).  After the parameters have been 
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optimized using the OP6/27 cells, this experiment will be repeated in OE and OB 
primary cell cultures prepared from young adult mice. 
 The entire experiment in the paragraph above will be repeated in the 
reverse order of PACAP and C2-ceramide.  The apoptosis stimulating C2-
ceramide will be preincubated in the cell cultures then high PACAP concentration 
required to trigger apoptosis will be added. 
Predicted outcome:  The high PACAP treated cells will be given the time 
required to start the apoptotic process.  By the time C2-ceramide is added, the 
apoptotic process is already in full force and we predict that ceramide will 
accelerate the apoptotic process.  Other potential outcomes are that ceramide 
has no effect on the rate of PACAP-induced apoptosis or that ceramide actually 
slows PACAP apoptosis by an unknown mechanism.  In the case of C2-ceramide 
pre-incubation, the late addition of PACAP is predicted to slow down the 
apoptotic process, which may be useful information for future investigations on 
treating neurodegenerative diseases. 
Potential Problems:  The timing of PACAP preincubation and addition of C2-
ceramide may need some adjusting such as addition of C2-ceramide at 120 
minutes instead of 30 to 60 minutes.  The incubation time may need to be even 
longer if the time required to complete Aim1 is longer.  If the late addition of C2-
ceramide is able to “save” the cells through the interfering of late pro-apoptotic 
factor to PACAP-induced factors, this can suggest that when overexpressing the 
PACAP, having the overexposure of pro-apoptotic factor expression will help 




D2:  Methods 
Cell Lines:  OP6 and OP27 are the olfactory system’s cell lines harvested by Dr. 
Roskams from E18 mice embryos.  Both were characterized to have different 
responses to PACAP treatments.  For start, both have different ratios of PAC1 
receptors.  These cell lines are necessary for some preliminary work because 
they are more stable than primary cell cultures.  For the passaging, maintenance, 
and differentiation of these cells, we will follow the methods published by Illing et 
al. (Illing et al., 2002).  
 
Animals:  PAC-1 receptors are present on OB GABAergic interneurons.  Either 
the GAD65-GFP mice from Dr. Dudek’s lab, which have high quantity of greenish 
tagged GABAergic interneurons in the OBs (Lopez-Bendito et al., 2004) or the 
wild type C57/B16 strain mice injected with a live cell marker alamarBlue® 
(Invitrogen, Eugene, OR) in the SVZ will be used to make olfactory bulb primary 
cell cultures and/or olfactory bulb slices to confirm the results collected from 
OP6/OP27 cell lines.  These cell markers will discern the primary culture mixture 
of olfactory and non-olfactory cells.  An estimated minimum of twelve mice will be 
used at sets of two in each primary culture.  The animals are housed in the 24˚C 
departmental animal facility on a 12 hr light/dark cycle and provided with 
unlimited food and water.   
 
Tracer injection:  If the wild type C57/B16 strain mice have to be used, the live 
cell marker will be stereotaxic injected into mice pups between one to two days 
old as described (De Marchis et al., 2001).  Briefly, the pups were anesthetized 
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by hypothermia, heads immobilized on a chilled (4 ˚C) stereotaxic apparatus 
during surgery.  The skin is peeled to expose the skull and small holes will be 
drilled for injection access.  A total of 100 nl of alamarBlue® (Invitrogen, Eugene, 
OR) will be injected with a glass micropipette at stereotaxic coordinates of 0 mm 
bregma, 0.8 mm lateral to sagittal sinus, and 1.5 mm deep.  After injection, the 
skin will be sutured and the pups quickly warmed under a heat lamp, then 
returned to their mothers.  In about 30 days, the injected pups will have 
alamarBlue-labeled cells integrated into the OB (De Marchis et al., 2007). 
 
Primary cultures:  Young adult mice between 21 to 35 days old will be 
anesthetized (50:50 of ketamine and xyleme at 65 mg/kg) then decapitated.  
After quick removal of skin and lower jaw, the skull is immediately placed in cold 
Ringer’s solution bath.  The OEs and OBs are then are separately removed and 
kept in cold Ringer’s solution bath until the next step.  For the individual cell 
cultures to last over 8 hours, they are prepared using the published procedure 
(Cunningham et al., 1999).  For the cultures to be used within six hours, the OEs 
and OBs will be chopped up with a sterile razor and incubated in treatments at 
37˚C. 
 
Quantitative RT-PCR:  The cultured cells will be washed twice with PBS at 37˚C 
and resuspended in 0.1 M PBS at 4˚C.  These cells are then pelleted by 
centrifugation (350 x g; 4˚C; 10 minutes).  The total RNA will be isolated using 
Trizol (GIBCO BRL) followed by polyadenylation selection using a cellulose 
oligo(dT) matrix (QuickPrep® Mirco mRNA purification kit, Amersham Pharmacia 
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Biotech).  An aliquot of each will be incubated in RNAse to use as a negative 
control.  First-strand cDNA synthesis will be carried out with 40 ng of mRNA in a 
random hexamer-primed 20-ul reverse transcriptase (RT) reaction using 
SuperScriptTM II RNase H- RT and reagents (GIBCO BRL), incubated at 42˚C 
for 50 minutes.  A second control reaction omitting the reverse transcriptase will 
be included to confirm absence of genomic contamination.  A 2-ul sample of the 
first stand cDNA will be used as a template for each 50 µl PCR, and will be 
amplified using Platinum® Taq DNA polymerase (GIBCO BRL).  Primers for 
detection of transcripts will be the following:  Bcl-2 forward primer, 5’-
CTGGCATCTTCTCCTTCCAGC-3’; Bcl-2 reverse primer, 5’-
ACCTACCCAGCCTCCGTTATC-3’; Bax forward primer, 5’-
TCGCTCTGTGGATGACTGAGTAC-3’; Bax reverse primer, 5’-
GGGCCATATAGTTCCACAAAGG-3’; c-jun forward primer, 5’-
TCCACGGCCAACATGCT-3’; c-jun reverse primer, 5’-
GGTGACAATTGCACCAAGTACTG-3’; c-fos forward primer, 5’-
GATGTTCTCGGGTTTCAACGCG-3’; c-fos reverse primer, 5’-
ACGTCGGTAGAATAAGGAAAGGG-3’; beta-actin forward primer, 5’-
TTCTTTGCAGCTCCT TCGTTGCCG-3’; beta-actin reverse primer, 5’-
TGGATGGCTACGTACATGGCTGGG-3’ 
 The initial PCR experiment will use primer pairs (100 µM) with a 35 cycle 
profile performed as follows:  95˚C denaturation (5 min), start 94˚C denaturation 
(30 sec), 55˚C annealing (1 min) and 72˚C extension (3 min) and 4 ˚C hold 
(Perkin-Elmer PCR thermal cycler).  PCR products will be separated and 
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visualized using ethidium bromide-stained agarose gels (1%), and will be viewed 
under UV transillumination followed by densitometric scanning. Values are 
corrected for differences in fragment size because equal numbers of the larger 
cDNA products will stain more strongly in proportion to the size difference. 
 To verify PCR products, resulting cDNA will be excised from the gel and 
purified using the GlassMAX DNA Isolation Matrix System (GIBCO BRL) and 
then sequenced at the University Sequencing Center.  
 
Quantitative Western blotting:  The solubilized proteins will be prepared from 
cell cultures after treatment.  First, they will be homogenized in ice-cold Buffer A 
(50mM Tris-HCL, 8 mM MgCl2, 5 mM EDTA, 10 µg/ml leupeptin, 5 µg/ml 
pepstatin, 5 µg/ml aprotinin, and 1 mM phenylmethyl sulfonylfluoride pH 7.4).  
This homogenate will be centrifuged at 49,000 x g for 20 minutes at 4˚C.  The 
intermediate pellet will be resuspended in Buffer A and centrifuged again for 20 
minutes.  The final pellet will be resuspended in Buffer B (50 mM Tris-HCl, 120 
mM NaCl, 5 mM KCl, 5 mM MgCl2, 1.5 mM CaCl2, 1 mM EDTA, 10 uM pargylin-
HCl, 0.1% ascorbic acid, 0.001% bovine serum albumin pH 7.4) at a 
concentration of 2 mg/ml.  They will be stored at –80˚C until use with trace 
amounts of bromphenyl blue loaded on 4–15% sodium dodecyl sulfate 
polyacrylamide gels along with molecular weight standards.  The gels will be 
electrophoresed at 80–120V until the tracking dye reaches the bottom.  The 
proteins in the gels then will be transferred to nitrocellulose.  They then will 
undergo antibody procedures of first being blocked in block buffer (10mM Tris-
HCl, 154 mM NaCl, 0.02% thimerosal, 5% (w/v) non-fat dry milk) for 30 minutes 
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at room temperature.  The membrane is then incubated in the chosen primary 
antibody washing buffer (10mM Tris-HCl, 154 mM NaCl, 0.05% Tween-20) with 
5% non-fat milk added for two hours at room temperature, then washed three 
times in washing buffer without non-fat dry milk.  These primary antibodies will be 
against c-fos, actin, phosphor-c-jun, Bcl-2 (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA), and c-jun (Oncogene, Fontenay-sous-Bois, France).  Finally, 
the secondary antibody will be applied in washing buffer with 5% non-fat milk for 
an hour and washed three times in washing buffer without non-fat dry milk.  The 
blot bands then are developed with 4-choloronapthol, exposed to film, then 
quantified with a densitometer.  This data will be normalized to the amount of 
protein in the loaded samples. 
 
Measurements of apoptosis onset:  The cultured cells will be washed twice 
with PBS at 37˚C and resuspended in 0.1 M PBS at 4˚C.  These cells are then 
harvested by centrifugation (350 x g; 4˚C; 10 minutes) and treated with the 
fluorometric caspase assay systems (Promega and R&D Systems).  In brief, the 
pellet is resuspended in 10 ul hypotonic cell lysis buffer and then incubated with 
10 ul of the appropriate caspase substrate at 30˚C for one hour.  The substrates 
for the different caspases will be, respectively:  Ac-YVADAMC for caspase 1, Ac-
VDVAD-AFC for caspase 2, Ac-DEVD-AMC for caspase-3, Ac-VEID-AFC for 
caspase-6, AcIETD-pNA for caspase-8, and Ac-LEHD-AFC for caspase-9.  
Fluorescence intensity will be measured with a microplate reader.  The specificity 
of the assay will be verified by adding 2.5 mM caspase 1 inhibitor Ac-YVAD-CHO 
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Fig. A.1:  Appearance of olfactory bulbs in WT and PAC1-overexpressing 
mouse.  The brain on left was from wild type mouse and has olfactory bulbs 
(yellow dots.)  The brain on right was from PAC1-overexpressing mouse and the 
















Fig. A.2:  Approach for testing PACAP with and without C2-ceramide.  (A) 
Only PACAP control; (B) Only C2-ceramide control; (C) PACAP and C2-
ceramide at same time (Aim 3A); (D) PACAP then C2-ceramide (Aim 3B); (E) 
C2-ceramide then PACAP (Aim 3B.)  All arrows are independent Student’s t-test 
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 The olfactory system is composed of a number of distinct subsystems that 
can be distinguished by the location of their sensory neurons, their specific 
receptors, and their signaling pathways (Munger et al., 2009; Kaupp, 2010).  In 
the canonical olfactory transduction pathway (Buck and Axel, 1991; Reed, 1992; 
Ache and Young, 2005), the binding of an odorant molecule to an odorant 
receptor (OR) activates the olfactory heterotrimeric G-protein comprised of Golfα 
(Jones and Reed, 1989), Gβ1, and  Gγ13 (Kerr et al., 2008).  In contrast to 
phototransduction, one odorant-bound OR activates just one Golf, providing no 
amplification at the OR/G protein interface of the transduction cascade (Ben-
Chaim et al., 2011).  Golfα activation of adenylate cyclase III (ACIII) (Bakalyar and 
Reed, 1990) increases levels of cAMP, thereby opening CNG channels 
consisting of two CNGA2, one CNGA4, and one CNGB1b subunit (Bonigk et al., 
1999).  The resulting Ca2+ influx depolarizes the membrane and activates 
additional Ca2+- and voltage-gated channels (Ronnett and Moon, 2002).  
 While studying the retina phenotype of Pde6d-/- mice, we noted a reduced 
body weight in the first month of life.  We suspected dysosmia (impaired sense of 
smell) to occur in these mutants as the Pde6d-/- mice recover their body weight 
after weaning.  The Pde6d gene encodes a ubiquitous prenyl-binding proteins 
termed PrBP/δ that associates with prenylated proteins by inserting their prenyl 
anchors into a hydrophobic pocket formed by a immunoglobulin-like β-sandwich 
fold (Hanzal-Bayer et al., 2002).  PrBP/δ interacts with multiple partners, such as 
small GTPases of the Ras superfamily, including Ras and Rap (Nancy et al., 
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2002), Rho6 and Rheb (Hanzal-Bayer et al., 2002), Rab8 (Norton et al., 2005) 
and Rab13 (Marzesco et al., 2002; Marzesco et al., 1998), all of which are 
prenylated.  In the retina, this interaction regulates stability and ciliary transport of 
several prenylated proteins, including G protein-coupled receptor kinase 1 
(GRK1) and cGMP phosphodiesterase 6 (PDE6) subunits (Zhang et al., 2007).  
Deletion of the Pde6d gene resulted in disrupted trafficking of GRK1 and PDE to 
the outer segments and a recessive rod/cone degeneration phenotype.  
 A second lipid binding protein abundantly expressed in photoreceptors is 
Uncoordinated 119 (UNC119), which shares structural similarity with PrBP/δ 
(Zhang et al., 2011).  It was recognized to be an acyl-binding protein with 
specificity for the acylated N-terminus of the transducin α-subunit (Tα). In 
photoreceptors, UNC119 plays a key role in regulating the return of Tα to the 
outer segments in the dark, after its light-induced translocation to the inner 
segment.  UNC119, originally identified in C. elegans, was also shown to interact 
with G protein α-subunits ODR-3 and GPA-13 in C. elegans olfactory neurons 
(Zhang et al., 2011).  UNC119 deletion leads to photoreceptor degeneration in 
mouse (Ishiba et al., 2007) and deficiencies in chemosensation in C. elegans 
(Maduro and Pilgrim, 1995).  
 In this communication, we investigated the consequences of PrBP/δ and 
UNC119 deletion on transport of Golf in mouse olfactory neurons.  We reasoned 
that these lipid binding proteins may regulate trafficking of Golf as Golfα and Gγ13 
are myristoylated and prenylated, respectively.  Mistrafficking of Golf subunits and 
absence in cilia may lead to impaired or loss of ability to smell (Zufall and 
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Munger, 2001; Belluscio et al., 1998; Brunet et al., 1996; Jenkins et al., 2009; 
Kulaga et al., 2004). Gαolf is predicted to be N-acylated at its N-terminal Gly (G2) 
and S-palmitoylated at C3, whereas Gγ13, forming a tight complex with Gβ1, is 
predicted to be geranylgeranylated at its C-terminal cysteine (Schwindinger and 
Robishaw, 2001; Linder and Deschenes, 2007; Marrari et al., 2007).  These 
posttranslational processing steps are essential for membrane association, 
protein-protein interactions, and trafficking (Kizhatil et al., 2009; Magee and 
Seabra, 2005; Jenkins et al., 2009).  
 We show that in the Unc119-/- mice, Golfα trafficked normally to the cilia 
and olfaction was largely normal.  In Pde6d-/- OSNs, in contrast, Golfα 
mislocalized and electrical responses to odorants were significantly reduced 
compared to age-matched control mice.  EOG responses evoked by forskolin, 
bypassing olfactory receptors, were similar in WT and Pde6d-/- mice consistent 
with a defect upstream of ACIII at Golf.  Our studies suggest that PrBP/δ plays a 
role in trafficking of heterotrimeric Golf to the cilia of mouse OSNs and is required 
for normal transduction of odorant information in OSNs.  
 
Materials and Methods 
Animals  
 Four PDE6d-/- (SV129/C57BL mixed background), four Unc119-/-, and 
twelve WT mice (C57BL) between 7 weeks to 28 months old were used for 
behavioral experiments.  All animal procedures were approved by the University 
of Utah Institutional Animal Care and Use Committee and were conducted under 




 The ability of mice to discriminate a second novel odorant (odor 2) 
following habituation to a first repeated odorant (odor 1) was tested.  A 10 mm 
diameter disk of filter paper was placed into a 1 ml pipette tip and 6 µl of pure 
odorant was applied to the filter paper.  Mice were removed from the home cage 
and placed in a clean testing cage for 30 min.  The odor was introduced by 
attaching the pipette tip to the top of the cage, and the time of active investigative 
sniffing was recorded.  There were a total of 5 odor presentations or trials, each 
lasting 2 min with 1 min between presentations.  R-carvone was used for the first 
three and last presentations, whereas the enantiomer S-carvone was the novel 
odor used for the fourth trial.  Investigation time was compared between WT and 
Pde6d-/- or Unc119-/- mice for each odorant trial (unpaired) and within a genotype 
across trials (paired) using Student’s t-test (p < 0.05).  
 
Preparation for EOG 
 Mice were anesthetized with CO2, followed by cervical dislocation and 
decapitation.  The EOG recordings were performed on a subset of the 
behaviorally tested mice: 3 each of Pde6d-/- and Unc119-/- mice, as well as their 
respective age-matched WT control mice (n = 3 each, 6 total).  The lower jaw 
and skin were removed, and the skull was hemisectioned along the midsagittal 
plane. The left half of each skull was immediately immersion fixed and used for 
immunocytochemistry.  The other half with turbinates exposed was secured on a 
stereomicroscope stage and maintained in a constant low-pressure 34C 




 The glass recording electrode (~1 µm tip) was filled with Ringer’s solution 
(140 mM NaCl, 5 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 10 mM HEPES, 10 mM 
glucose) and recordings were made at three locations on the exposed turbinates 
using a stereomicroscope.  The ground electrode was a silver chlorided wire 
inserted into a 3 M KCl agar bridge and placed just inside the skull.  EOG 
responses were acquired at a sampling rate of 5 ms and filtered at 200 Hz using 
Axoscope 7.0 software, an Axoclamp 200B, and Digidata 1340 interface.  
Odorants (15 µl) were applied to a pipette filter and introduced into the humidified 
air stream using a picospritzer.  The picospritzer durations were adjusted to 
generate approximately the same peak amplitudes for the three odorants: 2-
heptanone (200 ms), n-amyl acetate (500 ms), and (-)-menthone (1 sec).  Each 
odorant was applied twice at 2 min intervals except for the menthone application, 
which had a 4–5 min interval.  Following odorant testing, a water control was 
applied through the same setup.  Stock solutions of forskolin (10 mM), to directly 
stimulate ACIII, and IBMX (50 mM), to inhibit the breakdown of ACIII, were made 
up in EtOH and diluted to create a working concentration of 100 µM forskolin and 
1 mM IBMX (F/I) in water.  The F/I mixture and water controls were applied using 
a hand-held nebulizer. 
 
EOG Data Analysis 
 Axoscope 7.0 software was used to determine the amplitude in mV of the 
EOG responses.  Initial analysis indicated that the EOG amplitudes were not 
significantly different at the three different recording sites within the same animal.  
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Thus, the peak amplitudes of all three recording sites were recorded for each 
mouse and averaged across all mice according to odorant and genotype.  The 
experimenter was blind to genotype when making the recordings and 
measurements.  Statistical analyses included unpaired Student’s t-tests (p < 
0.01) of the EOG responses in WT versus Pde6d-/-, WT versus Unc119-/-, overall 
odorant responses versus water controls (p < 0.01), and WT and Pde6d-/- F/I 
versus water controls (p < 0.05).  
 
Immunocytochemistry 
 The hemisection of the mouse head was immersion-fixed in 4% 
paraformaldehyde for 2 hr at 4°C followed by decalcifying (Rapid decalcifier, 
Apex Engineering Products Corp. Plainfield, IL) for 4 hr at room temperature.  
For cryoprotection, the tissue was incubated in 30% sucrose in PBS overnight at 
4°C. The tissue was embedded in OCT and 12 µm thick sections were cut.  For 
immunostaining, the sections were blocked in PBS buffer containing 10% goat 
serum,1% BSA, 0.1% Triton X-100 for 1 hr at room temperature in a humidified, 
rotating chamber.  Primary antibodies were applied to the sections overnight at 
4°C.  FITC or TRIC-conjugated secondary antibodies (1:300; Jackson Immuno 
Research Laboratory) were incubated with the sections for 1 hr at room 
temperature.  Zero primary and secondary controls were used to confirm 
specificity.  The images of the sections were acquired by a Zeiss LSM510 
confocal microscope.  The dilutions for the primary antibodies were 1:100 for 
anti-Gαolf (Santa Cruz Biotechnology), 1:200 for anti-ACIII (Santa Cruz 
Biotechnology), 1:1:00 for anti-Gγ13 (gift from Dr. R. Margolskee, Mount Sinai 
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School of Medicine of New York University), 1:100 for anti-CNGA2 (Alomone 
Labs) and 1:1,000 for anti-acetylated tubulin (Sigma–Aldrich).  
 
Pulldown Assay 
 GST-PrBP/δ was expressed and purified as described previously (Zhang 
et al., 2004).  Olfactory tissue from three WT mice was homogenized by brief 
sonication in 1 ml PBS buffer with 1mM DTT and 10 µl protease inhibitor cocktail 
(Roche).  The insoluble debris was removed by centrifugation at 8,000 g for 10 
minutes.  Pulldown assays were performed as previously described (Zhang et al., 
2011). Western blots were probed with polyclonal anti- Gγ13 (1:150; sc-26782, 
Santa Cruz Biotechnology).  The signal was visualized by ECL (enhanced 
chemiluminescence) kit (Perkin Elmer). 
 
Results 
Altered Behavioral Responses to Odorants  
in Pde6d-/- and Unc119-/- Mice 
 We first investigated olfactory function in Pde6d-/- and Unc119-/- mice 
using an odor habituation behavioral paradigm.  In experiments involving three 
repeated exposures to an odorant, the animals are expected to habituate and 
spend less time investigating the odor source with each presentation.  When a 
novel second odorant is presented on the fourth trial, the time that the animals 
spend investigating the source should increase if they can detect a difference 
from the first odorant.  Using R-carvone as the first odorant, WT and mutant 
groups showed relatively normal habituation (Fig. B.1).  However, Pde6d-/- mice 
  
216
exhibited significantly shorter investigation times than WT mice for the first (p = 
0.047) and second (p = 0.04) odor presentations (indicated by *), suggesting 
reduced odor sensitivity.  Even though the Unc119-/- mice habituated to R-
carvone, they had significantly longer investigation time than WT at the third 
presentation (indicated by #, p = 0.024).  The increased investigation times by 
WT and both sets of mutant mice in response to odorant 2 (S-carvone) compared 
to Trial 3 showed that all groups could identify odorant 2 as novel.  
 
Olfactory Function Is Reduced in Mice Lacking  
PrBP/δ, but not in Mice Lacking UNC119 
 Olfactory function was also assessed at the level of the olfactory 
epithelium (OE) using EOG recordings, which measure the electrical field 
potential responses of OSNs to odor stimuli [for review see (Scott and Scott-
Johnson, 2002)].  Three different odorants (2-heptanone, n-amyl acetate, and (-)-
menthone) together with water as a control were tested on OE from litter-mate or 
age matched WT, Pde6d-/-, and Unc119-/- mice.  The Pde6d-/- mice had 
significantly reduced EOG amplitudes that were 21–25% of the average WT 
responses (Fig. B.2, A and C Student’s t-test; p < 0.01), while Unc119-/- EOG 
responses resembled WT responses (Fig. B.2B; p > 0.05).  Collectively, these 
results indicate that Pde6d-/- mice have impaired peripheral olfactory function and 






Localization of PrBP/δ, Gγ13 and Gαolf in WT  
and Mutant Olfactory Cilia 
 PrBP/δ is a soluble protein that forms diffusable complexes with lipidated 
proteins (Zhang et al., 2011; Zhang et al., 2004).  In WT OSNs, PrBP/δ is present 
in dendritic knobs, dendrites and the cell bodies (somata) (Fig. B.3, A and B, left 
panels), but is undetectable in Pde6d-/- OSNs (Fig. B.3, A and B, right panels).  
Colabeling with Ac-tubulin antibody reveals strong colocalization in cilia, and 
weaker colocalization in dendrites, dendritic knobs and soma of WT mice (Fig. 
B.3B, left panel).  This distribution is distinct to that seen in rod photoreceptors 
where PrBP/δ is present in inner segments and the outer nuclear layer, but not 
the photosensitive cilia (the outer segments) (Ishiba et al., 2007; Zhang et al., 
2007).  
 We next investigated the localization of Golf subunits in WT and Pde6d-/-  
by immunocytochemistry (Fig. B.3, C and D).  Both prenylated Gγ13 and acylated 
Gαolf are prominently localized to WT OSN cilia (Fig. B.3, C and D, left panels).  
In Pde6d-/- OE, in contrast, prenylated Gγ13 and acylated Gαolf were essentially 
undetectable (Fig. B.3, C and D middle panels).  Reduction of Golf levels in 
Pde6d-/- olfactory cilia predicts decreased olfactory responses, in agreement with 
habituation and EOG experiments (Figs. B.1 and C.2).  In Unc119-/- OSNs, Gαolf 
and Gγ13  levels were very similar to WT (Fig. B.3, C and D, right panels) again 
consistent with normal EOG results (Fig. B.2B).  Interestingly, PrBP/δ deletion in 
mouse did not affect the localization of the prenylated transducin γ-subunit (Tγ) in 
retinal photoreceptors (Zhang et al., 2007), but deletion of UNC119 affected 
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transport of Tα in rods after light induced translocation (Zhang et al., 2011).  The 
reasons for these differential specificities are unclear.  
 The results in Fig. B.3, A–D, predict a strong interaction of PrBP/δ with 
Gγ13 at the level of biosynthesis, or a role of PrBP/δ as a chaperone in Gγ13 
trafficking to the olfactory cilia (see discussion).  To test the interaction of PrBP/δ 
with Gγ13, we used the glutathione S-transferase (GST) pulldown technique with 
GST-PrBP/δ as a bait.  The result indicated that GST- PrBP/δ, but not a GST 
control, could pulldown Gγ13 suggesting that interaction between PrBP/δ and Golf 
is mediated by the geranylgeranyl group attached to the C-terminus of Gγ13 (Fig. 
B.3E).  Pulldowns of Gαolf with GST-UNC119 were negative. 
 
The Pde6d-/- Olfactory Transduction Pathway  
Is Functional Downstream of Golf 
 To test the functionality of the olfactory transduction pathway downstream 
of Golf in Pde6d-/- mice, EOGs were recorded using forskolin to bypass the ORs 
and directly activate ACIII.  The results show that Pde6d-/- mice had similar EOGs 
in response to forskolin compared to WT (Fig. B.4, A and B; n = 4; p > 0.05), 
consistent with the notion that the defect in olfactory function in Pde6d-/- mice is 
upstream of ACIII.  To test for normal presence of downstream components ACIII 
and CNGA2, we specifically labeled cilia of WT and Pde6d-/- OSNs with anti-
acetylated α-tubulin (red, Fig. B.5, middle panels) and double labeled with 
antibodies against either ACIII or CNGA2 (green, Fig. B.5, left panels).  As 
expected, immunostaining showed that in contrast to the absence of targeting of 
Gαolf and Gγ13 to Pde6d-/- olfactory cilia (Fig. B.3, A–D), the downstream effector 
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proteins ACIII and CNGA2 showed normal colocalization with acetylated α-
tubulin (Fig. B.5, A–D, right panels).  These results indicate that the olfactory 
deficits that we observed in Pde6d-/- mice are a consequence of defective 
transport of G-proteins to OSN cilia.  
 
Discussion 
 In this communication we investigated trafficking of Golf in Pde6d-/- and 
Unc119-/- olfactory cilia.  Behavioral and EOG recordings revealed that the  
Pde6d-/- mouse is dysosmic, suggesting mistrafficking of Golf, the only lipidated 
peripheral membrane protein in the olfactory cascade.  Our main findings are 1) 
the odorant investigation times and the peak amplitudes of odorant stimulated 
EOGs recorded from nasal turbinates are reduced in Pde6d-/- mice compared 
with age-matched or littermate controls; 2) Golf subunits traffic normally to the cilia 
in Unc119-/- OSNs, while trafficking of Gαolf and Gγ13 to the cilia is impeded in 
Pde6d-/- OSNs; 3) GST-PrBP/δ pulls down Gγ13 in a GST binding assay; 4) EOG 
responses evoked by forskolin, bypassing olfactory receptors/Golf and directly 
activating ACIII, were unaffected in Pde6d-/- mice consistent with a defect 
upstream of ACIII; 5) consistent with (4), the labeling of OSN cilia in WT and 
Pde6d-/- with antibodies against either ACIII or CNGA2 showed normal 
localization of these downstream transduction components of Golf. 
 Mechanisms regarding trafficking and ciliary targeting of heterotrimeric G 
proteins in sensory neurons are largely unknown.  Most of the details concerning 
G protein trafficking and assembly of GPCR-signaling complexes for trafficking to 
the plasma membrane (PM) are based on transfection of recombinant constructs 
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in tissue culture (HEK293 cells, yeast) [for review, see (Marrari et al., 2007)].  In 
the canonical model, Gα subunits carrying the myristoylation consensus 
sequence [Fig. B.6A and (Farazi et al., 2001)] are cotranslationally acylated, and 
Gβ and Gγ subunits combine following biosynthesis and prenylation of Gγ.  Gβγ 
then dock to the ER for processing.  At the ER, the prenylated C-termini of Gγ 
(prenyl-CAAX) are modified by removal of the three penultimate amino acids 
(AAX) and carboxymethylation of the C-terminal Cys (Hannoush and Sun, 2010).  
There is general agreement that Gαβγ heterotrimer formation is essential for PM 
targeting (Marrari et al., 2007).  It is unclear, however, where in the cell Gα and 
Gβγ interact and how the complex traffics to the PM or to cilia in polarized 
neurons.  When Gαs and Gβγ were overexpressed in HEK cells, they targeted to 
the PM independent of the Golgi.  However, when a GPCR was co-expressed, 
PM targeting was Golgi dependent, and both GPCR and G protein followed the 
classic secretory pathway (Dupre and Hebert, 2006).  In olfactory sensory 
neurons, Golf is predicted to cotransport with ORs following the secretory 
pathway.  Little is known about assembly of ACIII with Golf and OR receptors.  
There is evidence that transmembrane AC dimers and GPCR dimers are the 
basic structural units that are assembled at the ER level (Cooper and 
Crossthwaite, 2006; Palczewski, 2010).  Apparently, entire signaling complexes 
including GPCRs, G protein, and target enzyme are assembled during 
biosynthesis and prior to PM targeting (Dupre et al., 2009; Dupre et al., 2007).  
One role of PrBP/δ may be involvement in assembly of the signaling complex 
consisting of ORs, Golf, and ACIII (Fig. B.6, A and B).  
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 Mistrafficking of Gαolf in Pde6d-/- OSNs is in contrast to the effect of 
PrBP/δ deletion in photoreceptors, where trafficking of Tγ and Tα subunits 
proceeds mostly normally.  The main differences between Golf and transducin 
heterotrimers lie in the γ-subunits.  Gγ13 is widely expressed in the olfactory and 
taste epithelia, olfactory bulb, brain (Huang et al., 1999), On-bipolar cells (Ghosh 
et al., 2004), and mouse ovaries (Fujino et al., 2007).  Rod and cone Tγ subunits 
are farnesylated (C15), whereas Gγ13 is geranylgeranylated (C20); both have 
limited (25%) sequence similarity to Gγ13.  Farnesyl moieties are more tightly 
associated with PrBP/δ than geranylgeranyl chains (KD of 0.7 μM and 19 μM, 
respectively) (Zhang et al., 2004).  Despite this 27-fold difference in favor of 
farnesyl, geranylgeranylated Gγ13 is pulled down by GST-PrBP/δ, and its 
trafficking is affected in Pde6d-/- OSNs, while rod Tγ is not pulled down and 
trafficking is largely unaffected.  As the C-terminal ten residues of the γ-subunits 
are very similar (Fig. B.6C), other domains located on Gγ13 may contribute to 
strengthen the interaction between Gγ13 and PrBP/δ.  
 Absence of a Golf trafficking defect in Unc119-/- OSNs was unexpected as 
Gαolf is predicted to be N-myristoylated (C14 chain) at glycine 2 (G2), the site of 
interaction Gα subunits with UNC119 (Zhang et al., 2011).  However, it has 
recently been observed that Gαs, which is closely related to Gαolf and with which 
it shares an identical N-terminal sequence (MGCLGNSSKT), is N-palmitoylated 
(C16 side chain) (Kleuss and Krause, 2003).  Thus it is likely that Gαolf may be N-
palmitoylated as well and that a C16 chain may be too bulky to fit into the 
hydrophobic cavity of UNC119, providing an explanation for pulldown failure.  
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 The Pde6d-/- OSN phenotype essentially resembles a Golf knockdown.  
Consistent with a knockdown, we observed that Pde6d-/- EOG responses to 
odorants were significantly reduced, with peak amplitudes of the odorant 
responses approximately ranging from 21% to 25% of age-matched WT mice.  
Similarly, in rod photoreceptors, genetic deletion of rod Tγ led to a major 
downregulation of Tβ and Tα, yet low levels of Tα present in mutant outer 
segments were sufficient to support phototransduction at reduced sensitivity 
(Lobanova et al., 2008).  The relatively mild phenotype of dysosmia seen in 
Pde6d-/- mice contrasts with that in adult Gαolf knockouts, where EOG amplitudes 
in response to a variety of odors were essentially zero consistent with anosmia 
and failure to thrive (Belluscio et al., 1998).  The few Gαolf knockout mice that do 
survive have reduced body weight and suffer competitive disadvantages for 
feeding.  The phenotype of reduced body weight in Pde6d-/- mice is much less 
dramatic, and the mutant mouse eventually recovers a normal body weight by >1 
month of age (Zhang et al., 2007).  It is conceivable that Pde6d-/- mice have taste 
deficiencies (hypogeusia or dysgeusia) or are unable to taste sweet and bitter 
substances, as gustducin and Golf share the Gγ13 subunit, further contributing to 
the low body weight phenotype (Huang et al., 1999).  
 Human diseases associated with olfactory and visual defects include 
some forms of Leber Congenital Amaurosis (LCA) and Bardet-Biedl syndrome 
(BBS) (den Hollander et al., 2006; Harville et al., 2010; Jin and Nachury, 2009).  
An in-frame deletion in CEP290 (NPHP5), a protein localized to the centrosome 
and cilia, is associated with LCA, a type of severe retinal degeneration 
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characterized by visual impairment from birth (den Hollander et al., 2006; den 
Hollander et al., 2008).  This mutation has also been linked to abnormal olfactory 
function in both humans and mice due to disrupted trafficking of olfactory signal 
transduction G-proteins to the cilia (McEwen et al., 2007).  BBS proteins that are 
mutated in Bardet-Biedl syndrome are associated with basal bodies, 
centromeres, and microtubule transport (May-Simera et al., 2009; Ross et al., 
2005). BBS1, BBS4, and BBS8 knock-out mice have reduced responses to 
odorants caused by impaired protein trafficking, including Gγ13 and ACIII as well 
as disrupted cilia structure (Kulaga et al., 2004; Tadenev et al., 2011).  Although 
the human PDE6D gene has not yet been associated with a human olfactory or 
retinal dysfunction, our data suggest that patients lacking the PDE6D gene may 
be dysosmic, hypogeusic, and may develop a recessive cone-rod dystrophy.  
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Fig. B.1: Odor presentations to WT, Pde6d-/- , and Unc119-/- mice in a habituation 
behavioral paradigm. Odor 1, R-carvone; odor 2, S-carvone. All groups showed 
normal habituation to R-carvone. Pde6d-/- mice have significantly shorter investigation 
times than WT mice; the Unc119-/- mice had significantly longer investigation time than 
WT. WT and both mutant mice identified odorant 2 as novel. Significance was 
determined by unpaired Student’s t-tests; * indicates significance at P ≤ 0.05; # 
indicates significance at P ≤ 0.03. The results show that Pde6d-/- mice are dysosmic and 

































Fig. B.2: EOG responses to various odorants (2-heptanone, n-amyl acetate, (-)-
menthone) in WT and mutant mice. (A) representative EOG traces from WT and 
Pde6d-/- mice in response to a water control and the odorants indicated. (B) 
representative EOG traces from WT and Unc119-/- mice. Pde6d-/- mice are dysosmic 
while Unc119-/- mice have normal olfaction. Prolonged responses in the (-)-menthone 
traces (green) were occasionally observed in both WT and Pde6d-/- and are likely due to 
the longer 1-sec pulse used to generate a similar response amplitude to other odorants 
(see Methods). (C) average peak EOG responses to the three odorants and water 
controls are shown for both WT (open bars) and Pde6d-/- mice (solid bars). For each 
odorant, Student’s t-tests were performed on the averaged peak EOG responses in 
knockouts compared to the averaged WT responses. * indicates significance at P ≤ 





















Fig. B.3: Localization of PrBP/δ, Gγ13 and Gαolf in WT and mutant olfactory 
epithelia. (A) WT and Pde6d-/- olfactory epithelium (OE) cryosections were probed with 
anti-PrBP/δ (green) antibody. PrBP/δ is present in dendrites and cell bodies of WT 
mice, but is essentially undetectable in the Pde6d-/- OSNs. (B) PrBP/δ colocalizes with 
acetylated tubulin (AcTub, red) in olfactory cilia. (C, D) WT, Pde6d-/-, and Unc119-/- OE 
cryosections probed with polyclonal anti-Gγ13 and anti-Gαolf antibody. Gγ13 is localized to 
cilia in WT and Unc119-/-OSNs but is undetectable in Pde6d-/- cilia (C).  Gαolf is localized 
to the cilia in WT and Unc119-/- mice, but is essentially absent from cilia of Pde6d-/- mice 
(D). (E) direct interaction between PrBP/δ, the protein encoded by the Pde6d gene, and 
Gγ13. Mouse olfactory extract pulldowns with GST-PrBP/δ and GST as a control were 
identified with anti-Gγ13 antibody. Input, olfactory crude extract. Pulldown, proteins 













Fig. B.4: Forskolin stimulation of ACIII. (A) representative EOG traces before, during, 
and after H2O control, and 100 µM Forskolin + 1 mM IBMX (F/I) are shown for WT and 
Pde6d-/- mice. (B) Average peak EOG responses to F/I and H2O control were not 
significantly different using a Student’s t-test p = 0.3; n = 3 WT, 3 Pde6d-/-. The results 
show that the cAMP signal transduction pathway is functional downstream of the 





Fig. B.5: ACIII and CNGA2 in OSNs show proper targeting to OSN cilia. (A, C) 
Confocal images of immunostainted (WT) and (B, D) (Pde6d-/-) olfactory epithelium 
cryosections. Cilia are identified by the acetylated α-tubulin immunoreactivity (red). ACIII 
and CNGA2 (green) are located in cilia and colocalize with acetylated tubulin in both 






























Fig. B.6: Cartoon of Golf trafficking in OSNs. (A) Normal trafficking of membrane 
proteins. Following biosynthesis, prenylated Gγ13 and acylated Gαolf dock at the 
endoplasmic reticulum (ER) and form a soluble complex with the help of lipid binding 
protein(s). Transmembrane proteins (ORs, ACIII, olfactory channel subunits CNGolf) are 
synthesized at the ER, exit the ER, and combine with Golf to form a signaling complex to 
be trafficked to the olfactory cilia. (B) Trafficking in the absence of PrBP/δ. In the 
absence of PrBP/δ, Gβ1γ13 and Gαolf remain bound to the ER and are likely degraded. 
The signaling complex lacking Golf subunits, but containing ORs, ACIII, and CNG 
subunits traffics normally. (C) The C-terminal regions of rod, cone, and olfactory Gγ 
subunits. The last 21 residues of rod Tγ, cone Tγ, and Gγ13 are shown. The penultimate 
10 residues are highly conserved, yet only Gγ13 is pulled down by GST-PrBP/δ (GST- 













METHODS AND TECHNIQUES 
 
Introduction 
 I wrote this appendix to give people more details on the methods and 
techniques used to obtain the data.  I feel that the amount of information about 
the methods in the journal articles (Chapter 2, 3, and 4) is not enough for another 
person to successfully repeat my work without the following suggestions, which 
may be helpful in terms of producing ideas and possibly saving time and 
resources.   
 For the tissue slices used in Chapters 2 and 3, there is an art to prepare, 
transport, position in chamber, maintain the solution flow through chamber, and 
image a great spot.  It took me a few years to develop my skills to achieve my 
standards for healthy slices, especially olfactory bulb ones.   
 The challenge I had for Chapter 4 was to get reliable, strong EOG 
responses for a full hour without the tissue getting wet or dry.  The application of 
dissolved IMBX/FSX was also tweaked to obtain the most reliable data.   
 
Chapter 2:  Preparing Live Acute OB Slices 
 First week neonatal mice pups were used both for their adaptability to a 
relatively simple acute live slicing method and for study of PACAP effects during 
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early maturation.  The slightest physical trauma to a live OB acute slice often 
significantly decreases the vitality of the slice (personal observations).  I 
speculated that the low success rate of acute live brain slices in older animals is 
why some researchers only collect acute live slices from mouse or rat embryos 
up to 24 hours postnatal (personal conversations).  I, however, developed tricks 
that sometimes gave slices with good vitality from P2 to P5 neonatal pups. 
Minimizing the steps between the live animal and recording from slices helped 
increase the viability of the acute slice.  One step-saver was to use the skull as a 
natural embedding material instead of embedding the OB in a foreign material 
such as the typical agarose, gel, or carrots. For pups older than P6, when the 
skull becomes calcified and difficult to slice through, an approach I would like to 
try is cutting off the skull at the eye sockets, but keeping the lower part of skull as 
a way to hold the OB in place.  There will be an age when it would be better to 
remove the OB from the skull.  As the animals mature,  meninges enclose the 
OB, and one has to peel these off the OB in order to make good adult OB slices 
(personal observations). 
 
Chapter 2:  Permeant Ca2+ Sensitive Dyes  
  Experiments on the same slice often last about 4 hours. When imaging 
the same tissue for prolonged amounts of time, the bleaching of fluorescent 
labels on the tissues is a common problem. When I did experiments on 
sustentacular cells (Chapter 3), I was able to incubate the slices in Fluo-4 AM for 
about 15 minutes at 37ºC and complete the experiment within an hour after 
incubation.  This is because I had no need to wash out the treatments for over 60 
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minutes after each application as I did for PACAP, which has a long response 
duration. When I worked with PACAP, each slice was imaged for about 4 hours.  
Thus, it was necessary to load the slices with Fluo-4 AM for nearly an hour at 
37ºC and use them within an hour. Fluo-4 then lasts throughout the experiment 
with small adjustments for the loss of fluorescent dye near the end.  
 In Chapter 2, we showed data for GAD65-dtTomato transgenic mice and 
we wished we could look at GAD67 labeled transgenic mice.  Unfortunately, we 
did not have a GAD67-dtTomato transgenic mouse colony.  However, we did 
have access to a GAD67-GFP transgenic mouse colony, and we put in the effort 
to use the mice.  We have showed that using Rhod-3 as an alternative permeant 
Ca2+ sensitive dye would work, but Rhod-3 has the problem of loading in the 
dendrites more than the soma.  Figure C.1 shows the double loading of both 
Rhod-3 (Fig. C.1A) and Fluo-4 (Fig. C.1B) on an olfactory bulb (OB) live slice of a 
wildtype (WT) mouse.  Figure C.2 shows a x2 magnification of where the Rhod-3 
and Fluo-4 dyes are loaded.  Figure C.3 shows how Rhod-3 looks in the GAD67-
GFP transgenic mouse OB.  Rhod-3 rarely overlaps with the GAD67-GFP label 
found mainly on the soma, proving the dye to be useless for recording Ca2+ 
activation of somas but potentially useful for imaging Ca2+ in dendrites.   
 
Chapter 2:  dtTomato Fluorescent Bleaching 
 For the mice expressing the fluorescent dtTomatomarker, the confocal 
imaging bleaching unfortunately happened quicker compared to mice expressing 
GFP fluorescence.  To minimize the exposure to background light, I built a black 
box to place over the microscope. The box has a removable door on the front so 
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the experimenter can look into the eyepiece (Fig. C.4, A and B). The side shown 
in Fig. C.4 has a large opening toward the back for accessing the stage shifters. I 
used the box when I needed to image the red fluorescent of the dtTomato 
throughout experiments lasting as long as 4 hours.   
 
Chapters 2 and 3:  Perfusion System 
 For Chapters 2 and 3 calcium imaging of live slices, a perfusion system 
was used to manage a constant, slow flow of 1–2 mL per minute from the bottles 
containing the physiologic solutions. A vacuum pump was used at the opposite 
side of the chamber from the incoming flow. The vacuum pump got clogged from 
time to time, mainly due to air bubbles or loose pieces of tissue. When the pump 
is not working, the chamber can overflow and solutions drip over the stage onto 
the air table, making a mess. Furthermore, the chamber where the slices were 
placed has its challenges. When the chamber bath is too high, the loop injected 
solution often flows along the sides and very little hits the tissue. When the 
chamber bath is too low, the static from the chamber walls draws the solution 
away from the center where the slice is being held.  Here, I want to share my 
ideas to make the experiments more pleasurable to do.   
 The key thing to look at is the chamber itself.  Figure C.5 shows the 
chamber I used for calcium imaging live slices.  The whole chamber size was 24 
x 60 mm, and the width of the chamber bath was 14 mm.  I discovered that this 
width is more effective than wider chambers.  However, the disadvantage was 
the limited range of areas to take pictures of during perfusion due to the need for 
avoiding close connection with the side walls of chamber.  The incoming solution 
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comes in on the right side and the pipe opening fit into the chamber should be 
horizontal and perpendicular to the chamber bottom geometry (Fig. C.5A).    The 
chamber walls are made from plexiglass (Fig. C.5B) with a separable, 
replaceable thick coverslip glass bottom (Fig. C.5C).  Vacuum grease was used 
to seal the edges between chamber wall and coverslip bottom, which was stuck 
together using vacuum grease.  The wire running between the chamber wall and 
coverslip bottom is a very thin stainless steel wire.  This wire is used for holding 
slices in place during experiments with minimum perfusion flow displacement.  
The pipe on the left side is the vacuuming end, where solution is being drawn out 
of the chamber (Fig. C.5D).   
 To maintain a reliable, constant perfusion flow throughout the 
experiments, I found that keeping the chamber bath level low is the most 
promising approach.  We want the experimental drugs, especially those applied 
through loop injection, to run smoothly directly over the slice and effectively get 
washed out.   What I did was to put films of silicone coating (Sigmacote, from 
Sigma Chemicals) on the surface and interior walls of the chamber plexiglass 
and along the edges of the glass coverslip bottom.  Sigmacote makes the 
surfaces water repellant and once it is applied, the film can last a long time. The 
glass coverslip bottom has a narrow silicone-free lane down the length of the 
middle so the solution tends to flow along the center, where the slice is 
positioned, instead of detouring along the sides of the chamber bath.  A small 
piece of kimwipe (2 x 3 cm square, folded twice in one-thirds to make a 1 x 2 
piece) is placed 4–6 mm from the slice to draw solution away from the whole 
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diameter of the slice (8 mm diameter for mouse pup noses).  The vacuum is 
connected to surface of the kimwipe, pulling off the solution at a steady rate.    
 
Chapter 4 and Appendix C:  Electro-olfactogram Setup 
 Figure C.6 shows the setup of the electro-olfactogram system.  Humidity is 
kept at moderate levels.  If the humidity is too high, the olfactory epithelium (OE) 
surface becomes watery and does not perform as well. To keep the humidity 
from soaking the tissue, I used a lamp light as a drying agent (Fig. C.6; below 
yellow arrow).  When the humidity is low, the plastic sheet helps keep the 
moisture in the work space (Fig. C.6A).  The small water bath under the plastic 
sheet (Fig. C.6B) aids in increasing the warm moisture. (A humidifier may supply 
moisture, but it is often too chilly for the tissue.) Not pictured was the heated 
(34ºC) water bath source for the low-pressure moisture vapor, which is supplied 
through the white vaporizing-tube (Fig. C.6; above green arrow).   
 Odorants are applied using a picospritzer (not pictured), which makes the 
odorants air-bound through the side of the vaporizing-tube, about 3 inches from 
the opening (Fig. C.6; red arrow).  The odorant is loaded onto the filter of pipette 
tips (the tips were autoclaved to make the filter pores bigger) and snapped onto 
the holder (Fig. C.6; white arrow).  The opening of the vaporing-tube is placed 
2.5–3.0 cm from the surface of OE.  The glass funnel sucks away the odorants, 
clearing the smell out of the work space, especially when covering the space with 
plastic sheet (Fig. C.6; blue arrow).   
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 Other parts included the perfusion system for loop injecting solution-bound 
drugs (e.g., IBMX/FSK) for testing the function of downstream mechanisms (Fig. 
C.6C) and the electrode holder (Fig. C.6D).   
 
Chapter 4 and Appendix C:  Animals Used 
The biggest challenge I encountered was keeping the OE tissue at a 
constant humidity throughout the experiments.  I am very confident with the data 
I collected because the wild type data results were consistent for seven different 
odorants tested between 2009 and 2013.  However, a strictly controlled 
environment with accurate humidity and temperature would undoubtedly improve 
recordings.  Over the years of EOG recordings, I observed that the wild type 
mice in animal facility A had an overall 30% smaller response to odors than the 
wild type mice in animal facility B.   Could it be the long-term humidity?  
Population density?  Cleanliness of cages?  We can only speculate because the 
animal facility environments were supposed to be the same.  For this reason, I 




Fig. C.1:  Projection of all layers of live olfactory blub slice in wildtype mice.  (A)  
Rhod-3 labels mainly the dendrites and a few soma (most of the somas were observed 
to be dead cells). (B)  Fluo-4 loads into the soma more effectively than Rhod-3.  (C)  
Combination of A and B, showing the labeling of layers [glomerular layer (GL), mitral 
cell layer (MCL), granule cell layer (GCL)].  The glomeruli balls of dendrites from tufted 
cells and mitral cells are where the Ca2+ activity is best reported for Rhod-3.  Scale bar 




Fig. C.2:  Close up projection of granule cell layer in live olfactory blub slice of 
wildtype mouse.  (A)  Rhod-3 labels mainly the dendrites and a few soma (most of the 
somas that are labeled with Rhod-3 were observed to be dead cells). (B)  Fluo-4 loads 




Fig. C.3:  Projection of all layers of live olfactory blub slice in GPF-GAD67 mice.  
(A)  Rhod-3 rarely loads into the soma of the GPF-GAD67 label (B).  (C)  Combination 
of A and B, showing the label of layers [glomerular layer (GL), mitral cell layer (MCL), 
granule cell layer (GCL)].  The glomeruli balls of dendrites from tufted cells and mitral 










Fig. C.4:  Black box designed for minimizing light exposure to dtTomato 
fluorescent in experiments taking hours to complete.  (A) The box has a removable 
door on the front so the investigator can look into the eyepiece.  (B) The removable door 
is sealed into the box when there is no need to look into the eyepiece.  The large 










Fig. C.5:  The chamber used with the perfusion system for live slice experiments.  
(A)  Incoming solution side, the stainless metal pipe is fitted into the hole (blue arrow).  
(B)  Chamber walls made from plexiglass.  (C) Thick coverslip glass bottom.  (D)  
Vacuuming end, another stainless metal pipe is sandwiched between the split in the 












Fig. C.6:  Electro-olfactogram setup.  (A)  Plastic sheet for keeping moist within the 
work space (cover entire system when not looking into scope).  (B)  Small water bath as 
humidifier.  (C) Perfusion system for solution-bound drug application.  (D)  Electrode 
holder and headstage, which is plugged to axopatch.  Yellow arrow:  Lamp.  Green 
arrow: Vaporing-tube.  Red arrow:  Air-bound odorant input on side of vaporing-tube.  
White arrow:  Odorant-loaded pipette tip holder.  Blue arrow: Glass funnel, which is 
hooked to vacuum for sucking away odorants.   
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